methadone has been researched along with Neonatal Abstinence Syndrome in 366 studies
Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3)
methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.
6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.
Neonatal Abstinence Syndrome: Fetal and neonatal addiction and withdrawal as a result of the mother's dependence on drugs during pregnancy. Withdrawal or abstinence symptoms develop shortly after birth. Symptoms exhibited are loud, high-pitched crying, sweating, yawning and gastrointestinal disturbances.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eight sites enrolled 116 full-term newborn infants with neonatal abstinence syndrome born to mothers maintained on methadone or buprenorphine into a randomized trial of morphine vs methadone." | 9.34 | Neurodevelopmental Outcomes of Neonates Randomized to Morphine or Methadone for Treatment of Neonatal Abstinence Syndrome. ( Bogen, DL; Czynski, AJ; Dansereau, LM; Davis, JM; Engelhardt, B; Hudak, ML; Lester, BM; Marro, P; Oliveira, EL; Shenberger, J; Wachman, EM, 2020) |
| "Compare duration of treatment of neonatal abstinence syndrome between methadone and morphine." | 9.20 | Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. ( Brown, MS; Hayes, MJ; Thornton, LM, 2015) |
| "To characterize the population pharmacokinetics of oral methadone in neonates requiring pharmacologic treatment of neonatal abstinence syndrome and to develop a pharmacokinetic (PK) model toward an evidence-based treatment protocol." | 9.20 | Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study. ( Akinbi, H; Isemann, B; Mizuno, T; Tabangin, ME; Vinks, AA; Ward, LP; Wiles, JR, 2015) |
| " While methadone-maintenance currently is the standard of care for opioid dependence during pregnancy, research suggests that buprenorphine-maintenance may be associated with shorter infant hospital lengths of stay (LOS) relative to methadone-maintenance." | 9.19 | Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome. ( Hall, ES; Lewis, D; Marcotte, M; Theobald, J; Van Hook, J; Wexelblatt, SL; Wilder, C; Winhusen, T, 2014) |
| "To compare the profile of signs of neonatal abstinence syndrome (NAS) in methadone- versus buprenorphine-exposed infants." | 9.16 | Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. ( Arria, AM; Badger, GJ; Coyle, MG; Gaalema, DE; Heil, SH; Jones, HE; Kaltenbach, K; Martin, PR; Scott, TL; Stine, SM, 2012) |
| "To determine if oral clonidine would reduce the duration of opioid detoxification for neonatal abstinence syndrome." | 9.14 | Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. ( Agthe, AG; Chavez-Valdez, R; Gauda, EB; Hendrix, CW; Jansson, L; Kim, GR; Lewis, TR; Mathias, KB; Yaster, M, 2009) |
| "Methadone, a full mu-opioid agonist, is the recommended treatment for opioid dependence during pregnancy." | 9.14 | Neonatal abstinence syndrome after methadone or buprenorphine exposure. ( Arria, AM; Coyle, MG; Fischer, G; Heil, SH; Jones, HE; Kaltenbach, K; Martin, PR; O'Grady, KE; Selby, P; Stine, SM, 2010) |
| "The aim of the study was to evaluate the effect of substitution therapy in heroin addicted pregnant women on the course of pregnancy, perinatal outcomes and course of the neonatal abstinence syndrome." | 9.13 | Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the ( Binder, T; Vavrinková, B, 2008) |
| "Though methadone pharmacotherapy is the treatment of choice for opiate-dependence during pregnancy in the USA, most methadone-exposed neonates develop neonatal abstinence syndrome (NAS)." | 9.12 | Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates. ( Dipietro, JA; Elko, A; Jansson, LM; Velez, M, 2007) |
| "Treating opioid-addicted women with methadone in pregnancy increased the number of newborns suffering from neonatal abstinence syndrome (NAS)." | 9.11 | Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. ( Birkenfeld, L; Hellmich, M; Herkenrath, P; Langenfeld, S; Müller, C; Theisohn, M, 2005) |
| "This study was designed to compare the neonatal abstinence syndrome (NAS) in neonates of methadone and buprenorphine maintained pregnant opioid-dependent women and to provide preliminary safety and efficacy data for a larger multi-center trial." | 9.11 | Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. ( Chisholm, CA; Choo, RE; Crocetti, M; Dudas, R; Harrow, C; Huestis, MA; Jansson, LM; Jasinski, DR; Johnson, RE; Jones, HE; Lantz, M; Lester, BM; Milio, L; O'Grady, KE, 2005) |
| "To determine whether morphine has better outcomes for neonatal abstinence syndrome treatment than methadone." | 9.01 | Methadone versus morphine treatment outcomes in neonatal abstinence syndrome: A meta-analysis. ( Xiao, F; Yan, K; Zhou, W, 2019) |
| "To compare the effects of morphine and methadone on length of hospital stay (LOS) or treatment (LOT) and adverse effects in infants with neonatal abstinence syndrome (NAS)." | 8.98 | Morphine and Methadone for Neonatal Abstinence Syndrome: A Systematic Review. ( Gregory, PJ; Hein, DJ; Risoldi Cochrane, Z; Slowiczek, L, 2018) |
| "A literature search of PubMed (1966 to March 2016) and EMBASE (1973 to March 2016) was completed using the search terms buprenorphine, methadone, pregnancy, opioid, and neonatal abstinence syndrome Priority was given to randomized controlled trials and trials directly comparing buprenorphine and methadone during pregnancy." | 8.93 | Buprenorphine Versus Methadone for Opioid Dependence in Pregnancy. ( Campbell, K; Crannage, E; Forinash, A; Noormohammadi, A; Shyken, J; Yancey, A, 2016) |
| "Buprenorphine and methadone are opioid-receptor agonists used as opioid substitution therapy during pregnancy to limit exposure of the fetus to cycles of opioid withdrawal and reduce the risk of infectious comorbidities of illicit opioid use." | 8.90 | Buprenorphine and methadone for opioid addiction during pregnancy. ( Mozurkewich, EL; Rayburn, WF, 2014) |
| "This article provides an overview and discussion of the collective maternal, fetal and neonatal outcome research on women maintained on methadone or buprenorphine during pregnancy." | 8.88 | Methadone and buprenorphine for the management of opioid dependence in pregnancy. ( Finnegan, LP; Jones, HE; Kaltenbach, K, 2012) |
| "To determine if there is a relationship between maternal methadone dose in pregnancy and the diagnosis or medical treatment of neonatal abstinence syndrome (NAS)." | 8.86 | Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. ( Clarke, M; Cleary, BJ; Donnelly, J; Fahey, T; Gallagher, PJ; Murphy, DJ; Strawbridge, J, 2010) |
| "The aim of the study is to assess the correlation between maternal methadone dose and severity of neonatal abstinence syndrome (NAS) in infants that required pharmacological treatment for NAS." | 8.12 | Is Maternal Methadone Dose Associated with the Severity of Neonatal Abstinence Syndrome? ( Adeniyi-Jones, S; Aghai, ZH; Boelig, RC; Carola, D; Greenspan, JS; Kraft, WK; Lafferty, M; Smith, J, 2022) |
| "This pilot study evaluated the relationship between maternal and neonatal R- and S-methadone and R- and S-2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) exposure and the severity of neonatal abstinence syndrome (NAS)." | 8.02 | Stereoselective Analysis of Methadone and EDDP in Laboring Women and Neonates in Plasma and Dried Blood Spots and Association with Neonatal Abstinence Syndrome. ( Evrard, CA; Haas, DM; Haneline, LS; Jones, DR; Masters, AR; Metzger, IF; Quinney, SK; Thomas, AE, 2021) |
| "To compare clonidine versus phenobarbital as adjunctive therapy in infants who failed monotherapy with morphine for neonatal abstinence syndrome (NAS)." | 7.96 | Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. ( Brusseau, C; Burnette, T; Heidel, RE, 2020) |
| "The mainstay of the management of opioid use disorder in pregnancy is with methadone or buprenorphine medication-assisted treatment." | 7.96 | Use of naltrexone in treating opioid use disorder in pregnancy. ( Katz, E; Towers, CV; Visconti, K; Weitz, B, 2020) |
| "To assess safety and effectiveness of transitioning from methadone to buprenorphine when necessary during pregnancy." | 7.88 | Transitioning from methadone to buprenorphine maintenance in management of opioid use disorder during pregnancy. ( Johnson, S; Martin, PR, 2018) |
| "Antenatal exposure to methadone or buprenorphine often causes neonatal abstinence syndrome (NAS) in newborns." | 7.88 | Antenatal methadone vs buprenorphine exposure and length of hospital stay in infants admitted to the intensive care unit with neonatal abstinence syndrome. ( Benjamin, DK; Bennett, MM; Clark, RH; Miller, ES; Murthy, K; Smith, PB; Tolia, VN, 2018) |
| "Our objective was to estimate the association between methadone and neonatal abstinence syndrome compared with buprenorphine using a probabilistic bias analysis to account for unmeasured confounding by severity of addiction." | 7.88 | Methadone Versus Buprenorphine for Opioid Use Dependence and Risk of Neonatal Abstinence Syndrome. ( Bodnar, LM; Caritis, SN; Lemon, LS; Platt, RW; Venkataramanan, R, 2018) |
| " The objective of this study was to compare duration of opioid treatment and length of stay outcomes for neonatal abstinence syndrome (NAS) using sublingual buprenorphine versus traditional weaning with methadone or morphine." | 7.88 | Comparison of Neonatal Abstinence Syndrome Treatment with Sublingual Buprenorphine versus Conventional Opioids. ( Folger, AT; Hall, ES; Rice, WR; Wexelblatt, SL, 2018) |
| "To estimate the relationship of initial pharmacotherapy with methadone or morphine and length of stay (LOS) in infants with neonatal abstinence syndrome (NAS) admitted to the neonatal intensive care unit (NICU)." | 7.88 | Morphine vs Methadone Treatment for Infants with Neonatal Abstinence Syndrome. ( Benjamin, DK; Bennett, MM; Clark, RH; Greenberg, RG; Murthy, K; Smith, PB; Tolia, VN, 2018) |
| "Through retrospective chart review, this study described characteristics and length of stay for a cohort of newborns discharged on methadone following an inpatient weaning for neonatal abstinence syndrome (NAS)." | 7.85 | An Outpatient Methadone Weaning Program by a Neonatal Intensive Care Unit for Neonatal Abstinence Syndrome. ( Boucher, J; Lai, A; Meyer, A; Philpot, P, 2017) |
| "The development, characterization and stability evaluation of methadone (MI, MII, MIII) and phenobarbital (PI, PII) can be used for the treatment of neonatal abstinence syndrome (NAS)." | 7.83 | Design of pediatric oral formulations with a low proportion of methadone or phenobarbital for the treatment of neonatal abstinence syndrome. ( Calpena, AC; Clares, B; Mallandrich, M; Provenza, N; Pueyo, B, 2016) |
| "To compare the duration of opioid treatment and length of stay among infants treated for neonatal abstinence syndrome (NAS) by using a pilot buprenorphine vs conventional methadone treatment protocol." | 7.83 | A Cohort Comparison of Buprenorphine versus Methadone Treatment for Neonatal Abstinence Syndrome. ( Akinbi, HT; Hall, ES; Harvey, S; Isemann, BT; Meinzen-Derr, J; Wexelblatt, SL; Wiles, JR, 2016) |
| "To compare neonatal abstinence syndrome prevalence and characteristics among neonates born to women prescribed buprenorphine and naloxone compared with methadone during pregnancy." | 7.81 | Buprenorphine and naloxone compared with methadone treatment in pregnancy. ( Jones, H; Seashore, C; Stringer, EM; Stuebe, AM; Thorp, J; Wiegand, SL, 2015) |
| "This article aims to describe neonatal outcomes, clinical correlates, and the rate for neonatal abstinence syndrome (NAS) for women on methadone maintenance therapy." | 7.81 | Maternal methadone treatment and neonatal abstinence syndrome. ( Faisal, M; Li, S; Liu, WF; Singh, K, 2015) |
| "To evaluate neonatal abstinence syndrome (NAS) treatment outcomes achieved using an optimized methadone weaning protocol developed using pharmacokinetic (PK) modeling compared with standard methadone weaning." | 7.81 | Cohort Analysis of a Pharmacokinetic-Modeled Methadone Weaning Optimization for Neonatal Abstinence Syndrome. ( Hall, ES; Meinzen-Derr, J; Wexelblatt, SL, 2015) |
| "The primary objective was to determine whether oral morphine sulfate contributed to decreased length of stay, both in the hospital and neonatal intensive care unit (NICU), when compared to oral methadone for the treatment of neonatal abstinence syndrome (NAS)." | 7.81 | Retrospective chart review comparing morphine and methadone in neonates treated for neonatal abstinence syndrome. ( Hager, SJ; Spurlock, D; Young, ME, 2015) |
| "To evaluate the effectiveness of methadone for the treatment of neonatal abstinence syndrome when used according to a preexisting clinical pathway." | 7.80 | Effectiveness of a clinical pathway with methadone treatment protocol for treatment of neonatal abstinence syndrome following in utero drug exposure to substances of abuse*. ( Bhatt-Mehta, V; Ng, CM; Schumacher, RE, 2014) |
| "The recommended standard of care calls for treating opioid-dependent pregnant women with methadone and observing neonates exposed in utero for five to seven postnatal days to see if treatment for neonatal abstinence syndrome (NAS) is needed." | 7.79 | Time to initiation of treatment for neonatal abstinence syndrome in neonates exposed in utero to buprenorphine or methadone. ( Badger, GJ; Gaalema, DE; Heil, SH; Johnston, AM; Metayer, JS, 2013) |
| "In a tertiary neonatal care center in Taiwan, three neonates whose mothers self-reported heroin abuse with methadone treatment during pregnancy were studied." | 7.78 | Perinatal effects of combined use of heroin, methadone, and amphetamine during pregnancy and quantitative measurement of metabolites in hair. ( Chang, YZ; Chen, JY; Chen, SC; Ng, YY; Su, PH; Yang, C, 2012) |
| "To identify maternal and neonatal factors that impact response to methadone therapy for neonatal abstinence syndrome." | 7.77 | Maternal and neonatal factors impacting response to methadone therapy in infants treated for neonatal abstinence syndrome. ( Akinbi, H; Isemann, B; Meinzen-Derr, J, 2011) |
| "Determine whether infants exposed to chronic maternal methadone with abnormal intrapartum fetal heart rate (FHR) patterns are more likely to require treatment for neonatal abstinence syndrome (NAS)." | 7.77 | Association between intrapartum fetal heart rate patterns and neonatal abstinence syndrome in methadone exposed neonates. ( Albright, B; Brown, SA; Hsi, A; Leeman, LM; Rayburn, WF; Skipper, B, 2011) |
| "05), birth weight, and neonatal morbidities were similar regardless of the maternal methadone dose." | 7.77 | Higher maternal doses of methadone does not increase neonatal abstinence syndrome. ( Bombrys, A; Grier, M; Habli, M; Livingston, J; Pizarro, D; Sibai, B, 2011) |
| "This study suggests that a treatment of neonatal abstinence syndrome with clonidine in omission of opiates is possible without causing short-term adverse cardiovascular effects." | 7.76 | Treatment of neonatal abstinence syndrome with clonidine and chloral hydrate. ( Bastanier, C; Beske, F; Esmaeili, A; Keinhorst, AK; Schlösser, R; Schuster, T, 2010) |
| "To estimate the relationship between maternal methadone dose and the incidence of neonatal abstinence syndrome (NAS)." | 7.76 | Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome. ( Almario, CV; Baxter, JK; Berghella, V; Dysart, KC; Hayes, EJ; Seligman, NS, 2010) |
| "Methadone is standard pharmacotherapy for opioid-dependent pregnant women, yet the relationship between maternal methadone dose and neonatal abstinence syndrome (NAS) severity is still unclear." | 7.76 | Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome. ( Choo, RE; Concheiro, M; Elko, A; Gray, TR; Huestis, MA; Jansson, LM; Jones, HE; Williams, E, 2010) |
| "The purpose of this study was to examine high-dose methadone in pregnant women and its effect on the duration of neonatal abstinence syndrome." | 7.75 | High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome. ( Cordero, L; Gardner, DK; Lim, S; Prasad, MR; Samuels, P, 2009) |
| "Four hundred and fifty singleton pregnancies of drug-misusing women prescribed substitute methadone in pregnancy." | 7.75 | Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. ( Dryden, C; Hepburn, M; Mactier, H; Young, D, 2009) |
| "We determined the effect of preterm delivery on the course of neonatal abstinence syndrome (NAS) in infants born to mothers participating in a methadone maintenance program." | 7.74 | Sequela of preterm versus term infants born to mothers on a methadone maintenance program: differential course of neonatal abstinence syndrome. ( Dysart, K; Greenspan, JS; Hsieh, HC; Kaltenbach, K, 2007) |
| "Data from this non-randomized comparison suggest that buprenorphine may offer advantages for treatment of opiate dependence during pregnancy." | 7.74 | Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. ( Heilig, M; Kakko, J; Sarman, I, 2008) |
| "The aim of the study was to analyze the neonatal impact of a methadone maintenance program in pregnancy, and the social resources of the families involved." | 7.73 | Methadone maintenance program in pregnancy in a Swiss perinatal center (II): neonatal outcome and social resources. ( Arlettaz, R; Bucher, HU; Das-Kundu, S; Fauchère, JC; Kashiwagi, M; Lang, A, 2005) |
| "This study assesses the effect of higher doses of methadone during pregnancy on maternal and fetal outcomes." | 7.73 | High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. ( Anania, B; Leamon, MH; McCarthy, JJ; Parr, MS, 2005) |
| "Length of hospital stay (LOS) of infants treated for neonatal abstinence syndrome (NAS) with methadone was compared to LOS of those treated with an oral morphine preparation (OMP, neonatal morphine solution, or deodorized tincture of opium)." | 7.73 | A retrospective study of length of hospital stay in infants treated for neonatal abstinence syndrome with methadone versus oral morphine preparations. ( Blackwell, MT; Brown, ER; Hagadorn, JI; Lainwala, S; Weinschenk, NP, 2005) |
| "To assess the usefulness of cord and serum methadone concentrations at 2 days of age in predicting the severity of neonatal abstinence syndrome (NAS) in infants whose mothers received methadone during pregnancy." | 7.72 | Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome? ( Austerberry, L; Cornwell, M; Couch, R; Kuschel, CA; Rowley, RS, 2004) |
| "Methadone was also associated with reduced median LOS (16 vs 20 days, P = ." | 6.87 | Comparison of Safety and Efficacy of Methadone vs Morphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Clinical Trial. ( Bogen, D; Breeze, JL; Czynski, A; D'Apolito, K; Davis, JM; Engelhardt, B; Harvey-Wilkes, K; Hudak, M; Lester, B; Marro, P; Oliveira, EL; Shenberger, J; Terrin, N; Wachman, EM, 2018) |
| "Methadone is an opioid analgesic commonly prescribed for pharmacologic management of NAS." | 5.56 | Utilizing Pediatric Physiologically Based Pharmacokinetic Models to Examine Factors That Contribute to Methadone Pharmacokinetic Variability in Neonatal Abstinence Syndrome Patients. ( Akinbi, H; Butler, D; Emoto, C; Fukuda, T; McPhail, BT; Vinks, AA; Wiles, JR, 2020) |
| "Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome NCT02851303 , initiated 01/08/2016." | 5.51 | Morphine versus methadone for neonatal opioid withdrawal syndrome: a randomized controlled pilot study. ( Leeman, L; Sutter, MB; Watson, H; Weitzen, S; Yonke, N, 2022) |
| "Weight loss was less in small for gestational age compared to appropriately grown infants (p<0." | 5.38 | Postnatal weight loss in substitute methadone-exposed infants: implications for the management of breast feeding. ( Campbell, N; Dryden, C; Mactier, H; Young, D, 2012) |
| "Pregnancy care for these women needs to continue to develop to improve overall outcomes." | 5.38 | Maternal and neonatal outcomes following methadone substitution during pregnancy. ( Ash, A; Douiri, A; Greig, E, 2012) |
| " A picture of one of each infant's eyes was taken under controlled illumination conditions with a standard digital camera just prior to dosing and 0-1, 2-4, 5-7, and 8-10h after dosing." | 5.38 | Infant pupillary response to methadone administration during treatment for neonatal abstinence syndrome: a feasibility study. ( Badger, GJ; Gaalema, DE; Heil, SH; Higgins, ST; Johnston, AM; Sigmon, SC, 2012) |
| " Maternal opiate dosing has been investigated with conflicting results." | 5.36 | Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy. ( Cook, CM; Jones, MP; Liu, AJ; Murray, H; Nanan, R, 2010) |
| "Eight sites enrolled 116 full-term newborn infants with neonatal abstinence syndrome born to mothers maintained on methadone or buprenorphine into a randomized trial of morphine vs methadone." | 5.34 | Neurodevelopmental Outcomes of Neonates Randomized to Morphine or Methadone for Treatment of Neonatal Abstinence Syndrome. ( Bogen, DL; Czynski, AJ; Dansereau, LM; Davis, JM; Engelhardt, B; Hudak, ML; Lester, BM; Marro, P; Oliveira, EL; Shenberger, J; Wachman, EM, 2020) |
| "Newborns who are prenatally exposed to methadone are at risk for neonatal abstinence syndrome and the associated excess weight loss and poor weight gain." | 5.27 | Randomized Clinical Trial of Standard- Versus High-Calorie Formula for Methadone-Exposed Infants: A Feasibility Study. ( Baker, R; Bogen, DL; Cohlan, B; Hanusa, BH; Medoff-Cooper, B, 2018) |
| "Methadone and buprenorphine are recommended to treat opioid use disorders during pregnancy." | 5.27 | Prenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes. ( Coyle, MG; Fischer, G; Heil, SH; Jones, HE; Kaltenbach, K; Martin, PR; O'Grady, KE; Salisbury, AL; Stine, S, 2018) |
| "Compare duration of treatment of neonatal abstinence syndrome between methadone and morphine." | 5.20 | Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. ( Brown, MS; Hayes, MJ; Thornton, LM, 2015) |
| "To characterize the population pharmacokinetics of oral methadone in neonates requiring pharmacologic treatment of neonatal abstinence syndrome and to develop a pharmacokinetic (PK) model toward an evidence-based treatment protocol." | 5.20 | Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study. ( Akinbi, H; Isemann, B; Mizuno, T; Tabangin, ME; Vinks, AA; Ward, LP; Wiles, JR, 2015) |
| " While methadone-maintenance currently is the standard of care for opioid dependence during pregnancy, research suggests that buprenorphine-maintenance may be associated with shorter infant hospital lengths of stay (LOS) relative to methadone-maintenance." | 5.19 | Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome. ( Hall, ES; Lewis, D; Marcotte, M; Theobald, J; Van Hook, J; Wexelblatt, SL; Wilder, C; Winhusen, T, 2014) |
| "To identify factors that predict the expression of neonatal abstinence syndrome (NAS) in infants exposed to methadone or buprenorphine in utero." | 5.16 | Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. ( Coyle, MG; Heil, SH; Holbrook, AM; Jones, HE; Kaltenbach, K; Martin, PR; Salisbury, AL; Stine, SM, 2012) |
| "To compare the profile of signs of neonatal abstinence syndrome (NAS) in methadone- versus buprenorphine-exposed infants." | 5.16 | Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. ( Arria, AM; Badger, GJ; Coyle, MG; Gaalema, DE; Heil, SH; Jones, HE; Kaltenbach, K; Martin, PR; Scott, TL; Stine, SM, 2012) |
| " Methadone maintenance yielded to a significantly higher neonatal birth weight." | 5.15 | Randomized controlled trials in pregnancy: scientific and ethical aspects. Exposure to different opioid medications during pregnancy in an intra-individual comparison. ( Arria, A; Aschauer, C; Bäwert, A; Fischer, G; Jagsch, R; Jones, H; Leitich, H; Rohrmeister, K; Unger, A; Winklbaur, B, 2011) |
| "In order to investigate the effects of exposure to buprenorphine compared with methadone during pregnancy, a prospective multicenter study was conducted in collaboration with maternity hospitals, maintenance therapy centers, and general practitioners involved in addiction care." | 5.15 | Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. ( Berrebi, A; Chaumerliac, C; Damase-Michel, C; Garipuy, D; Hammou, Y; Lacroix, I; Lapeyre-Mestre, M; Montastruc, JL; Schmitt, L, 2011) |
| "One hundred and fourteen subjects were included in the analysis, with 77 in SP (n = 51 methadone, n = 26 buprenorphine), and 37 in CT (n = 19 methadone, n = 18 buprenorphine), comparing maternal concomitant consumption during third trimester, demographic birth data, duration of treatment for neonatal abstinence syndrome (NAS), morphine dose for NAS treatment and length of hospital stay (LOS)." | 5.15 | Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women. ( Aschauer, C; Ebner, N; Fischer, G; Jagsch, R; Metz, V; Pribasnig, A; Würzl, J, 2011) |
| "This was a secondary analysis of data collected in a prospective randomized, double-blind, double-dummy, multicenter trial (MOTHER study) that examined the comparative safety and efficacy of methadone and buprenorphine during pregnancy." | 5.15 | Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates? ( Bäwert, A; Coyle, M; Fischer, G; Jagsch, R; Martin, PR; Rohrmeister, K; Unger, A; Winklbaur, B, 2011) |
| "To determine if oral clonidine would reduce the duration of opioid detoxification for neonatal abstinence syndrome." | 5.14 | Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. ( Agthe, AG; Chavez-Valdez, R; Gauda, EB; Hendrix, CW; Jansson, L; Kim, GR; Lewis, TR; Mathias, KB; Yaster, M, 2009) |
| "Methadone, a full mu-opioid agonist, is the recommended treatment for opioid dependence during pregnancy." | 5.14 | Neonatal abstinence syndrome after methadone or buprenorphine exposure. ( Arria, AM; Coyle, MG; Fischer, G; Heil, SH; Jones, HE; Kaltenbach, K; Martin, PR; O'Grady, KE; Selby, P; Stine, SM, 2010) |
| " Free and total buprenorphine and norbuprenorphine, nicotine, opiates, cocaine, benzodiazepines, and metabolites were quantified in meconium from 10 infants born to women who had received buprenorphine during pregnancy." | 5.13 | Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. ( Choo, RE; Huestis, MA; Johnson, RE; Jones, HE; Kacinko, SL, 2008) |
| "The aim of the study was to evaluate the effect of substitution therapy in heroin addicted pregnant women on the course of pregnancy, perinatal outcomes and course of the neonatal abstinence syndrome." | 5.13 | Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the ( Binder, T; Vavrinková, B, 2008) |
| "Eighteen women were assigned randomly to receive either methadone (n = 9) or buprenorphine (n = 9) during weeks 24-29 of pregnancy." | 5.12 | Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. ( Aschauer, H; Baewert, A; Fischer, G; Jagsch, R; Langer, M; Ortner, R; Rohrmeister, K, 2006) |
| " The mothers received methadone (n=22), slow-release oral morphine (n=17) or buprenorphine (n=14) throughout pregnancy." | 5.12 | Management of neonatal abstinence syndrome in neonates born to opioid maintained women. ( Baewert, A; Ebner, N; Fischer, G; Jagsch, R; Peternell, A; Rohrmeister, K; Thau, K; Winklbaur, B, 2007) |
| "Though methadone pharmacotherapy is the treatment of choice for opiate-dependence during pregnancy in the USA, most methadone-exposed neonates develop neonatal abstinence syndrome (NAS)." | 5.12 | Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates. ( Dipietro, JA; Elko, A; Jansson, LM; Velez, M, 2007) |
| "Treating opioid-addicted women with methadone in pregnancy increased the number of newborns suffering from neonatal abstinence syndrome (NAS)." | 5.11 | Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. ( Birkenfeld, L; Hellmich, M; Herkenrath, P; Langenfeld, S; Müller, C; Theisohn, M, 2005) |
| "This study was designed to compare the neonatal abstinence syndrome (NAS) in neonates of methadone and buprenorphine maintained pregnant opioid-dependent women and to provide preliminary safety and efficacy data for a larger multi-center trial." | 5.11 | Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. ( Chisholm, CA; Choo, RE; Crocetti, M; Dudas, R; Harrow, C; Huestis, MA; Jansson, LM; Jasinski, DR; Johnson, RE; Jones, HE; Lantz, M; Lester, BM; Milio, L; O'Grady, KE, 2005) |
| "To investigate whether the neonatal abstinence syndrome (NAS) is different in children born to women maintained on slow-release morphine, compared with those maintained on methadone, and to compare additional drug consumption in these groups of women." | 5.09 | Comparison of methadone and slow-release morphine maintenance in pregnant addicts. ( Aschauer, HN; Eder, H; Etzersdorfer, P; Fischer, G; Gombas, W; Jagsch, R; Schatten, C; Schmidl-Mohl, K; Weninger, M, 1999) |
| "To determine whether morphine has better outcomes for neonatal abstinence syndrome treatment than methadone." | 5.01 | Methadone versus morphine treatment outcomes in neonatal abstinence syndrome: A meta-analysis. ( Xiao, F; Yan, K; Zhou, W, 2019) |
| "To compare the effects of morphine and methadone on length of hospital stay (LOS) or treatment (LOT) and adverse effects in infants with neonatal abstinence syndrome (NAS)." | 4.98 | Morphine and Methadone for Neonatal Abstinence Syndrome: A Systematic Review. ( Gregory, PJ; Hein, DJ; Risoldi Cochrane, Z; Slowiczek, L, 2018) |
| "A literature search of PubMed (1966 to March 2016) and EMBASE (1973 to March 2016) was completed using the search terms buprenorphine, methadone, pregnancy, opioid, and neonatal abstinence syndrome Priority was given to randomized controlled trials and trials directly comparing buprenorphine and methadone during pregnancy." | 4.93 | Buprenorphine Versus Methadone for Opioid Dependence in Pregnancy. ( Campbell, K; Crannage, E; Forinash, A; Noormohammadi, A; Shyken, J; Yancey, A, 2016) |
| "Parents of infants with neonatal abstinence syndrome (NAS) in the NICU may have questions about the long-term consequences of prenatal exposure to methadone, both asked and unasked." | 4.93 | Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome. ( Armstrong, K; Brooks, SS; Clark, L; Cline, GJ; Germain, AM; Maguire, DJ; Shaffer-Hudkins, E; Taylor, S, 2016) |
| "Buprenorphine and methadone are opioid-receptor agonists used as opioid substitution therapy during pregnancy to limit exposure of the fetus to cycles of opioid withdrawal and reduce the risk of infectious comorbidities of illicit opioid use." | 4.90 | Buprenorphine and methadone for opioid addiction during pregnancy. ( Mozurkewich, EL; Rayburn, WF, 2014) |
| "The present paper considers naltrexone to treat opioid dependence during pregnancy." | 4.89 | Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research. ( Chisolm, MS; Jansson, LM; Jones, HE; Terplan, M, 2013) |
| " The standard of care for illicit or prescription opioid dependence during pregnancy is opioid agonist (methadone or buprenorphine) substitution therapy, which are also frequently abused." | 4.89 | Novel pharmacotherapeutic strategies for treatment of opioid-induced neonatal abstinence syndrome. ( Gauda, EB; Jones, CH; Lewis, T; McLemore, GL, 2013) |
| "This article provides an overview and discussion of the collective maternal, fetal and neonatal outcome research on women maintained on methadone or buprenorphine during pregnancy." | 4.88 | Methadone and buprenorphine for the management of opioid dependence in pregnancy. ( Finnegan, LP; Jones, HE; Kaltenbach, K, 2012) |
| "While buprenorphine produces a less severe neonatal abstinence syndrome than methadone, both methadone and buprenorphine are important parts of a complete comprehensive treatment approach for opioid-dependent pregnant women." | 4.88 | Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. ( Arria, AM; Baewert, A; Coyle, MG; Fischer, G; Heil, SH; Jones, HE; Kaltenbach, K; Martin, PR; Selby, P; Stine, SM, 2012) |
| "After completing this CME activity, physicians should be better able to assess the treatment options available to patients with opioid addiction during pregnancy, compare the risk/safety profiles of methadone and buprenorphine, and evaluate the recommendations and current data surrounding breast-feeding while on opioid maintenance treatment." | 4.88 | Opioid addiction in pregnancy. ( Lee-Parritz, A; Saia, K; Shainker, SA, 2012) |
| "This manuscript provides an overview of the current scientific literature on the impact of maternal drug use, specifically opioids and cocaine, during pregnancy on the acute and long-term outcomes of infants and toddlers from birth through age 3 years." | 4.86 | Prenatal drug exposure: infant and toddler outcomes. ( Accornero, VH; Bandstra, ES; Mansoor, E; Morrow, CE, 2010) |
| "To determine if there is a relationship between maternal methadone dose in pregnancy and the diagnosis or medical treatment of neonatal abstinence syndrome (NAS)." | 4.86 | Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. ( Clarke, M; Cleary, BJ; Donnelly, J; Fahey, T; Gallagher, PJ; Murphy, DJ; Strawbridge, J, 2010) |
| "In the twenty years since the first case of neonatal drug addiction (resulting from the mother's use during pregnancy of morphine, heroin, methadone, cocaine) was referred to our attention, there has been a steady increase in the number of cases per year." | 4.80 | Neonatal drug addiction. ( Fabris, C; Perathoner, C; Prandi, G; Soldi, A, 1998) |
| "Of 400 eligible pregnancies, 85 and 137 individuals received buprenorphine and methadone, respectively, during early pregnancy." | 4.31 | Comparative Safety Analysis of Opioid Agonist Treatment in Pregnant Women with Opioid Use Disorder: A Population-Based Study. ( Brothers, TN; Hartzema, A; Lewkowitz, AK; Meador, KJ; Pawasauskas, J; Quilliam, BJ; Wang, S; Ward, KE; Wen, X, 2023) |
| " Research consistently demonstrates the efficacy of medications for OUD (MOUD); however, researchers have called for additional studies evaluating the safety of MOUD during pregnancy, particularly the relative safety of two commonly used MOUD medications-methadone and buprenorphine." | 4.12 | A retrospective, observational study on medication for opioid use disorder during pregnancy and risk for neonatal abstinence syndrome. ( Aujla, R; Boyars, L; Cleary, E; Douglas, E; Guille, C; Smith, C; Sujan, A, 2022) |
| " Opioid exposure during pregnancy included 16 202 pregnancies exposed to codeine, 4540 to oxycodone, 1244 to tramadol, 260 to methadone (dispensed for pain), 90 to hydromorphone, and 63 to morphine compared with 25 710 exposed to hydrocodone." | 4.12 | Characteristics of Prescription Opioid Analgesics in Pregnancy and Risk of Neonatal Opioid Withdrawal Syndrome in Newborns. ( Bateman, BT; Esposito, DB; Hernández-Díaz, S; Huybrechts, KF; Mogun, H; Straub, L; Werler, MM, 2022) |
| "To examine the evidence for emerging treatment options, buprenorphine or clonidine, as monotherapy for the treatment of neonatal abstinence syndrome (NAS) against standards of care, morphine or methadone." | 4.12 | Emerging therapies for the treatment of neonatal abstinence syndrome. ( Bobby, LE; Frazier, LM; Gawronski, KM, 2022) |
| "The aim of the study is to assess the correlation between maternal methadone dose and severity of neonatal abstinence syndrome (NAS) in infants that required pharmacological treatment for NAS." | 4.12 | Is Maternal Methadone Dose Associated with the Severity of Neonatal Abstinence Syndrome? ( Adeniyi-Jones, S; Aghai, ZH; Boelig, RC; Carola, D; Greenspan, JS; Kraft, WK; Lafferty, M; Smith, J, 2022) |
| "In our theoretical cohort, treatment of OUD with buprenorphine during pregnancy resulted in 2413 fewer cases of neonatal opioid withdrawal syndrome, 1089 fewer preterm births, 299 fewer cases of fetal growth restriction, 32 fewer stillbirths, and 13 fewer cases of cerebral palsy compared to methadone treatment." | 4.12 | Cost effectiveness of buprenorphine vs. methadone for pregnant people with opioid use disorder. ( Caughey, AB; Hersh, AR; John, C; Robin, AM, 2022) |
| " Treatment with buprenorphine-naloxone (compared with methadone) reduced odds of each outcome including neonatal abstinence syndrome (adjusted odds ratio: 0." | 4.02 | Opioid Use Disorder and Perinatal Outcomes. ( Homayra, F; Marchand, C; Mead, A; Min, JE; Ng, J; Nosyk, B; Piske, M; Woolner, M; Zhou, H, 2021) |
| "This pilot study evaluated the relationship between maternal and neonatal R- and S-methadone and R- and S-2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) exposure and the severity of neonatal abstinence syndrome (NAS)." | 4.02 | Stereoselective Analysis of Methadone and EDDP in Laboring Women and Neonates in Plasma and Dried Blood Spots and Association with Neonatal Abstinence Syndrome. ( Evrard, CA; Haas, DM; Haneline, LS; Jones, DR; Masters, AR; Metzger, IF; Quinney, SK; Thomas, AE, 2021) |
| "To compare clonidine versus phenobarbital as adjunctive therapy in infants who failed monotherapy with morphine for neonatal abstinence syndrome (NAS)." | 3.96 | Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. ( Brusseau, C; Burnette, T; Heidel, RE, 2020) |
| " Furthermore, buprenorphine is associated with milder symptoms of neonatal abstinence syndrome (NAS) compared with methadone." | 3.96 | Prevalence and Geographic Distribution of Obstetrician-Gynecologists Who Treat Medicaid Enrollees and Are Trained to Prescribe Buprenorphine. ( Culhane, J; Meisel, ZF; Nguemeni Tiako, MJ; South, E; Srinivas, SK, 2020) |
| "The mainstay of the management of opioid use disorder in pregnancy is with methadone or buprenorphine medication-assisted treatment." | 3.96 | Use of naltrexone in treating opioid use disorder in pregnancy. ( Katz, E; Towers, CV; Visconti, K; Weitz, B, 2020) |
| "There is lack of knowledge about the safety of treatment with methadone and buprenorphine as part of opioid maintenance treatment (OMT) during pregnancy." | 3.91 | Prenatal exposure to opioid maintenance treatment and neonatal outcomes: Nationwide registry studies from the Czech Republic and Norway. ( Engeland, A; Gabrhelík, R; Handal, M; Lund, IO; Mravčík, V; Nechanská, B; Skurtveit, S, 2019) |
| " We present a case report of a neonate born to a 25-year-old mother enrolled in a medication-assisted treatment program for substance use disorder who was noncompliant in prenatal care, using multiple substances throughout the pregnancy, including gabapentin and fentanyl." | 3.91 | Novel Withdrawal Symptoms of a Neonate Prenatally Exposed to a Fentanyl Analog. ( Davies, TH; Hansen, Z; Loudin, S; Murray, S; Nellhaus, EM, 2019) |
| "A dramatic increase in newborn infants with neonatal abstinence syndrome has been observed and these neonates are frequently treated with complex methadone dosing schemes to control their withdrawal symptoms." | 3.91 | Methadone dosing strategies in preterm neonates can be simplified. ( Bordbar, A; Kalani, M; Koch, G; Pfister, M; Samiee-Zafarghandy, S; van den Anker, J; van Donge, T, 2019) |
| "To assess safety and effectiveness of transitioning from methadone to buprenorphine when necessary during pregnancy." | 3.88 | Transitioning from methadone to buprenorphine maintenance in management of opioid use disorder during pregnancy. ( Johnson, S; Martin, PR, 2018) |
| "Antenatal exposure to methadone or buprenorphine often causes neonatal abstinence syndrome (NAS) in newborns." | 3.88 | Antenatal methadone vs buprenorphine exposure and length of hospital stay in infants admitted to the intensive care unit with neonatal abstinence syndrome. ( Benjamin, DK; Bennett, MM; Clark, RH; Miller, ES; Murthy, K; Smith, PB; Tolia, VN, 2018) |
| "Our objective was to estimate the association between methadone and neonatal abstinence syndrome compared with buprenorphine using a probabilistic bias analysis to account for unmeasured confounding by severity of addiction." | 3.88 | Methadone Versus Buprenorphine for Opioid Use Dependence and Risk of Neonatal Abstinence Syndrome. ( Bodnar, LM; Caritis, SN; Lemon, LS; Platt, RW; Venkataramanan, R, 2018) |
| " The objective of this study was to compare duration of opioid treatment and length of stay outcomes for neonatal abstinence syndrome (NAS) using sublingual buprenorphine versus traditional weaning with methadone or morphine." | 3.88 | Comparison of Neonatal Abstinence Syndrome Treatment with Sublingual Buprenorphine versus Conventional Opioids. ( Folger, AT; Hall, ES; Rice, WR; Wexelblatt, SL, 2018) |
| "Two national cohorts of women receiving opioid maintenance treatment during pregnancy showed small but not statistically significant differences in neonatal outcomes in favour of buprenorphine compared with methadone." | 3.88 | Neonatal outcomes after fetal exposure to methadone and buprenorphine: national registry studies from the Czech Republic and Norway. ( Engeland, A; Gabrhelík, R; Handal, M; Lund, IO; Mravčík, V; Nechanská, B; Skurtveit, S, 2018) |
| " When medically indicated, limiting use of multiple psychiatric medications, particularly benzodiazepines and gabapentin, during pregnancy should be considered to improve NAS outcomes." | 3.88 | Impact of psychiatric medication co-exposure on Neonatal Abstinence Syndrome severity. ( Nikita, FNU; Saia, K; Schiff, DM; Shaw, D; Shrestha, H; Thomas, Z; Thomas-Lewis, JA; Wachman, EM; Warden, AH, 2018) |
| "To estimate the relationship of initial pharmacotherapy with methadone or morphine and length of stay (LOS) in infants with neonatal abstinence syndrome (NAS) admitted to the neonatal intensive care unit (NICU)." | 3.88 | Morphine vs Methadone Treatment for Infants with Neonatal Abstinence Syndrome. ( Benjamin, DK; Bennett, MM; Clark, RH; Greenberg, RG; Murthy, K; Smith, PB; Tolia, VN, 2018) |
| "Through retrospective chart review, this study described characteristics and length of stay for a cohort of newborns discharged on methadone following an inpatient weaning for neonatal abstinence syndrome (NAS)." | 3.85 | An Outpatient Methadone Weaning Program by a Neonatal Intensive Care Unit for Neonatal Abstinence Syndrome. ( Boucher, J; Lai, A; Meyer, A; Philpot, P, 2017) |
| "The use of implant naltrexone during pregnancy was not associated with higher rates of negative birth outcomes compared with methadone- and buprenorphine-exposed neonates." | 3.85 | A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates. ( Hulse, G; Kelty, E, 2017) |
| "To report the presentation and characteristics of strabismus in children with prenatal methadone exposure." | 3.85 | Sensorimotor outcomes in children with prenatal exposure to methadone. ( Jansson, LM; Park, HJ; Yoo, SH, 2017) |
| "Maternal buprenorphine maintenance predisposes the infant to exhibit neonatal abstinence syndrome (NAS), but there is insufficient published information regarding the nature of NAS and factors that contribute to its severity in buprenorphine-exposed infants." | 3.85 | Maternal buprenorphine treatment and infant outcome. ( DiPietro, JA; Gandotra, N; Jansson, LM; Jones, H; King, VL; McConnell, K; Millio, L; Rios, R; Spencer, N; Tuten, M; Velez, ML, 2017) |
| "The development, characterization and stability evaluation of methadone (MI, MII, MIII) and phenobarbital (PI, PII) can be used for the treatment of neonatal abstinence syndrome (NAS)." | 3.83 | Design of pediatric oral formulations with a low proportion of methadone or phenobarbital for the treatment of neonatal abstinence syndrome. ( Calpena, AC; Clares, B; Mallandrich, M; Provenza, N; Pueyo, B, 2016) |
| "To compare the duration of opioid treatment and length of stay among infants treated for neonatal abstinence syndrome (NAS) by using a pilot buprenorphine vs conventional methadone treatment protocol." | 3.83 | A Cohort Comparison of Buprenorphine versus Methadone Treatment for Neonatal Abstinence Syndrome. ( Akinbi, HT; Hall, ES; Harvey, S; Isemann, BT; Meinzen-Derr, J; Wexelblatt, SL; Wiles, JR, 2016) |
| "To compare neonatal abstinence syndrome prevalence and characteristics among neonates born to women prescribed buprenorphine and naloxone compared with methadone during pregnancy." | 3.81 | Buprenorphine and naloxone compared with methadone treatment in pregnancy. ( Jones, H; Seashore, C; Stringer, EM; Stuebe, AM; Thorp, J; Wiegand, SL, 2015) |
| "This article aims to describe neonatal outcomes, clinical correlates, and the rate for neonatal abstinence syndrome (NAS) for women on methadone maintenance therapy." | 3.81 | Maternal methadone treatment and neonatal abstinence syndrome. ( Faisal, M; Li, S; Liu, WF; Singh, K, 2015) |
| "Pregnant women filling at least one prescription for an opioid analgesic at any time during pregnancy for whom opioid exposure characteristics including duration of therapy: short term (<30 days) or long term (≥ 30 days); timing of use: early use (only in the first two trimesters) or late use (extending into the third trimester); and cumulative dose (in morphine equivalent milligrams) were assessed." | 3.81 | Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study. ( Bateman, BT; Desai, RJ; Hernandez-Diaz, S; Huybrechts, KF; Kaltenbach, K; Kerzner, LS; Mogun, H; Patorno, E, 2015) |
| "To describe obstetrical and neonatal outcomes including neonatal abstinence syndrome (NAS) in a Canadian cohort of methadone-maintained pregnant women." | 3.81 | Obstetrical and neonatal outcomes of methadone-maintained pregnant women: a canadian multisite cohort study. ( Abrahams, R; Graves, L; Kahan, M; Kim, T; Ordean, A, 2015) |
| "To evaluate neonatal abstinence syndrome (NAS) treatment outcomes achieved using an optimized methadone weaning protocol developed using pharmacokinetic (PK) modeling compared with standard methadone weaning." | 3.81 | Cohort Analysis of a Pharmacokinetic-Modeled Methadone Weaning Optimization for Neonatal Abstinence Syndrome. ( Hall, ES; Meinzen-Derr, J; Wexelblatt, SL, 2015) |
| "The primary objective was to determine whether oral morphine sulfate contributed to decreased length of stay, both in the hospital and neonatal intensive care unit (NICU), when compared to oral methadone for the treatment of neonatal abstinence syndrome (NAS)." | 3.81 | Retrospective chart review comparing morphine and methadone in neonates treated for neonatal abstinence syndrome. ( Hager, SJ; Spurlock, D; Young, ME, 2015) |
| "To evaluate the effectiveness of methadone for the treatment of neonatal abstinence syndrome when used according to a preexisting clinical pathway." | 3.80 | Effectiveness of a clinical pathway with methadone treatment protocol for treatment of neonatal abstinence syndrome following in utero drug exposure to substances of abuse*. ( Bhatt-Mehta, V; Ng, CM; Schumacher, RE, 2014) |
| "The recommended standard of care calls for treating opioid-dependent pregnant women with methadone and observing neonates exposed in utero for five to seven postnatal days to see if treatment for neonatal abstinence syndrome (NAS) is needed." | 3.79 | Time to initiation of treatment for neonatal abstinence syndrome in neonates exposed in utero to buprenorphine or methadone. ( Badger, GJ; Gaalema, DE; Heil, SH; Johnston, AM; Metayer, JS, 2013) |
| "In Norway, most opioid-dependent women are in opioid maintenance treatment (OMT) with either methadone or buprenorphine throughout pregnancy." | 3.79 | Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009. ( Bakstad, B; Bjarkø, L; Jones, HE; Ravndal, E; Skurtveit, S; Waal, H; Welle-Strand, GK, 2013) |
| "This study aimed to (i) describe methadone dosing before, during and after pregnancy, (ii) to compare the incidence of neonatal abstinence syndrome (NAS) between those with dose decreases and those with steady or increasing doses and (iii) to describe prescribed medication use among opioid-dependent pregnant women." | 3.79 | Methadone dosing and prescribed medication use in a prospective cohort of opioid-dependent pregnant women. ( Carmody, D; Clarke, T; Cleary, BJ; Eogan, M; Fahey, T; Gallagher, PJ; Gleeson, J; McDermott, C; Murphy, DJ; O'Connell, MP; O'Sullivan, A; Reynolds, K; White, MJ, 2013) |
| " Methadone use in pregnancy has been associated with adverse perinatal outcomes and neonatal abstinence syndrome (NAS)." | 3.78 | Methadone and perinatal outcomes: a prospective cohort study. ( Carmody, D; Clarke, T; Cleary, BJ; Eogan, M; Fahey, T; Gallagher, PJ; Gleeson, J; McDermott, C; Murphy, DJ; O'Connell, MP; O'Sullivan, A; White, MJ, 2012) |
| "One hundred fifty-two opioid-dependent pregnant women on methadone maintenance therapy (MMT) (n = 136) or buprenorphine maintenance therapy (BMT) (n = 16) during pregnancy and their neonates." | 3.78 | Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome. ( Hayes, MJ; Paul, JA; Pritham, UA, 2012) |
| "In a tertiary neonatal care center in Taiwan, three neonates whose mothers self-reported heroin abuse with methadone treatment during pregnancy were studied." | 3.78 | Perinatal effects of combined use of heroin, methadone, and amphetamine during pregnancy and quantitative measurement of metabolites in hair. ( Chang, YZ; Chen, JY; Chen, SC; Ng, YY; Su, PH; Yang, C, 2012) |
| "To identify maternal and neonatal factors that impact response to methadone therapy for neonatal abstinence syndrome." | 3.77 | Maternal and neonatal factors impacting response to methadone therapy in infants treated for neonatal abstinence syndrome. ( Akinbi, H; Isemann, B; Meinzen-Derr, J, 2011) |
| "Determine whether infants exposed to chronic maternal methadone with abnormal intrapartum fetal heart rate (FHR) patterns are more likely to require treatment for neonatal abstinence syndrome (NAS)." | 3.77 | Association between intrapartum fetal heart rate patterns and neonatal abstinence syndrome in methadone exposed neonates. ( Albright, B; Brown, SA; Hsi, A; Leeman, LM; Rayburn, WF; Skipper, B, 2011) |
| "The purpose of this study was to examine the relationship among methadone maintenance treatment, perinatal outcomes, and neonatal abstinence syndrome." | 3.77 | Methadone and perinatal outcomes: a retrospective cohort study. ( Cleary, BJ; Donnelly, JM; Fahey, T; Gallagher, PJ; Murphy, DJ; Strawbridge, JD; White, MJ, 2011) |
| "05), birth weight, and neonatal morbidities were similar regardless of the maternal methadone dose." | 3.77 | Higher maternal doses of methadone does not increase neonatal abstinence syndrome. ( Bombrys, A; Grier, M; Habli, M; Livingston, J; Pizarro, D; Sibai, B, 2011) |
| "To examine the relationship between maternal opioid agonists, methadone, or buprenorphine (BPH), and concurrent psychiatric medication use on length of hospitalization (LOS) among infants with neonatal abstinence syndrome (NAS)." | 3.77 | The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome. ( Bauchner, H; Bonzagni, A; Byun, J; Newby, PK; Philipp, BL; Vreeland, J; Wachman, EM, 2011) |
| "Twenty-eight term infants that were exposed to methadone in utero and exhibited symptoms of neonatal abstinence syndrome (NAS) prior to hospital discharge were included into the study." | 3.77 | The impact of infant feeding method on neonatal abstinence scores of methadone-exposed infants. ( Gerlach, K; McQueen, KA; Montelpare, W; Murphy-Oikonen, J, 2011) |
| "This study suggests that a treatment of neonatal abstinence syndrome with clonidine in omission of opiates is possible without causing short-term adverse cardiovascular effects." | 3.76 | Treatment of neonatal abstinence syndrome with clonidine and chloral hydrate. ( Bastanier, C; Beske, F; Esmaeili, A; Keinhorst, AK; Schlösser, R; Schuster, T, 2010) |
| "To estimate the relationship between maternal methadone dose and the incidence of neonatal abstinence syndrome (NAS)." | 3.76 | Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome. ( Almario, CV; Baxter, JK; Berghella, V; Dysart, KC; Hayes, EJ; Seligman, NS, 2010) |
| "Methadone is standard pharmacotherapy for opioid-dependent pregnant women, yet the relationship between maternal methadone dose and neonatal abstinence syndrome (NAS) severity is still unclear." | 3.76 | Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome. ( Choo, RE; Concheiro, M; Elko, A; Gray, TR; Huestis, MA; Jansson, LM; Jones, HE; Williams, E, 2010) |
| "The purpose of this study was to examine high-dose methadone in pregnant women and its effect on the duration of neonatal abstinence syndrome." | 3.75 | High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome. ( Cordero, L; Gardner, DK; Lim, S; Prasad, MR; Samuels, P, 2009) |
| "Four hundred and fifty singleton pregnancies of drug-misusing women prescribed substitute methadone in pregnancy." | 3.75 | Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. ( Dryden, C; Hepburn, M; Mactier, H; Young, D, 2009) |
| " This study investigated whether maternal methadone/buprenorphine dose and nicotine use in pregnancy affects the occurrence and duration of neonatal abstinence syndrome (NAS) in the infant." | 3.75 | Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study. ( Bakstad, B; Ravndal, E; Sarfi, M; Welle-Strand, GK, 2009) |
| "Retrospective cohort study of 232 metropolitan and 67 rural infants born to mothers maintained on methadone throughout pregnancy for the treatment of opiate dependency, between January 2000 and December 2006." | 3.75 | Pregnancy and neonatal characteristics of opioid-dependent Indigenous Australians: a rural and metropolitan comparison. ( An, EI; Canalese, J; Liu, AJ; Nanan, R; Tetstall, E, 2009) |
| "Majority of neonates born to mothers on methadone exhibit neonatal abstinence syndrome and require pharmacological treatment." | 3.74 | Neonatal abstinence syndrome. ( Kurian, O; Serane, VT, 2008) |
| " Maternal and neonatal outcomes were evaluated, including cholestasis of pregnancy, preterm birth, low birth weight, neonatal intensive care unit admissions, and neonatal methadone withdrawal." | 3.74 | Chronic hepatitis C in pregnancy. ( Arora, S; Berkley, EM; Dunkelberg, JC; Leslie, KK; Qualls, C, 2008) |
| " Use of heroin alone during pregnancy was recorded in 51 women (50%), methadone alone in 6 (7%), and a combination of heroin and methadone in 9 (11%)." | 3.74 | Maternal and neonatal effects of substance abuse during pregnancy: our ten-year experience. ( Banovic, I; Bucat, M; Capkun, V; Roje, D; Vucinovic, M; Vucinovic, Z, 2008) |
| "Descriptive analysis of data in live births of women enrolled in a methadone maintenance programme in 1991-1994 (n = 78) and 1997-2001 (n = 98), including time spent in hospital, treatment for neonatal abstinence syndrome (NAS), admission to the neonatal medical unit (NMU) and follow-up for child health checks." | 3.74 | Methadone-exposed newborn infants: outcome after alterations to a service for mothers and infants. ( D'Souza, SW; Macrory, F; Miles, J; Sims, DG; Sugumar, K, 2007) |
| "We determined the effect of preterm delivery on the course of neonatal abstinence syndrome (NAS) in infants born to mothers participating in a methadone maintenance program." | 3.74 | Sequela of preterm versus term infants born to mothers on a methadone maintenance program: differential course of neonatal abstinence syndrome. ( Dysart, K; Greenspan, JS; Hsieh, HC; Kaltenbach, K, 2007) |
| "The objective of this study was to determine the population prevalence and correlates of neonatal abstinence syndrome among neonates born to women on methadone, using a cross-sectional analysis of linked population health data." | 3.74 | Using population data to examine the prevalence and correlates of neonatal abstinence syndrome. ( Burns, L; Mattick, RP, 2007) |
| "We selected 32 women in the city of Vancouver known to have used heroin or methadone during pregnancy between October 2001 and December 2002." | 3.74 | Rooming-in compared with standard care for newborns of mothers using methadone or heroin. ( Abrahams, RR; Janssen, PA; Kelly, SA; Mackintosh, J; Payne, S; Thiessen, PN, 2007) |
| "Statistically birth weight of newborns was significantly lowest in the group of heroin-addicted women as compared to the group receiving substitution with buprenorphine p<0." | 3.74 | [The effect of substitution therapy on the birth weight of the newborn, its postpartum adaptation, trophic and course of the neonatal abstinence syndrome]. ( Binder, T; Vavrinková, B, 2007) |
| "This study was undertaken to evaluate the adequacy of a hospital formulated oral morphine preparation for management of neonatal abstinence syndrome (NAS) and to compare clinical features in infants exposed to methadone or buprenorphine in utero." | 3.74 | Hospital morphine preparation for abstinence syndrome in newborns exposed to buprenorphine or methadone. ( Bues-Charbit, M; Busuttil, M; Colombini, N; Dubuc, M; Einaudi, MA; Elias, R, 2008) |
| "To assess potential risks related to the duration or total amount of fetal methadone exposure during gestation, we compared babies of women who conceived and maintained on methadone throughout pregnancy with babies of women who began methadone treatment during the second or third trimester." | 3.74 | Outcomes of neonates conceived on methadone maintenance therapy. ( Biles, LA; Leamon, MH; McCarthy, JJ; Stenson, G, 2008) |
| "Data from this non-randomized comparison suggest that buprenorphine may offer advantages for treatment of opiate dependence during pregnancy." | 3.74 | Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. ( Heilig, M; Kakko, J; Sarman, I, 2008) |
| "The aim of the study was to analyze the neonatal impact of a methadone maintenance program in pregnancy, and the social resources of the families involved." | 3.73 | Methadone maintenance program in pregnancy in a Swiss perinatal center (II): neonatal outcome and social resources. ( Arlettaz, R; Bucher, HU; Das-Kundu, S; Fauchère, JC; Kashiwagi, M; Lang, A, 2005) |
| "This study assesses the effect of higher doses of methadone during pregnancy on maternal and fetal outcomes." | 3.73 | High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. ( Anania, B; Leamon, MH; McCarthy, JJ; Parr, MS, 2005) |
| " Women who took heroin in later pregnancy were significantly more likely than women who were stabilised on methadone to have a baby who needed morphine (40% versus 19%), had higher mean maximum neonatal abstinence scores (NAS) (5." | 3.73 | Pregnancy outcome in women who use opiates. ( Armstrong, D; Fajemirokun-Odudeyi, O; Lindow, SW; Pairaudeau, P; Phillips, T; Sinha, C; Tutty, S, 2006) |
| "Length of hospital stay (LOS) of infants treated for neonatal abstinence syndrome (NAS) with methadone was compared to LOS of those treated with an oral morphine preparation (OMP, neonatal morphine solution, or deodorized tincture of opium)." | 3.73 | A retrospective study of length of hospital stay in infants treated for neonatal abstinence syndrome with methadone versus oral morphine preparations. ( Blackwell, MT; Brown, ER; Hagadorn, JI; Lainwala, S; Weinschenk, NP, 2005) |
| "To assess the usefulness of cord and serum methadone concentrations at 2 days of age in predicting the severity of neonatal abstinence syndrome (NAS) in infants whose mothers received methadone during pregnancy." | 3.72 | Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome? ( Austerberry, L; Cornwell, M; Couch, R; Kuschel, CA; Rowley, RS, 2004) |
| "Neonatal abstinence syndrome is seen commonly in infants born to women on methadone maintenance." | 3.70 | Neonatal abstinence syndrome following abrupt cessation of breastfeeding. ( Darlow, BA; Malpas, TJ, 1999) |
| "Lower peak doses of TOS and shorter dosing intervals may be associated with shorter hospital stays for infants with neonatal abstinence syndrome secondary to maternal methadone treatment." | 3.70 | Shorter dosing interval of opiate solution shortens hospital stay for methadone babies. ( Jones, HC, 1999) |
| " The drug-dependent women had used combinations of methadone, heroin, cocaine and other drugs during pregnancy." | 3.69 | Development after prenatal exposure to cocaine, heroin and methadone. ( Akkerhuis, GW; Gunning, WB; Soepatmi, S; van Baar, AL, 1994) |
| "A prospective longitudinal study on the development of children of drug-dependent mothers who used combinations of cocaine, heroin and methadone during pregnancy was carried out in Amsterdam." | 3.69 | Cognitive development at preschool-age of infants of drug-dependent mothers. ( de Graaff, BM; van Baar, A, 1994) |
| " Persistent weight retardation at 12 months was correlated with methadone dosage during pregnancy, but not the need for phenobarbitone therapy." | 3.69 | Infants born to narcotic dependent mothers: physical growth patterns in the first 12 months of life. ( Chant, DC; Gray, PH; Hayes, AJ; Tudehope, DI; Vance, JC, 1997) |
| "This spectrum of relationships supports the concept that careful reduction of the maternal methadone dosage during pregnancy under intensive medical and psychosocial surveillance may benefit the drug-exposed new-born infant clinically." | 3.68 | Relationship between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal. ( Doberczak, TM; Friedmann, P; Kandall, SR, 1993) |
| "This report describes a case in which cocaine abuse during pregnancy was related temporally to abruptio placentae, preterm labour and to rapid delivery." | 3.67 | Perinatal cocaine intoxication. ( Collins, E; Hardwick, RJ; Jeffery, H, 1989) |
| "In 50 infants born to women who continued to take heroin during all or part of their pregnancy the drug withdrawal symptoms were mild and were noted in 21 infants (42%)." | 3.67 | Maternal narcotic abuse and the newborn. ( Alroomi, LG; Davidson, J; Evans, TJ; Galea, P; Howat, R, 1988) |
| "Methadone was also associated with reduced median LOS (16 vs 20 days, P = ." | 2.87 | Comparison of Safety and Efficacy of Methadone vs Morphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Clinical Trial. ( Bogen, D; Breeze, JL; Czynski, A; D'Apolito, K; Davis, JM; Engelhardt, B; Harvey-Wilkes, K; Hudak, M; Lester, B; Marro, P; Oliveira, EL; Shenberger, J; Terrin, N; Wachman, EM, 2018) |
| " This review discusses the utility of pharmacometric techniques for enhancing precision dosing in infants requiring opioid treatment for NOWS." | 2.72 | Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches. ( Akinbi, H; Butler, D; Emoto, C; Fukuda, T; McPhail, BT; Vinks, AA, 2021) |
| "Perinatal prognosis of pregnant drug abusers is better with intensive prenatal care and substitution maintenance programs." | 2.70 | [Withdrawal syndromes of newborns of pregnant drug abusers maintained under methadone or high-dose buprenorphine: 246 cases]. ( Aubisson, S; Cneude, F; Gourarier, L; Lejeune, C; Piquet, M; Simmat-Durand, L, 2001) |
| "15 l kg-1 day-1 and a bioavailability of 100% was 17." | 2.68 | Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme. ( Dusci, LJ; Hackett, LP; Ilett, KF; Kristensen, JH; Wojnar-Horton, RE; Yapp, P, 1997) |
| "Opioid use during pregnancy has serious consequences for mother and baby." | 2.66 | Management and monitoring of opioid use in pregnancy. ( Ibsen, IO; Jørgensen, JS; Lamont, RF; Rausgaard, NLK; Ravn, P, 2020) |
| "Treatment with buprenorphine or methadone is associated with NOWS, but neither medication appears to have significant adverse effects on early childhood development." | 2.61 | Opioid Use in Pregnancy. ( Forray, A; Habecker, E; Tobon, AL, 2019) |
| "Neonatal abstinence syndrome is defined by signs and symptoms of withdrawal that infants develop after intrauterine maternal drug exposure." | 2.61 | Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS). ( Kraft, WK; Mangat, AK; Schmölzer, GM, 2019) |
| "When opioid misuse rises in the United States, pregnant women and their neonates are affected." | 2.61 | Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome. ( Jones, HE; Kraft, WK, 2019) |
| "Clonidine was a significantly better adjunctive therapy than phenobarbital in reducing morphine treatment days." | 2.61 | Therapeutic approaches for neonatal abstinence syndrome: a systematic review of randomized clinical trials. ( Ghazanfarpour, M; Keramat-Roudi, A; Mashhadi, ME; Mégarbane, B; Moghaddam, MMM; Najafi, MN; Rezaee, R; Roozbeh, N; Tsatsakis, A, 2019) |
| "Buprenorphine was associated with the shortest overall durations of treatment and hospitalization." | 2.61 | Comparative effectiveness of opioid replacement agents for neonatal opioid withdrawal syndrome: a systematic review and meta-analysis. ( Chen, J; Davis, JM; Eisler, L; Lee, JJ; Li, G; Sun, LS, 2019) |
| "Options for treatment of opioid dependence, acute pain management, and perioperative multimodal analgesia are discussed." | 2.55 | Peripartum Anesthetic Management of the Opioid-tolerant or Buprenorphine/Suboxone-dependent Patient. ( Pan, A; Zakowski, M, 2017) |
| "Methadone is a valid option, but its safety profile is not completely known." | 2.55 | Neonatal Abstinence Syndrome: Update on Diagnostic and Therapeutic Strategies. ( Agosti, M; Allegaert, K; Cavallaro, G; Fumagalli, M; Mosca, F; Raffaeli, G; Tibboel, D; Wildschut, ED, 2017) |
| "Pregnant women with opioid use disorder can be treated with methadone, buprenorphine, or naltrexone to reduce opioid use and improve retention to treatment." | 2.55 | Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women. ( Griffin, BL; Stone, RH; Todd, TJ; Tran, TH; Vest, KM, 2017) |
| "Recommendations and options for treating postoperative pain in patients on methadone and buprenorphine are outlined below." | 2.53 | New Pain Management Options for the Surgical Patient on Methadone and Buprenorphine. ( Arulkumar, S; Cornett, EM; Flower, RR; Fox, CJ; Gayle, JA; Kaye, AD; Sen, S, 2016) |
| "Buprenorphine is a newer treatment for maternal opioid addiction and appears to result in a milder withdrawal syndrome than methadone." | 2.50 | Neonatal opioid withdrawal syndrome. ( Hsi, A; Leeman, L; Sutter, MB, 2014) |
| "A standard protocol to treat neonatal abstinence syndrome has not been developed." | 2.49 | Management of neonatal abstinence syndrome from opioids. ( Grim, K; Harrison, TE; Wilder, RT, 2013) |
| "Managing opioid dependence in pregnant women is a complex and potentially challenging task." | 2.49 | Managing opioid dependence in pregnancy -- a general practice perspective. ( Arunogiri, S; Foo, L; Frei, M; Lubman, DI, 2013) |
| "Neonatal abstinence syndrome has become a growing concern in infants born to substance-abusing mothers in the State of Florida." | 2.49 | Pharmacologic management of neonatal abstinence syndrome in a community hospital. ( Calhoun, DA; Napolitano, A; Seng, SK; Theophilopoulos, D, 2013) |
| "Methadone is a long-acting synthetic opioid with high affinity for various opioid receptors, especially for m-opioid receptors." | 2.45 | [Methadone treatment and its dangers]. ( Jodziūniene, L; Lazauskas, R; Reingardiene, D, 2009) |
| "Methadone maintenance for the treatment of opioid dependence is described in this article." | 2.40 | Opioid dependence during pregnancy. Effects and management. ( Berghella, V; Finnegan, L; Kaltenbach, K, 1998) |
| " There were no significant differences in NOWS hospital outcomes between groups in adjusted models: transition to scheduled dosing (methadone 31." | 1.72 | Neonatal Opioid Withdrawal Syndrome: A Comparison of As-Needed Pharmacotherapy. ( Gupta, M; MacMillan, KDL; Melvin, P; Morrison, TM; Murzycki, J; O'Shea, TF; Rothstein, R; Schiff, DM; Singh, R; Van Vleet, MW; Wachman, EM, 2022) |
| "Mothers who screen positive for opioid abuse should be referred to a provider experienced in opioid maintenance therapy." | 1.62 | Neonatal Abstinence Syndrome: Prevention, Recognition, Treatment, and Follow-up. ( Schroeder, M; White, J, 2021) |
| "Women with histories of opioid misuse face drug-related stigma, which can be amplified during pregnancy." | 1.62 | Conceptualizing stigma in contexts of pregnancy and opioid misuse: A qualitative study with women and healthcare providers in Ohio. ( Clapp, J; Howard, H; Madden, D; Spadola, C; Syvertsen, JL; Toneff, H, 2021) |
| "Longer duration of medication for opioid use disorder use during pregnancy appears to be associated with improved maternal and perinatal outcomes." | 1.62 | Outcomes associated with the use of medications for opioid use disorder during pregnancy. ( Chen, Q; James, AE; Jarlenski, MP; Kelley, D; Kim, JY; Krans, EE; Rothenberger, SD, 2021) |
| "Methadone is an opioid analgesic commonly prescribed for pharmacologic management of NAS." | 1.56 | Utilizing Pediatric Physiologically Based Pharmacokinetic Models to Examine Factors That Contribute to Methadone Pharmacokinetic Variability in Neonatal Abstinence Syndrome Patients. ( Akinbi, H; Butler, D; Emoto, C; Fukuda, T; McPhail, BT; Vinks, AA; Wiles, JR, 2020) |
| "Neonatal abstinence syndrome is an array of signs and symptoms experienced by a newborn due to abrupt discontinuation of intrauterine exposure to certain drugs, primarily opioids." | 1.56 | Screening for Opioid and Stimulant Exposure In Utero Through Targeted and Untargeted Metabolomics Analysis of Umbilical Cords. ( Danell, AS; Forbes, L; Kew, K; Kuehn, D; Mamillapalli, SS; May, L; McIntyre, K; Poppenfuse, S; Ravisankar, S; Rushing, B; Smith-Joyner, A; Strom, C, 2020) |
| "The methadone group had a lower mean newborn birthweight (2874±459 g) and a greater incidence of low birth weight (11." | 1.56 | Comparison of buprenorphine and methadone in the management of maternal opioid use disorder in full term pregnancies. ( Davis, JA; Garretto, D; Garry, ET; Herrera, KM; Ly, V; Staszewski, CL, 2020) |
| "Preterm birth is associated with less risk of neonatal abstinence syndrome (NAS)." | 1.48 | The Role of Preterm Birth in the Association Between Opioid Maintenance Therapy and Neonatal Abstinence Syndrome. ( Bodnar, LM; Caritis, SN; Lemon, LS; Naimi, A; Platt, RW; Venkataramanan, R, 2018) |
| "Participants were recruited from an opioid dependence treatment center in an urban setting in the Southeastern United States." | 1.48 | Barriers and Facilitators of Breastfeeding Reported by Postpartum Women in Methadone Maintenance Therapy. ( Hicks, J; Morse, E; Wyant, DK, 2018) |
| " With no difference in medical and safety outcomes and a significant reduction in charges, the MAiN model can be considered safe and cost-effective." | 1.48 | Early Treatment Innovation for Opioid-Dependent Newborns: A Retrospective Comparison of Outcomes, Utilization, Quality, and Safety, 2006-2014. ( Charron, E; Chen, L; Dickes, L; Hudson, JA; Mayo, R; Sherrill, WW; Summey, J, 2018) |
| "Methadone was most frequently used for prenatal opioid dependence; there was little buprenorphine or buprenorphine + naloxone use." | 1.46 | Infants Born to Opioid-Dependent Women in Ontario, 2002-2014. ( Brogly, SB; Davies, G; Dow, K; Johnson, A; Lajkosz, K; Newman, A; Turner, S, 2017) |
| "Poly-drug exposed infants and those treated for neonatal abstinence syndrome performed significantly poorer (p=0." | 1.42 | Infants of opioid-dependent mothers: neurodevelopment at six months. ( Mactier, H; McGlone, L, 2015) |
| "Pregnancy is an opportune time to identify opioid dependence, facilitate conversion to opioid maintenance treatment, and coordinate care with specialists in addiction medicine, behavioral health, and social services." | 1.42 | Caring for Opioid-dependent Pregnant Women: Prenatal and Postpartum Care Considerations. ( Bogen, DL; Cochran, G; Krans, EE, 2015) |
| "Methadone treatment was not found to increase the treatment requirement for neonatal abstinence syndrome compared with those using heroin only (P = 0." | 1.39 | Predictors of neonatal outcomes amongst a methadone- and/or heroin-dependent population referred to a multidisciplinary Perinatal and Family Drug Health Service. ( Buckley, V; Haber, P; Razaghi, A, 2013) |
| "Weight loss was less in small for gestational age compared to appropriately grown infants (p<0." | 1.38 | Postnatal weight loss in substitute methadone-exposed infants: implications for the management of breast feeding. ( Campbell, N; Dryden, C; Mactier, H; Young, D, 2012) |
| "Neonatal abstinence syndrome is an expected and treatable condition that follows prenatal exposure to opioid agonists." | 1.38 | ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy. ( , 2012) |
| "Our findings suggest a role for our rooming-in program in mitigating the relationship between maternal methadone dosage and the need to treat opiate withdrawal in the newborn." | 1.38 | A rooming-in program to mitigate the need to treat for opiate withdrawal in the newborn. ( Abrahams, RR; Hodgson, ZG, 2012) |
| "The prevalence of opioid abuse is increasing in North America." | 1.38 | Are infants exposed to methadone in utero at an increased risk for mortality? ( Bridgman-Acker, K; Kelly, LE; Koren, G; Lauwers, A; Madadi, P; Rieder, MJ, 2012) |
| "Pregnancy care for these women needs to continue to develop to improve overall outcomes." | 1.38 | Maternal and neonatal outcomes following methadone substitution during pregnancy. ( Ash, A; Douiri, A; Greig, E, 2012) |
| "Buprenorphine as maintenance treatment of opioid dependence during pregnancy has promise and may offer some benefits, but more research is needed, especially regarding induction of actively addicted women during pregnancy." | 1.38 | Treatment of opioid dependence in the setting of pregnancy. ( Martin, PR; Young, JL, 2012) |
| " A picture of one of each infant's eyes was taken under controlled illumination conditions with a standard digital camera just prior to dosing and 0-1, 2-4, 5-7, and 8-10h after dosing." | 1.38 | Infant pupillary response to methadone administration during treatment for neonatal abstinence syndrome: a feasibility study. ( Badger, GJ; Gaalema, DE; Heil, SH; Higgins, ST; Johnston, AM; Sigmon, SC, 2012) |
| "R-Methadone concentration was 1." | 1.37 | Estimated infant exposure to enantiomer-specific methadone levels in breastmilk. ( Bogen, DL; Hanusa, BH; Helsel, JC; Perel, JM; Thompson, M; Wisner, KL, 2011) |
| " Maternal opiate dosing has been investigated with conflicting results." | 1.36 | Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy. ( Cook, CM; Jones, MP; Liu, AJ; Murray, H; Nanan, R, 2010) |
| "Morphine sulphate was the most commonly used first line agent for both opiate (92%) and polysubstance (69%) withdrawal." | 1.35 | Management of neonatal abstinence syndrome: a national survey and review of practice. ( Hopewell, J; O'Grady, MJ; White, MJ, 2009) |
| "During pregnancy, drug addiction represents one of the most dangerous situations." | 1.35 | Drug addiction during pregnancy: correlations between the placental health and the newborn's outcome - elaboration of a predictive score. ( Boldrini, A; Cuttano, A; Domenici, C; Ghirri, P; Nardini, V; Varese, L, 2009) |
| "They were also offered residential treatment before pregnancy and after the child was born." | 1.35 | Patterns in sleep-wakefulness in three-month old infants exposed to methadone or buprenorphine. ( Bakstad, B; Martinsen, H; Røislien, J; Sarfi, M; Waal, H, 2009) |
| "To determine the monitoring and treatment of neonatal abstinence syndrome (NAS) in neonatal intensive care units (NICUs) following opiate or polydrug exposure in utero." | 1.33 | Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. ( Donn, SM; Sarkar, S, 2006) |
| "Symptoms of the neonatal withdrawal syndrome are excitation of the central nervous system, the gastrointestinal tract and the respiratory tract." | 1.33 | [A multidisciplinary approach is necessary in the neonatal withdrawal syndrome]. ( Clement-de Boers, A; de Vries, MC; Leeuwenburgh-Pronk, WG, 2006) |
| "The purpose of this study was to determine whether maternal methadone dosage correlates with neonatal withdrawal in a large heroin-addicted pregnant population." | 1.32 | Maternal methadone dose and neonatal withdrawal. ( Berghella, V; Chennat, J; Cherpes, J; Hill, MK; Kaltenbach, K; Lim, PJ, 2003) |
| " Daily supervised dosing by a pharmacist for the first six months resulted in significantly better treatment retention (80% vs 46%) and lower heroin use." | 1.32 | French field experience with buprenorphine. ( Auriacombe, M; Daulouède, JP; Dubernet, J; Fatséas, M; Tignol, J, 2004) |
| "Methadone dosage was also correlated with both duration of neonatal hospitalization and neonatal abstinence score (r(s) =." | 1.31 | Relationship between maternal methadone dosage and neonatal withdrawal. ( Dashe, JS; Jackson, GL; Olscher, DA; Sheffield, JS; Todd, SJ; Wendel, GD, 2002) |
| "Methadone exposed pups were more active and vocalized more when injected with naltrexone than with saline." | 1.30 | Neonatal withdrawal following pre- and postnatal exposure to methadone in the rat. ( Barr, GA; Hamowy, AS; Hutchings, DE; Liu, PY; Wang, S; Zmitrovich, A, 1998) |
| "The aim of this study was to assess the influence of maternal methadone dosage on the severity of neonatal withdrawal." | 1.29 | Maternal methadone dosage and neonatal withdrawal. ( Darlow, BA; Horwood, LJ; Lennox, R; Malpas, TJ, 1995) |
| "Heroin (88%) was the most popular drug." | 1.29 | [The clinical and epidemiological aspects of the neonatal abstinence syndrome]. ( Arrate-Zugazabeitia, JK; Delgado-Rubio, A; Echaniz-Urcelay, I; Fortea-Jimeno, E; Pérez-Bescos, L; Saitua-Iturriaga, G, 1993) |
| " However, cocaine exposed infants did not require more medication for withdrawal management either in terms of dosage or of days treated." | 1.29 | Neonatal withdrawal syndrome in infants exposed to cocaine and methadone. ( Carroll, KM; Mayes, LC, 1996) |
| " The severity of abstinence symptoms correlated with maternal methadone dosage in both term and preterm infants." | 1.28 | Neonatal opiate abstinence syndrome in term and preterm infants. ( Doberczak, TM; Kandall, SR; Wilets, I, 1991) |
| "The increased rate of prematurity, intrauterine growth retardation, and perinatal complications associated with perinatal exposure to cocaine or methamphetamine was greater than that predicted by coexisting risk factors and was consistent with the pharmacologic properties of these drugs." | 1.27 | Perinatal cocaine and methamphetamine exposure: maternal and neonatal correlates. ( Dixon, SD; Oro, AS, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (3.28) | 18.7374 |
| 1990's | 45 (12.30) | 18.2507 |
| 2000's | 75 (20.49) | 29.6817 |
| 2010's | 191 (52.19) | 24.3611 |
| 2020's | 43 (11.75) | 2.80 |
| Authors | Studies |
|---|---|
| Piske, M | 1 |
| Homayra, F | 1 |
| Min, JE | 1 |
| Zhou, H | 1 |
| Marchand, C | 1 |
| Mead, A | 1 |
| Ng, J | 1 |
| Woolner, M | 1 |
| Nosyk, B | 1 |
| Mossabeb, R | 1 |
| Sowti, K | 1 |
| Sujan, A | 1 |
| Cleary, E | 1 |
| Douglas, E | 1 |
| Aujla, R | 1 |
| Boyars, L | 2 |
| Smith, C | 1 |
| Guille, C | 2 |
| Devlin, LA | 2 |
| Young, LW | 1 |
| Kraft, WK | 5 |
| Wachman, EM | 15 |
| Czynski, A | 3 |
| Merhar, SL | 1 |
| Winhusen, T | 2 |
| Jones, HE | 23 |
| Poindexter, BB | 1 |
| Wakschlag, LS | 1 |
| Salisbury, AL | 4 |
| Matthews, AG | 1 |
| Davis, JM | 5 |
| Schroeder, M | 1 |
| White, J | 1 |
| Morrison, TM | 1 |
| MacMillan, KDL | 3 |
| Melvin, P | 1 |
| Singh, R | 1 |
| Murzycki, J | 1 |
| Van Vleet, MW | 1 |
| Rothstein, R | 1 |
| O'Shea, TF | 1 |
| Gupta, M | 1 |
| Schiff, DM | 5 |
| Sutter, MB | 2 |
| Watson, H | 1 |
| Yonke, N | 1 |
| Weitzen, S | 1 |
| Leeman, L | 3 |
| Esposito, DB | 1 |
| Huybrechts, KF | 2 |
| Werler, MM | 1 |
| Straub, L | 1 |
| Hernández-Díaz, S | 3 |
| Mogun, H | 2 |
| Bateman, BT | 2 |
| Ronan, K | 1 |
| Hughes Driscoll, CA | 1 |
| Decker, E | 1 |
| Gopalakrishnan, M | 1 |
| El Metwally, D | 1 |
| Wang, S | 2 |
| Meador, KJ | 1 |
| Pawasauskas, J | 1 |
| Lewkowitz, AK | 1 |
| Ward, KE | 1 |
| Brothers, TN | 1 |
| Hartzema, A | 2 |
| Quilliam, BJ | 1 |
| Wen, X | 1 |
| Lee, JJ | 2 |
| Saraiya, N | 1 |
| Kuzniewicz, MW | 1 |
| Heller, NA | 3 |
| Logan, BA | 4 |
| Shrestha, H | 5 |
| Morrison, DG | 3 |
| Hayes, MJ | 6 |
| Laptook, A | 1 |
| Das, A | 1 |
| Smith, B | 1 |
| Simon, A | 1 |
| Greenberg, R | 1 |
| Annett, R | 1 |
| Lee, J | 2 |
| Snowden, J | 1 |
| Pedroza, C | 1 |
| Lester, B | 4 |
| Eggleston, B | 1 |
| Bremer, D | 1 |
| McGowan, E | 1 |
| Rajalingam, D | 1 |
| Boix, F | 1 |
| Khoder, A | 1 |
| Andersen, JM | 1 |
| Paulsen, RE | 1 |
| Handal, M | 2 |
| Nechanská, B | 2 |
| Skurtveit, S | 4 |
| Lund, IO | 2 |
| Gabrhelík, R | 2 |
| Engeland, A | 2 |
| Mravčík, V | 2 |
| Minear, S | 4 |
| Xiao, F | 1 |
| Yan, K | 1 |
| Zhou, W | 1 |
| Metpally, RP | 1 |
| Krishnamurthy, S | 1 |
| Moran, KM | 1 |
| Weller, AE | 1 |
| Crist, RC | 1 |
| Reiner, BC | 1 |
| Doyle, GA | 1 |
| Ferraro, TN | 1 |
| Radhakrishna, U | 1 |
| Bahado-Singh, R | 1 |
| Troiani, V | 1 |
| Berrettini, WH | 1 |
| Tobon, AL | 1 |
| Habecker, E | 1 |
| Forray, A | 1 |
| Bivin, B | 1 |
| Waring, A | 1 |
| Alves, P | 1 |
| McPhail, BT | 2 |
| Emoto, C | 2 |
| Fukuda, T | 2 |
| Butler, D | 2 |
| Wiles, JR | 3 |
| Akinbi, H | 4 |
| Vinks, AA | 3 |
| Oberoi, R | 1 |
| Chu, T | 1 |
| Mellen, N | 1 |
| Jagadapillai, R | 1 |
| Ouyang, H | 1 |
| Cai, J | 1 |
| Khan, L | 1 |
| Czynski, AJ | 2 |
| Dansereau, LM | 2 |
| Engelhardt, B | 2 |
| Marro, P | 2 |
| Bogen, DL | 4 |
| Hudak, ML | 1 |
| Shenberger, J | 2 |
| Oliveira, EL | 3 |
| Lester, BM | 4 |
| Metzger, IF | 1 |
| Thomas, AE | 1 |
| Evrard, CA | 1 |
| Jones, DR | 1 |
| Masters, AR | 1 |
| Haas, DM | 1 |
| Haneline, LS | 1 |
| Quinney, SK | 1 |
| Mamillapalli, SS | 1 |
| Smith-Joyner, A | 1 |
| Forbes, L | 1 |
| McIntyre, K | 1 |
| Poppenfuse, S | 1 |
| Rushing, B | 1 |
| Strom, C | 1 |
| Danell, AS | 1 |
| May, L | 1 |
| Kuehn, D | 1 |
| Kew, K | 1 |
| Ravisankar, S | 1 |
| Frazier, LM | 1 |
| Bobby, LE | 1 |
| Gawronski, KM | 1 |
| Andrews, L | 1 |
| Davies, TH | 2 |
| Haas, J | 1 |
| Loudin, S | 3 |
| Heyward, A | 1 |
| Werthammer, J | 2 |
| Brusseau, C | 1 |
| Burnette, T | 2 |
| Heidel, RE | 1 |
| McDaniel, CE | 1 |
| Test, M | 1 |
| Deodhar, P | 1 |
| Jennings, R | 1 |
| Bove, J | 1 |
| Carlin, K | 1 |
| Staszewski, CL | 1 |
| Garretto, D | 1 |
| Garry, ET | 1 |
| Ly, V | 1 |
| Davis, JA | 1 |
| Herrera, KM | 1 |
| Ma, J | 1 |
| Sahasranaman, V | 1 |
| Kirby, RS | 1 |
| Boaz, T | 1 |
| Brown, HL | 1 |
| Goyal, NK | 1 |
| Kair, LR | 1 |
| Flannery, T | 1 |
| Camardo, SA | 1 |
| Kaplan, HC | 1 |
| Kuhnell, P | 1 |
| Walsh, MC | 3 |
| Crowley, M | 3 |
| McClead, R | 1 |
| Wexelblatt, S | 1 |
| Ford, S | 1 |
| Provost, LP | 1 |
| Lannon, C | 1 |
| Macaluso, M | 1 |
| Wouldes, TA | 1 |
| Woodward, LJ | 1 |
| Curran, M | 1 |
| Holt, C | 1 |
| Arciero, M | 1 |
| Quinlan, J | 1 |
| Cox, D | 1 |
| Craig, A | 1 |
| Nguemeni Tiako, MJ | 1 |
| Culhane, J | 1 |
| South, E | 1 |
| Srinivas, SK | 1 |
| Meisel, ZF | 1 |
| Smith, J | 1 |
| Lafferty, M | 1 |
| Boelig, RC | 1 |
| Carola, D | 1 |
| Adeniyi-Jones, S | 1 |
| Greenspan, JS | 2 |
| Aghai, ZH | 1 |
| Andenes, M | 1 |
| Sævold, E | 1 |
| Griffiths, ST | 1 |
| Sirnes, E | 1 |
| Robin, AM | 1 |
| Hersh, AR | 1 |
| John, C | 1 |
| Caughey, AB | 1 |
| Syvertsen, JL | 1 |
| Toneff, H | 1 |
| Howard, H | 1 |
| Spadola, C | 1 |
| Madden, D | 1 |
| Clapp, J | 1 |
| Krans, EE | 2 |
| Kim, JY | 1 |
| Chen, Q | 1 |
| Rothenberger, SD | 1 |
| James, AE | 1 |
| Kelley, D | 1 |
| Jarlenski, MP | 1 |
| Flanagan, KE | 1 |
| Lal, K | 1 |
| Blankenship, K | 1 |
| Gorji, N | 1 |
| Rork, J | 1 |
| Wiss, K | 1 |
| Zankl, A | 1 |
| Martin, J | 1 |
| Davey, JG | 1 |
| Osborn, DA | 1 |
| Mactier, H | 6 |
| McLaughlin, P | 1 |
| Gillis, C | 1 |
| Osselton, MD | 1 |
| Brogly, SB | 5 |
| Turner, S | 1 |
| Lajkosz, K | 1 |
| Davies, G | 2 |
| Newman, A | 2 |
| Johnson, A | 1 |
| Dow, K | 2 |
| Pan, A | 1 |
| Zakowski, M | 1 |
| Brandt, L | 1 |
| Finnegan, LP | 2 |
| Lai, A | 1 |
| Philpot, P | 1 |
| Boucher, J | 1 |
| Meyer, A | 1 |
| Raffaeli, G | 1 |
| Cavallaro, G | 1 |
| Allegaert, K | 3 |
| Wildschut, ED | 1 |
| Fumagalli, M | 1 |
| Agosti, M | 1 |
| Tibboel, D | 2 |
| Mosca, F | 1 |
| Kelty, E | 1 |
| Hulse, G | 1 |
| Tran, TH | 1 |
| Griffin, BL | 1 |
| Stone, RH | 1 |
| Vest, KM | 1 |
| Todd, TJ | 1 |
| Paul, JA | 3 |
| Brown, MS | 5 |
| Grossman, MR | 3 |
| Berkwitt, AK | 2 |
| Osborn, RR | 2 |
| Xu, Y | 1 |
| Esserman, DA | 1 |
| Shapiro, ED | 1 |
| Bizzarro, MJ | 1 |
| Yoo, SH | 1 |
| Jansson, LM | 13 |
| Park, HJ | 1 |
| Johnson, S | 1 |
| Martin, PR | 8 |
| Velez, ML | 3 |
| McConnell, K | 1 |
| Spencer, N | 1 |
| Tuten, M | 1 |
| Jones, H | 3 |
| Rios, R | 1 |
| King, VL | 1 |
| Gandotra, N | 1 |
| Millio, L | 1 |
| DiPietro, JA | 3 |
| Christiansen, S | 1 |
| Adeniyi-Jones, SC | 1 |
| Ehrlich, ME | 1 |
| Whalen, B | 2 |
| MacMillan, K | 1 |
| Edwards, W | 1 |
| Ohler, KH | 1 |
| Pham, JT | 1 |
| Tolia, VN | 2 |
| Murthy, K | 2 |
| Bennett, MM | 2 |
| Miller, ES | 1 |
| Benjamin, DK | 2 |
| Smith, PB | 2 |
| Clark, RH | 2 |
| Lemon, LS | 2 |
| Caritis, SN | 2 |
| Venkataramanan, R | 2 |
| Platt, RW | 2 |
| Bodnar, LM | 2 |
| Hall, ES | 6 |
| Rice, WR | 1 |
| Folger, AT | 1 |
| Wexelblatt, SL | 6 |
| Hanusa, BH | 2 |
| Baker, R | 1 |
| Medoff-Cooper, B | 1 |
| Cohlan, B | 1 |
| Naimi, A | 1 |
| Rendon, CP | 1 |
| Verma, K | 1 |
| Riblet, N | 1 |
| Washer, DB | 1 |
| Volpe Holmes, A | 1 |
| Kaltenbach, K | 13 |
| O'Grady, KE | 6 |
| Heil, SH | 7 |
| Coyle, MG | 10 |
| Fischer, G | 13 |
| Stine, S | 1 |
| Nguyen, L | 1 |
| Lander, LR | 1 |
| Marshalek, PJ | 1 |
| Schmidt, A | 1 |
| Kelly, AK | 1 |
| Haycraft, AL | 1 |
| Nnoli, A | 1 |
| Seligman, NS | 4 |
| Dysart, K | 2 |
| Baxter, JK | 4 |
| Ballas, SK | 1 |
| Hicks, J | 1 |
| Morse, E | 1 |
| Wyant, DK | 1 |
| Silverstein, M | 1 |
| Philipp, B | 1 |
| Joseph, K | 1 |
| Taveras, EM | 1 |
| Parker, MGK | 1 |
| Grossman, M | 1 |
| Philipp, BL | 5 |
| Hutton, E | 2 |
| Saia, K | 6 |
| Nikita, F | 1 |
| Khattab, A | 1 |
| Nolin, A | 1 |
| Alvarez, C | 1 |
| Barry, K | 2 |
| Combs, G | 3 |
| Stickney, D | 2 |
| Driscoll, J | 1 |
| Humphreys, R | 2 |
| Burke, J | 1 |
| Farrell, C | 1 |
| Whalen, BL | 1 |
| Maalouf, FI | 1 |
| Cooper, WO | 1 |
| Slaughter, JC | 1 |
| Dudley, J | 1 |
| Patrick, SW | 3 |
| Chernicky, L | 1 |
| Towers, CV | 2 |
| Summey, J | 2 |
| Chen, L | 2 |
| Mayo, R | 2 |
| Charron, E | 1 |
| Hudson, JA | 1 |
| Sherrill, WW | 2 |
| Dickes, L | 2 |
| Terrin, N | 1 |
| Breeze, JL | 1 |
| Hudak, M | 1 |
| Harvey-Wilkes, K | 1 |
| D'Apolito, K | 2 |
| Bogen, D | 1 |
| Warden, AH | 1 |
| Thomas, Z | 1 |
| Thomas-Lewis, JA | 1 |
| Nikita, FNU | 1 |
| Shaw, D | 1 |
| Greenberg, RG | 1 |
| Wang, MJ | 1 |
| Kuper, SG | 1 |
| Sims, B | 1 |
| Paddock, CS | 1 |
| Dantzler, J | 1 |
| Muir, S | 1 |
| Harper, LM | 1 |
| Bracero, LA | 1 |
| Subit, M | 1 |
| Seybold, DJ | 1 |
| Vargo, M | 1 |
| Broce, M | 1 |
| Nellhaus, EM | 1 |
| Murray, S | 2 |
| Hansen, Z | 1 |
| Rose-Jacobs, R | 1 |
| Trevino-Talbot, M | 1 |
| Lloyd-Travaglini, C | 1 |
| Cabral, HJ | 1 |
| Vibbert, M | 1 |
| Ahmed, MS | 1 |
| Slowiczek, L | 1 |
| Hein, DJ | 1 |
| Risoldi Cochrane, Z | 1 |
| Gregory, PJ | 1 |
| Mangat, AK | 1 |
| Schmölzer, GM | 1 |
| van Donge, T | 1 |
| Samiee-Zafarghandy, S | 1 |
| Pfister, M | 1 |
| Koch, G | 1 |
| Kalani, M | 1 |
| Bordbar, A | 1 |
| van den Anker, J | 1 |
| O'Connor, A | 1 |
| O'Brien, L | 1 |
| Watson, L | 1 |
| Ghazanfarpour, M | 1 |
| Najafi, MN | 1 |
| Roozbeh, N | 1 |
| Mashhadi, ME | 1 |
| Keramat-Roudi, A | 1 |
| Mégarbane, B | 1 |
| Tsatsakis, A | 1 |
| Moghaddam, MMM | 1 |
| Rezaee, R | 1 |
| Rausgaard, NLK | 1 |
| Ibsen, IO | 1 |
| Jørgensen, JS | 1 |
| Lamont, RF | 1 |
| Ravn, P | 1 |
| Cooney, H | 1 |
| Hodgson, K | 1 |
| Davis, P | 1 |
| Cook, CE | 1 |
| Fantasia, HC | 1 |
| Hirashima, M | 1 |
| Hansbury, A | 1 |
| Slater, C | 1 |
| Walley, AY | 2 |
| Chen, J | 1 |
| Eisler, L | 1 |
| Li, G | 1 |
| Sun, LS | 1 |
| Dave, CV | 1 |
| Goodin, A | 1 |
| Zhu, Y | 1 |
| Winterstein, A | 1 |
| Wang, X | 1 |
| Alrwisan, A | 1 |
| Paterno, MT | 1 |
| Jablonski, L | 1 |
| Klepacki, A | 1 |
| Friedmann, PD | 1 |
| Katz, E | 1 |
| Weitz, B | 1 |
| Visconti, K | 1 |
| Buckley, V | 1 |
| Razaghi, A | 1 |
| Haber, P | 1 |
| Stewart, RD | 1 |
| Nelson, DB | 1 |
| Adhikari, EH | 1 |
| McIntire, DD | 1 |
| Roberts, SW | 1 |
| Dashe, JS | 3 |
| Sheffield, JS | 3 |
| Gaalema, DE | 3 |
| Badger, GJ | 3 |
| Metayer, JS | 1 |
| Johnston, AM | 2 |
| Welle-Strand, GK | 3 |
| Bakstad, B | 4 |
| Bjarkø, L | 2 |
| Ravndal, E | 3 |
| Stanhope, TJ | 1 |
| Gill, LA | 1 |
| Rose, C | 1 |
| Grim, K | 1 |
| Harrison, TE | 1 |
| Wilder, RT | 1 |
| Krishnan, R | 1 |
| Pritham, UA | 3 |
| Tisher, PW | 1 |
| Troese, M | 2 |
| Arunogiri, S | 1 |
| Foo, L | 1 |
| Frei, M | 1 |
| Lubman, DI | 1 |
| Bhatt-Mehta, V | 2 |
| Ng, CM | 2 |
| Schumacher, RE | 2 |
| Johnson, PN | 1 |
| Miller, JL | 1 |
| Hagemann, TM | 1 |
| Castro, C | 1 |
| Harrison, D | 1 |
| Ista, E | 1 |
| van Dijk, M | 1 |
| Mozurkewich, EL | 1 |
| Rayburn, WF | 3 |
| Hsi, A | 2 |
| van den Anker, JN | 1 |
| Kocherlakota, P | 1 |
| Grow, JL | 2 |
| Jasin, LR | 2 |
| Klebanoff, MA | 2 |
| McClead, RE | 2 |
| Meinzen-Derr, J | 5 |
| Mohan, VK | 2 |
| Stein, H | 2 |
| Saia, KA | 1 |
| Du, HM | 1 |
| Sebastiani, P | 2 |
| Wilder, C | 1 |
| Theobald, J | 1 |
| Lewis, D | 1 |
| Van Hook, J | 1 |
| Marcotte, M | 1 |
| Beckwith, AM | 1 |
| Burke, SA | 1 |
| Bagley, SM | 1 |
| Holland, E | 1 |
| Wolff, K | 1 |
| Perez-Montejano, R | 1 |
| Thornton, LM | 1 |
| McGlone, L | 1 |
| Artigas, V | 1 |
| Wiegand, SL | 1 |
| Stringer, EM | 1 |
| Stuebe, AM | 1 |
| Seashore, C | 2 |
| Thorp, J | 1 |
| McQueen, KA | 2 |
| Murphy-Oikonen, J | 3 |
| Desaulniers, L | 1 |
| Kreitinger, C | 1 |
| Gutierrez, H | 1 |
| Hamidovic, A | 1 |
| Schmitt, C | 1 |
| Sarangarm, P | 1 |
| Bakhireva, LN | 1 |
| Cochran, G | 1 |
| Lefevere, J | 1 |
| Hulman, S | 1 |
| Musci, M | 1 |
| Stang, E | 1 |
| Bier, JB | 1 |
| Finger, AS | 1 |
| Bier, BA | 1 |
| Johnson, TA | 1 |
| Liu, WF | 1 |
| Singh, K | 1 |
| Faisal, M | 1 |
| Li, S | 1 |
| Desai, RJ | 1 |
| Patorno, E | 1 |
| Kerzner, LS | 1 |
| Ordean, A | 1 |
| Kahan, M | 1 |
| Graves, L | 1 |
| Abrahams, R | 1 |
| Kim, T | 1 |
| Provenza, N | 1 |
| Calpena, AC | 1 |
| Mallandrich, M | 1 |
| Pueyo, B | 1 |
| Clares, B | 1 |
| Chasnoff, IJ | 1 |
| Gardner, S | 1 |
| Fielder, A | 1 |
| Isemann, B | 2 |
| Mizuno, T | 1 |
| Tabangin, ME | 1 |
| Ward, LP | 1 |
| Henderson, C | 1 |
| Karnack, C | 1 |
| Peltz, G | 1 |
| Anand, KJ | 1 |
| Young, ME | 1 |
| Hager, SJ | 1 |
| Spurlock, D | 1 |
| McKnight, S | 1 |
| Coo, H | 1 |
| Holmes, B | 1 |
| Newton, L | 1 |
| Isemann, BT | 1 |
| Harvey, S | 1 |
| Akinbi, HT | 1 |
| Brucknerová, I | 1 |
| Mach, M | 1 |
| Dubovický, M | 1 |
| Ujházy, E | 1 |
| Sen, S | 1 |
| Arulkumar, S | 1 |
| Cornett, EM | 1 |
| Gayle, JA | 1 |
| Flower, RR | 1 |
| Fox, CJ | 1 |
| Kaye, AD | 1 |
| Tsai, LC | 1 |
| Doan, TJ | 1 |
| Noormohammadi, A | 1 |
| Forinash, A | 1 |
| Yancey, A | 1 |
| Crannage, E | 1 |
| Campbell, K | 1 |
| Shyken, J | 1 |
| Anderson, PO | 1 |
| Johnson, E | 1 |
| Horton, E | 1 |
| Andringa, K | 1 |
| Holmes, AV | 1 |
| Maguire, DJ | 2 |
| Taylor, S | 2 |
| Armstrong, K | 2 |
| Shaffer-Hudkins, E | 2 |
| Germain, AM | 2 |
| Brooks, SS | 2 |
| Cline, GJ | 1 |
| Clark, L | 1 |
| DeBate, R | 1 |
| McPherson, C | 1 |
| Mücke, S | 1 |
| Nagel, M | 1 |
| Siedentopf, J | 1 |
| Bührer, C | 1 |
| Hüseman, D | 1 |
| Maguire, D | 1 |
| Gröer, M | 1 |
| Gibson, KS | 1 |
| Stark, S | 1 |
| Kumar, D | 1 |
| Bailit, JL | 1 |
| Prunty, L | 1 |
| Davies, T | 1 |
| Evans, J | 1 |
| Hudson, J | 1 |
| Dalton, B | 1 |
| Dankovich, K | 1 |
| McQueen, K | 1 |
| Werler, M | 1 |
| Chau, KT | 1 |
| Nguyen, J | 1 |
| Miladinovic, B | 1 |
| Lilly, CM | 1 |
| Ashmeade, TL | 1 |
| Balakrishnan, M | 1 |
| Serane, VT | 1 |
| Kurian, O | 1 |
| Berkley, EM | 1 |
| Leslie, KK | 1 |
| Arora, S | 1 |
| Qualls, C | 1 |
| Dunkelberg, JC | 1 |
| Kacinko, SL | 1 |
| Johnson, RE | 4 |
| Choo, RE | 4 |
| Huestis, MA | 7 |
| Winklbaur, B | 4 |
| Kopf, N | 1 |
| Ebner, N | 3 |
| Jung, E | 1 |
| Thau, K | 2 |
| Salva, N | 1 |
| Hayes, EJ | 2 |
| Dysart, KC | 2 |
| Pequignot, EC | 1 |
| Vucinovic, M | 1 |
| Roje, D | 1 |
| Vucinovic, Z | 1 |
| Capkun, V | 1 |
| Bucat, M | 1 |
| Banovic, I | 1 |
| Lim, S | 1 |
| Prasad, MR | 1 |
| Samuels, P | 1 |
| Gardner, DK | 1 |
| Cordero, L | 2 |
| O'Grady, MJ | 1 |
| Hopewell, J | 1 |
| White, MJ | 4 |
| Sandtorv, L | 1 |
| Reigstad, H | 1 |
| Bruarøy, S | 1 |
| Elgen, I | 1 |
| Laegreid, LM | 1 |
| Dryden, C | 3 |
| Young, D | 2 |
| Hepburn, M | 1 |
| Sarfi, M | 2 |
| Agthe, AG | 1 |
| Kim, GR | 1 |
| Mathias, KB | 1 |
| Hendrix, CW | 1 |
| Chavez-Valdez, R | 1 |
| Jansson, L | 1 |
| Lewis, TR | 1 |
| Yaster, M | 1 |
| Gauda, EB | 2 |
| Berghella, V | 4 |
| Reingardiene, D | 1 |
| Jodziūniene, L | 1 |
| Lazauskas, R | 1 |
| Tetstall, E | 1 |
| Liu, AJ | 4 |
| An, EI | 1 |
| Canalese, J | 1 |
| Nanan, R | 4 |
| Schroeder, J | 1 |
| Williams, E | 2 |
| Esmaeili, A | 1 |
| Keinhorst, AK | 1 |
| Schuster, T | 1 |
| Beske, F | 1 |
| Schlösser, R | 1 |
| Bastanier, C | 1 |
| Domenici, C | 1 |
| Cuttano, A | 1 |
| Nardini, V | 1 |
| Varese, L | 1 |
| Ghirri, P | 1 |
| Boldrini, A | 1 |
| Martinsen, H | 1 |
| Røislien, J | 1 |
| Waal, H | 2 |
| Elko, A | 4 |
| Velez, M | 3 |
| Bandstra, ES | 2 |
| Morrow, CE | 1 |
| Mansoor, E | 1 |
| Accornero, VH | 1 |
| Almario, CV | 1 |
| Holbrook, A | 1 |
| Jones, MP | 1 |
| Murray, H | 1 |
| Cook, CM | 1 |
| Campbell, N | 1 |
| Byun, J | 2 |
| Cleary, BJ | 4 |
| Donnelly, J | 1 |
| Strawbridge, J | 1 |
| Gallagher, PJ | 4 |
| Fahey, T | 4 |
| Clarke, M | 1 |
| Murphy, DJ | 4 |
| Gray, TR | 2 |
| Concheiro, M | 1 |
| Blandthorn, J | 1 |
| Forster, DA | 1 |
| Love, V | 1 |
| Stine, SM | 4 |
| Arria, AM | 3 |
| Selby, P | 3 |
| Leeman, LM | 1 |
| Brown, SA | 1 |
| Albright, B | 1 |
| Skipper, B | 1 |
| Donnelly, JM | 1 |
| Strawbridge, JD | 1 |
| Pizarro, D | 1 |
| Habli, M | 1 |
| Grier, M | 1 |
| Bombrys, A | 1 |
| Sibai, B | 1 |
| Livingston, J | 1 |
| Perel, JM | 1 |
| Helsel, JC | 1 |
| Thompson, M | 1 |
| Wisner, KL | 1 |
| Unger, A | 2 |
| Jagsch, R | 6 |
| Arria, A | 1 |
| Leitich, H | 1 |
| Rohrmeister, K | 4 |
| Aschauer, C | 2 |
| Bäwert, A | 2 |
| Lacroix, I | 1 |
| Berrebi, A | 1 |
| Garipuy, D | 1 |
| Schmitt, L | 1 |
| Hammou, Y | 1 |
| Chaumerliac, C | 1 |
| Lapeyre-Mestre, M | 1 |
| Montastruc, JL | 1 |
| Damase-Michel, C | 1 |
| de Castro, A | 1 |
| Shakleya, DM | 2 |
| Metz, V | 1 |
| Würzl, J | 1 |
| Pribasnig, A | 1 |
| Backes, CH | 1 |
| Backes, CR | 1 |
| Gardner, D | 1 |
| Nankervis, CA | 1 |
| Giannone, PJ | 1 |
| Newby, PK | 1 |
| Vreeland, J | 1 |
| Bonzagni, A | 1 |
| Bauchner, H | 1 |
| Bio, LL | 1 |
| Siu, A | 1 |
| Poon, CY | 1 |
| Knoppert, D | 1 |
| Müller, MJ | 1 |
| Lange, M | 1 |
| Paul, T | 1 |
| Seeliger, S | 1 |
| Di Pietro, JA | 1 |
| Williams, EL | 1 |
| Milio, L | 2 |
| Coyle, M | 1 |
| Gerlach, K | 1 |
| Montelpare, W | 1 |
| Eogan, M | 2 |
| O'Connell, MP | 2 |
| Clarke, T | 2 |
| McDermott, C | 2 |
| O'Sullivan, A | 2 |
| Carmody, D | 2 |
| Gleeson, J | 2 |
| Chisolm, MS | 1 |
| Terplan, M | 1 |
| Himes, SK | 1 |
| Goodwin, RS | 1 |
| Rock, CM | 1 |
| Wilkins, DG | 1 |
| Su, PH | 1 |
| Chang, YZ | 1 |
| Yang, C | 1 |
| Ng, YY | 1 |
| Chen, JY | 1 |
| Chen, SC | 1 |
| Hodgson, ZG | 1 |
| Abrahams, RR | 2 |
| Kelly, LE | 1 |
| Rieder, MJ | 1 |
| Bridgman-Acker, K | 1 |
| Lauwers, A | 1 |
| Madadi, P | 1 |
| Koren, G | 2 |
| Greig, E | 1 |
| Ash, A | 1 |
| Douiri, A | 1 |
| Young, JL | 1 |
| Sigmon, SC | 1 |
| Higgins, ST | 1 |
| Catlin, EA | 1 |
| Warren, HS | 1 |
| Shailam, R | 1 |
| Lahoud-Rahme, M | 1 |
| Lew, M | 1 |
| Siew, LT | 1 |
| Auerbach, M | 1 |
| Baum, CR | 1 |
| Pavlovic, L | 1 |
| Leventhal, JM | 1 |
| McLemore, GL | 1 |
| Lewis, T | 1 |
| Jones, CH | 1 |
| Baewert, A | 3 |
| Holbrook, AM | 1 |
| Scott, TL | 1 |
| Lin, H | 1 |
| Graf-Rohrmeister, K | 1 |
| Sublett, J | 1 |
| Reynolds, K | 1 |
| Shainker, SA | 1 |
| Lee-Parritz, A | 1 |
| Napolitano, A | 1 |
| Theophilopoulos, D | 1 |
| Seng, SK | 1 |
| Calhoun, DA | 1 |
| Stitzer, ML | 1 |
| Olscher, DA | 1 |
| Todd, SJ | 1 |
| Jackson, GL | 1 |
| Wendel, GD | 2 |
| Johnson, K | 2 |
| Gerada, C | 2 |
| Greenough, A | 2 |
| Loustauneau, A | 1 |
| Auriacombe, M | 2 |
| Daulouede, JP | 2 |
| Tignol, J | 2 |
| Gill, AC | 1 |
| Oei, J | 1 |
| Lewis, NL | 1 |
| Younan, N | 1 |
| Kennedy, I | 1 |
| Lui, K | 1 |
| Merewood, A | 1 |
| O'Brien, S | 1 |
| Vinner, E | 1 |
| Vignau, J | 1 |
| Thibault, D | 1 |
| Codaccioni, X | 1 |
| Brassart, C | 1 |
| Humbert, L | 1 |
| Lhermitte, M | 1 |
| Lim, PJ | 1 |
| Hill, MK | 1 |
| Cherpes, J | 1 |
| Chennat, J | 1 |
| Scully, M | 1 |
| Geoghegan, N | 1 |
| Corcoran, P | 1 |
| Tiernan, M | 1 |
| Keenan, E | 1 |
| Fatséas, M | 1 |
| Dubernet, J | 1 |
| Schroeder, JR | 2 |
| Shin, AS | 1 |
| Kuschel, CA | 1 |
| Austerberry, L | 1 |
| Cornwell, M | 1 |
| Couch, R | 1 |
| Rowley, RS | 1 |
| Langenfeld, S | 1 |
| Birkenfeld, L | 1 |
| Herkenrath, P | 1 |
| Müller, C | 1 |
| Hellmich, M | 1 |
| Theisohn, M | 1 |
| Ferguson, A | 2 |
| Lagasse, L | 2 |
| Liu, J | 1 |
| Arlettaz, R | 1 |
| Kashiwagi, M | 1 |
| Das-Kundu, S | 1 |
| Fauchère, JC | 1 |
| Lang, A | 1 |
| Bucher, HU | 1 |
| Sessler, J | 1 |
| Biswas, AK | 1 |
| Feldman, BL | 1 |
| Davis, DH | 1 |
| Zintz, EA | 1 |
| Jasinski, DR | 1 |
| Chisholm, CA | 1 |
| Crocetti, M | 1 |
| Dudas, R | 1 |
| Harrow, C | 2 |
| Lantz, M | 1 |
| McCarthy, JJ | 2 |
| Leamon, MH | 2 |
| Parr, MS | 1 |
| Anania, B | 1 |
| Fajemirokun-Odudeyi, O | 1 |
| Sinha, C | 1 |
| Tutty, S | 1 |
| Pairaudeau, P | 1 |
| Armstrong, D | 1 |
| Phillips, T | 1 |
| Lindow, SW | 1 |
| Lainwala, S | 1 |
| Brown, ER | 1 |
| Weinschenk, NP | 1 |
| Blackwell, MT | 1 |
| Hagadorn, JI | 1 |
| Sarkar, S | 1 |
| Donn, SM | 1 |
| Ortner, R | 1 |
| Langer, M | 1 |
| Aschauer, H | 1 |
| Leeuwenburgh-Pronk, WG | 1 |
| de Vries, MC | 1 |
| Clement-de Boers, A | 1 |
| Mawhinney, S | 1 |
| Ashe, RG | 1 |
| Lowry, J | 1 |
| Peternell, A | 1 |
| Miles, J | 1 |
| Sugumar, K | 1 |
| Macrory, F | 1 |
| Sims, DG | 1 |
| D'Souza, SW | 1 |
| Achsnick-Wetjen, C | 1 |
| Hsieh, HC | 1 |
| Crocetti, MT | 1 |
| Amin, DD | 1 |
| Burns, L | 1 |
| Mattick, RP | 1 |
| Kelly, SA | 1 |
| Payne, S | 1 |
| Thiessen, PN | 1 |
| Mackintosh, J | 1 |
| Janssen, PA | 1 |
| Vavrinková, B | 2 |
| Binder, T | 2 |
| Colombini, N | 1 |
| Elias, R | 1 |
| Busuttil, M | 1 |
| Dubuc, M | 1 |
| Einaudi, MA | 1 |
| Bues-Charbit, M | 1 |
| Stenson, G | 1 |
| Biles, LA | 1 |
| Stetson, A | 1 |
| Choo, R | 1 |
| Kakko, J | 1 |
| Heilig, M | 1 |
| Sarman, I | 2 |
| van Baar, AL | 4 |
| Soepatmi, S | 3 |
| Gunning, WB | 1 |
| Akkerhuis, GW | 1 |
| Wright, ML | 1 |
| Robinson, MJ | 1 |
| Baglin, S | 1 |
| Avenel, S | 1 |
| Renaud, C | 1 |
| Bavoux, F | 1 |
| Francoual, C | 1 |
| Badoual, J | 1 |
| Malpas, TJ | 2 |
| Darlow, BA | 2 |
| Lennox, R | 1 |
| Horwood, LJ | 1 |
| de Cubas, MM | 1 |
| Field, T | 1 |
| Shaw, NJ | 2 |
| McIvor, L | 1 |
| Kaltenbach, KA | 1 |
| Kempley, S | 1 |
| van Baar, A | 2 |
| de Graaff, BM | 1 |
| Fundarò, C | 2 |
| Solinas, A | 1 |
| Martino, AM | 1 |
| Genovese, O | 1 |
| Noia, G | 1 |
| Conte, GL | 1 |
| Segni, G | 1 |
| Davidson, DC | 1 |
| Gregg, JE | 1 |
| Weindling, AM | 1 |
| Pérez-Bescos, L | 1 |
| Arrate-Zugazabeitia, JK | 1 |
| Fortea-Jimeno, E | 1 |
| Echaniz-Urcelay, I | 1 |
| Saitua-Iturriaga, G | 1 |
| Delgado-Rubio, A | 1 |
| Hutchings, DE | 2 |
| Zmitrovich, A | 2 |
| Church, S | 1 |
| Malowany, D | 1 |
| Boer, K | 1 |
| Blondel, S | 1 |
| Lefebvre, P | 1 |
| Tondeur, M | 1 |
| Blum, D | 1 |
| Doberczak, TM | 2 |
| Kandall, SR | 2 |
| Friedmann, P | 1 |
| Jarvis, MA | 1 |
| Schnoll, SH | 1 |
| Robinson, SE | 1 |
| Mo, Q | 1 |
| Maher, JR | 1 |
| Wallace, MJ | 1 |
| Kunko, PM | 1 |
| Mayes, LC | 1 |
| Carroll, KM | 2 |
| Schneider, C | 1 |
| Diamant, K | 1 |
| Hauk, R | 1 |
| Pezawas, L | 1 |
| Lenzinger, E | 1 |
| Kasper, S | 1 |
| Theis, JG | 1 |
| Ikizler, Y | 1 |
| Wong, WM | 1 |
| Lao, TT | 1 |
| Wojnar-Horton, RE | 1 |
| Kristensen, JH | 1 |
| Yapp, P | 1 |
| Ilett, KF | 1 |
| Dusci, LJ | 1 |
| Hackett, LP | 1 |
| Vance, JC | 1 |
| Chant, DC | 1 |
| Tudehope, DI | 1 |
| Gray, PH | 1 |
| Hayes, AJ | 1 |
| Finnegan, L | 1 |
| Barr, GA | 1 |
| Hamowy, AS | 1 |
| Liu, PY | 1 |
| Fabris, C | 1 |
| Prandi, G | 1 |
| Perathoner, C | 1 |
| Soldi, A | 1 |
| Eder, H | 1 |
| Gombas, W | 1 |
| Etzersdorfer, P | 1 |
| Schmidl-Mohl, K | 1 |
| Schatten, C | 1 |
| Weninger, M | 1 |
| Aschauer, HN | 1 |
| Jones, HC | 1 |
| Isernhagen, K | 1 |
| Lee, TS | 1 |
| Anderson, IB | 1 |
| Kearney, TE | 1 |
| Ottenjann, H | 1 |
| Ziegler, M | 1 |
| Poustka, F | 1 |
| von Loewenich, V | 1 |
| Englert, E | 1 |
| Cayol, V | 1 |
| Corcos, M | 1 |
| Clervoy, P | 1 |
| Speranza, M | 1 |
| Floch-Tudal, C | 1 |
| Simonpoli, AM | 1 |
| Montamat, S | 1 |
| Couettoux, MP | 1 |
| Crenn-Hebert, C | 1 |
| Lejeune, C | 2 |
| Weinstein, LB | 1 |
| Schwejda, C | 1 |
| Bystron, C | 1 |
| Federmann, M | 1 |
| Schmidt, J | 1 |
| Bussello-Spieth, S | 1 |
| Tretter, F | 1 |
| Ballard, JL | 1 |
| Aubisson, S | 1 |
| Simmat-Durand, L | 1 |
| Cneude, F | 1 |
| Piquet, M | 1 |
| Gourarier, L | 1 |
| Oh, W | 1 |
| Lam, SK | 1 |
| To, WK | 1 |
| Duthie, SJ | 1 |
| Ma, HK | 1 |
| Chang, G | 1 |
| Behr, HM | 1 |
| Kosten, TR | 1 |
| Vering, A | 1 |
| Seeger, J | 1 |
| Becker, S | 1 |
| Halberstadt, E | 1 |
| Bender, HG | 1 |
| Weingart-Jesse, B | 2 |
| Stauber, M | 1 |
| Hiller, K | 1 |
| Jakobs, U | 1 |
| Lutz, R | 1 |
| Bschor, F | 1 |
| Bornemann, R | 1 |
| Kattner, E | 3 |
| Mack, G | 1 |
| Thomas, D | 1 |
| Giles, W | 1 |
| Buchanan, N | 1 |
| Wittmann, BK | 1 |
| Segal, S | 1 |
| Wilets, I | 1 |
| Thornton, L | 1 |
| Clune, M | 1 |
| Maguire, R | 1 |
| Griffin, E | 1 |
| O'Connor, J | 1 |
| Maas, U | 2 |
| Koch, S | 1 |
| Schfer, A | 1 |
| Obladen, M | 2 |
| Schäfer, A | 1 |
| Fleury, P | 2 |
| Ultee, CA | 2 |
| Wesselman, PJ | 1 |
| Hayford, SM | 1 |
| Epps, RP | 1 |
| Dahl-Regis, M | 1 |
| Bronson, ME | 1 |
| Sparber, SS | 1 |
| Collins, E | 1 |
| Hardwick, RJ | 1 |
| Jeffery, H | 1 |
| Torriolo, MG | 1 |
| Steffanini, MC | 1 |
| Mariotti, P | 1 |
| Calzolari, S | 1 |
| Tempesta, E | 1 |
| Thomas, CS | 1 |
| Osborn, M | 1 |
| Davis, DD | 1 |
| Templer, DI | 1 |
| Scherer, P | 1 |
| Oro, AS | 2 |
| Dixon, SD | 2 |
| Alroomi, LG | 1 |
| Davidson, J | 1 |
| Evans, TJ | 1 |
| Galea, P | 1 |
| Howat, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome[NCT02851303] | Phase 4 | 61 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| Improving Outcomes in Neonatal Abstinence Syndrome[NCT01958476] | Phase 3 | 117 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Pharmacological Treatment of Neonatal Abstinence Syndrome: Opiate Versus Non-Opiate[NCT01734551] | Phase 4 | 31 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy[NCT03092011] | Phase 4 | 90 participants (Anticipated) | Interventional | 2018-02-21 | Recruiting | ||
| Treatment of Neonatal Abstinence Syndrome: Evaluation of Efficacy of Phenobarbital in Combination With Either Methadone or Diluted Deodorized Tincture of Opium as Stabilizing and Tapering Regiments[NCT01723722] | Phase 4 | 40 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Randomized, Active-Control, Double-Blind, Double-Dummy Clinical Trial Comparing Sublingual Buprenorphine And Morphine Solution For The Treatment Of Neonatal Opioid Abstinence Syndrome[NCT01452789] | Phase 3 | 63 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| A Randomized Comparison of Sublingual Buprenorphine to Morphine Sulfate in the Treatment of Neonatal Abstinence Syndrome (NAS)[NCT01708707] | Phase 2 | 29 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Prospective Randomized Blinded Trial to Shorten Pharmacologic Treatment of Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS)[NCT04455802] | Phase 3 | 0 participants (Actual) | Interventional | 2020-10-01 | Withdrawn (stopped due to termination of funding) | ||
| Comparison of Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology[NCT03740243] | Phase 4 | 0 participants (Actual) | Interventional | 2018-11-30 | Withdrawn (stopped due to No enrollment) | ||
| The Effect of Kangaroo Mother Care Applied to the Healthy Newborns in the Early Postpartum Period on Breastfeeding: Randomized Controlled Study[NCT04619459] | 112 participants (Actual) | Interventional | 2016-06-01 | Completed | |||
| Optimizing the Use of Methadone in Newborn Infants[NCT01327079] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| A Pilot Randomized Comparative Effectiveness Clinical Trial of Buprenorphine vs. Methadone for the Treatment of Opioid Dependence in Pregnancy.[NCT03098407] | 55 participants (Actual) | Interventional | 2017-04-20 | Completed | |||
| Improving Alcohol and Substance Use Care Access, Outcomes, and Equity During the Reproductive Years: A Type 1 Hybrid Trial in Family Planning Clinics[NCT05910580] | 600 participants (Anticipated) | Interventional | 2024-04-01 | Not yet recruiting | |||
| PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)[NCT05128071] | Early Phase 1 | 40 participants (Anticipated) | Interventional | 2022-02-04 | Recruiting | ||
| MOms in REcovery (MORE): Defining Optimal Care for Pregnant Women and Infants[NCT04251208] | 444 participants (Actual) | Observational | 2019-07-30 | Active, not recruiting | |||
| The Utility and Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome in Neonates[NCT01754324] | 20 participants (Actual) | Observational | 2012-12-31 | Completed | |||
| Efficacy of Clonidine in the Treatment of Neonatal Abstinence Syndrome: A Prospective, Double Blind, Randomized Controlled Trial[NCT00510016] | Phase 2 | 80 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Phase I-II Clinical Trial to Determine the Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia[NCT01862250] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2013-10-03 | Completed | ||
| Efficacy of Clonidine in Reducing Iatrogenic-induced Opioid Dependence in Infants:[NCT01360450] | Phase 2/Phase 3 | 12 participants (Actual) | Interventional | 2011-07-31 | Terminated (stopped due to The study was treminated because of low accural) | ||
| Vagal Tone and Neonatal Abstinence Syndrome[NCT00496951] | 65 participants (Actual) | Observational | 2006-09-30 | Completed | |||
| Maternal Opioid Treatment: Human Experimental Research[NCT00271219] | Phase 3 | 175 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Fetal Neurobehavior in Non-methadone Maintained Women in Substance Abuse Treatment[NCT00522626] | 19 participants (Actual) | Observational | 2006-08-31 | Completed | |||
| Methadone, Buprenorphine and Fetal Neurobehavior[NCT00653692] | 29 participants (Actual) | Observational | 2007-05-31 | Completed | |||
| Safety, Efficacy, Pharmacokinetics, and Pharmacogenomics of Extended-Release Naltrexone in Pregnant Women[NCT03718104] | 100 participants (Anticipated) | Observational | 2018-12-01 | Recruiting | |||
| Improving Effective Contraceptive Use Among Opioid-maintained Women[NCT01425060] | Phase 1 | 31 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Breastfeeding Among Methadone Maintained Women[NCT00218010] | 25 participants (Actual) | Observational | 2000-11-30 | Completed | |||
| Pharmacokinetics and Safety of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants[NCT04862975] | 200 participants (Anticipated) | Observational | 2024-01-08 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assessed through chart review of discharge summary documentation of method of infant feeding at time of discharge (NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Morphine | 5 |
| Methadone | 5 |
Number of days in hospital after birth (NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | days (Mean) |
|---|---|
| Morphine | 17.9 |
| Methadone | 16.1 |
(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | days (Mean) |
|---|---|
| Morphine | 14.7 |
| Methadone | 12.8 |
clonidine (NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Morphine | 1 |
| Methadone | 0 |
(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Morphine | 11 |
| Methadone | 6 |
(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Morphine | 0 |
| Methadone | 3 |
(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | morphine equivalents mg (Mean) |
|---|---|
| Morphine | 9.86 |
| Methadone | 33.0 |
Average head circumference growth outcome at 18 month follow-up visit. (NCT01958476)
Timeframe: 18 month follow-up visit
| Intervention | cm (Mean) |
|---|---|
| Methadone | 47.8 |
| Neonatal Morphine Solution | 48.2 |
Average length (cm) at 18 month follow-up visit. (NCT01958476)
Timeframe: 18 month follow-up visit
| Intervention | cm (Mean) |
|---|---|
| Methadone | 82.1 |
| Neonatal Morphine Solution | 81.7 |
Growth outcome weight (lbs) depicted as difference in averaged weights from birth to 18 month follow-up visit. Standard deviations were averaged between birth and 18 mo time points. (NCT01958476)
Timeframe: Birth to 18 month follow-up visit
| Intervention | lbs (Mean) |
|---|---|
| Methadone | 19.1 |
| Neonatal Morphine Solution | 18.7 |
Participants were monitored for the duration of their hospitalization, an expected mean of 22 days. (NCT01958476)
Timeframe: Participants will be monitored during their entire hospitalization, expected mean 22 days.
| Intervention | days (Mean) |
|---|---|
| Methadone | 21.8 |
| Neonatal Morphine Solution | 23.2 |
Participants were monitored for the duration of their hospitalization attributable to NAS only. (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization, expected mean 22 days.
| Intervention | days (Mean) |
|---|---|
| Methadone | 18.9 |
| Neonatal Morphine Solution | 21.1 |
Total number of days infant treated with replacement opioids while admitted to the hospital. (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization.
| Intervention | days (Mean) |
|---|---|
| Methadone | 14.7 |
| Neonatal Morphine Solution | 16.6 |
"One Finnegan score ≥12, or two consecutive scores ≥8 affirms the requirement for pharmacological treatment or increasing treatment dosage. If the infant continued to have two consecutive Finnegan Scores ≥8 two times consecutively, or one ≥12, the dose was increased to the next level. (Level I: 0.3 mg/kg/day) (Level II: 0.5 mg/kg/day) (Level III: 0.7 mg/kg/day)~A higher Finnegan score indicates greater severity of NAS (min 0, max 50)." (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization, an average of 22 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Methadone | 22 |
| Neonatal Morphine Solution | 28 |
Number of infants treated with a second medication following protocol, phenobarbital. If the Finnegan Score remained elevated (still scored ≥8 two times consecutively, or still scored once ≥12) despite increasing to a predetermined maximal opioid dose (methadone or morphine), phenobarbital was administered (20-mg/kg loading dose followed by 4-5 mg/kg daily). (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization, an average of 22 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Methadone | 10 |
| Neonatal Morphine Solution | 17 |
The Bayley Scales of Infant and Toddler Development (BSID-III) assesses the development of infants and children (1-42 months) through a series of developmental play tasks, identifying children with developmental delay. Raw scores of completed items are summarized within three distinct scale scores (Cognitive Scale, Language Scale, Motor Scale). Scale scores are each converted to composite scores to determine the child's performance compared with scores of age-matched children of typical development (percentile rank). A higher composite score indicates more ideal developmental outcome (range 40-160). At 18 month follow-up visit, participants were assessed using the BSID-III for cognitive, language and motor scale composite score outcomes. (NCT01958476)
Timeframe: Assessment at 18 month follow-up visit
| Intervention | scores on a scale (Composite) (Mean) | ||
|---|---|---|---|
| Cognitive Composite | Language Composite | Motor Composite | |
| Methadone | 100.1 | 96.0 | 103.6 |
| Neonatal Morphine Solution | 98.1 | 94.2 | 99.1 |
Total number days of treatment (NCT01734551)
Timeframe: 120 days
| Intervention | days (Median) |
|---|---|
| Morphine | 39 |
| Clonidine | 27 |
Scores obtained Bayley Scales of Infant and Toddler Development Third Edition in the developmental domains of motor, cognitive, and language. This tool for measures of motor, cognitive and language development is a series of standardized measurements and for each domain, the standardized scores have a mean of 100 and standard deviation of 15. Scores below 1 standard deviation (= or less than 84) is considered below normal. Scores above 1 standard deviation (over 115) represent higher than normal functioning in each domain The score for each domain (motor, cognitive, and language functioning) represents the full-scale score (NCT01734551)
Timeframe: 1 year of life
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Bayley III motor | Cognitive | Language total | Language Receptive | Language Expressive | |
| Clonidine | 95.8 | 93.3 | 95.8 | 95.0 | 99.2 |
| Morphine | 97.6 | 92.9 | 98.0 | 101.1 | 100.0 |
Mean of total Finnegan Scores obtained every 3 hours on days 2, 7, and 14 following start of treatment; A score is a number representing the total score or sum from 21 items or symptoms or manifestations of opiate withdrawal in newborn infants. The total score ranges from 0 to 43. Reference: 1. Finnegan LP, Connaughton JF, Jr., Kron RE, et al. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975;2(1-2):141-58. Although normal newborn may manifest mild symptoms that will give scores in the range of 0 to 7. A score of 8 consecutively obtained times 3 indicate that infant will benefit from treatment, in this study morphine or clonidine. A decrease in scores especially to less than 8 is suggestive of a good response to treatment. (NCT01734551)
Timeframe: 14 days
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Finnegan scores day 2 of treatment | Finnegan scores day 7 of treatment | Finnegan scores day 14 of treatment | |
| Clonidine | 8.5 | 5.7 | 6.7 |
| Morphine | 7.5 | 6.6 | 7.1 |
The summary scores from the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) give a measure of infant neurobehavior in the following areas (score range): habituation (1-9), regulation (2.20-7.50), attention (1.29 -8.4), Handling (0 - 1), quality of movement (1.20 - 6.20), Non-optimal reflexes (0-12), Asymmetric reflexes (0-7), arousal (2.43 - 6.67), hypertonicity (0- 8), hypotonicity (0 - 5.0), excitability (0-11), lethargy (0 - 11.0). and stress/abstinence (0. - 0.57). A higher score for each item means a higher level of the construct. For example, a higher score for hypertonicity means the infant is more hypertonic and higher score on hypotonicity means the infant is more hypotonic. No cut-off score published for normal or abnormal behavioral performance. Reference: Lester BM et al. Summary Statistics of Neonatal Intensive Care Unit Network Neurobehavioral Scale Scores From the Maternal Lifestyle Study: A Quasinormative Sample, in Pediatrics 2004; 113,668. (NCT01734551)
Timeframe: 5-10 days after treatment starts
| Intervention | scores on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Attention | Handling | Quality of movement | Regulation | Non-optimal reflexes | Asymmetric reflexes | Stress/abstinence | Arousal | Hypertonicity | Hypotonicity | Excitability | Lethargy | |
| Clonidine | 4.51 | 0.42 | 4.92 | 5.26 | 4.13 | 0.00 | 0.08 | 3.95 | 0.25 | 0.19 | 2.38 | 5.13 |
| Morphine | 5.06 | 0.36 | 4.77 | 5.2 | 3.73 | 0.20 | 0.07 | 3.91 | 0.40 | 0.13 | 2.6 | 3.6 |
Up to 12 months (NCT01723722)
Timeframe: Up to 12 months
| Intervention | days (Mean) |
|---|---|
| Deodorized Tincture Opium After Phenobarbital for Withdrawal | 19.1 |
| Methadone After Phenobarbital for Withdrawal | 17.7 |
This endpoint will compare length of stay in the hospital (in days) using sublingual buprenorphine or morphine solution. (NCT01452789)
Timeframe: Duration of hospital stay is an expected average of 5 weeks.
| Intervention | days (Median) |
|---|---|
| Sublingual Buprenorphine | 21 |
| Oral Morphine | 33 |
This endpoint will compare length of treatment (in days) using sublingual buprenorphine or oral morphine solution. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.
| Intervention | days (Median) |
|---|---|
| Sublingual Buprenorphine | 15 |
| Oral Morphine | 28 |
Adverse events will be collected, graded by severity, and assessed for causality referent to study drug. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sublingual Buprenorphine | 7 |
| Oral Morphine | 8 |
This endpoint will compare requirement number of patients who require use of supplemental phenobarbital. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.
| Intervention | participants (Number) |
|---|---|
| Sublingual Buprenorphine | 5 |
| Oral Morphine | 7 |
Intravenous morphine (mg/kg) was given. The standard dose is 0.05 mg/kg per dose (NCT01862250)
Timeframe: Up to 2 days
| Intervention | mg/kg (Median) |
|---|---|
| Clonidine Infants With HIE | 0.02 |
Babies were assessed after administration of clonidine for the presence or absence of shivering. (NCT01862250)
Timeframe: 48hrs
| Intervention | Participants (Count of Participants) |
|---|---|
| Clonidine Infants With HIE | 0 |
"Trough clonidine blood levels were measured after 4-7 doses of clonidine were given intravenously with a dosing interval of every 8 hrs. Mean and standard deviation (SD) of the number of doses given prior to levels being drawn was 5.3 (mean) and 0.37 (SD).~Time after last dose before measurement was 9hrs (mean) and 2.7hrs (SD)." (NCT01862250)
Timeframe: 3 days
| Intervention | ng/ml (Median) |
|---|---|
| Clonidine Infants With HIE | 0.6 |
Following 2 hours of therapeutic hypothermia, the temperature of the thermo-blanket is adjusted up half degree per hour allowing passive rewarming until 36.5 degrees is reached (NCT01862250)
Timeframe: Beginning at 72 hours up to 12 hours
| Intervention | Hours (Median) |
|---|---|
| Clonidine Infants With HIE | 8.7 |
Time to complete detoxification is defined as 48 hrs off all opioids/benzodiazepines and study drug with acceptable withdrawal scores of <9 (on average we expect the infant to be enrolled in the study for 2-4 weeks). The scale used to assess withdrawal was the Modified Finnegan Neonatal Withdrawal Scale, which ranges from 0-41, 0 represents no withdrawal and 41 represent maximum withdrawal. (NCT01360450)
Timeframe: up to 4 weeks
| Intervention | days (Mean) | |
|---|---|---|
| total days on narcotics | duration on study drug in days | |
| Control | 37.2 | 14.2 |
| Treatment | 89.5 | 21 |
(NCT00271219)
Timeframe: birth
| Intervention | cm (Mean) |
|---|---|
| A Methadone | 33.0 |
| B Buprenorphine | 33.8 |
(NCT00271219)
Timeframe: delivery until hospital discharge (min=2 days, max=79 days)
| Intervention | days (Mean) |
|---|---|
| A Methadone | 17.5 |
| B Buprenorphine | 10.0 |
NAS was measured with the MOTHER NAS scale, which includes 28 items, 19 of which are used for scoring and medication decisions. Scores can range from 0 to 42, with higher scores indicating more severe withdrawal. (NCT00271219)
Timeframe: minimum twice daily from birth until NAS no longer measured (min=10 days)
| Intervention | Score on the scale (Mean) |
|---|---|
| A Methadone | 12.8 |
| B Buprenorphine | 11.0 |
(NCT00271219)
Timeframe: monthly from study entry until discontinuation or delivery (min=29 days, max=239 days)
| Intervention | percentage of HIV risk behaviors (Number) |
|---|---|
| A Methadone | NA |
| B Buprenorphine | NA |
Pregnant women maintained on an opioid agonist medication may require upward adjustment to their medication during the course of pregnant. The Dose Adequacy Measure represented a recordation of dosing adjustments during the course of the study. (NCT00271219)
Timeframe: from study entry until discontinuation or delivery (min=29 days, max=239 days)
| Intervention | dose increase per trimester (Number) |
|---|---|
| A Methadone | NA |
| B Buprenorphine | NA |
The Addiction Severity Index is a structured clinical interview that assesses problem severity in 7 areas of functioning: alcohol use, drug use, medical, legal, employment, psychosocial, and psychiatric status. Each area of functioning yields a composite scale score between 0 and 1, with higher scores indicating greater problem severity in that area. Only the psychosocial index was examined in this study. (NCT00271219)
Timeframe: at delivery
| Intervention | Score on the scale (Mean) |
|---|---|
| Methadone | .014 |
| Buprenorphine | .088 |
(NCT00271219)
Timeframe: monthly from study entry until discontinuation or delivery (min=29 days, max=239 days)
| Intervention | percentage of drug use (Number) |
|---|---|
| A Methadone | NA |
| B Buprenorphine | NA |
Neonatal abstinence syndrome (NAS) characterized by hyperirritability of the central nervous system and dysfunction in the autonomic nervous system, gastrointestinal tract, and respiratory system.11 When left untreated, NAS can result in serious illness (e.g., diarrhea, feeding difficulties, weight loss, and seizures) and death. (NCT00271219)
Timeframe: From birth until hospital discharge (min=4 days, max=10, depending on site)
| Intervention | participants (Number) |
|---|---|
| A Methadone | 41 |
| B Buprenorphine | 27 |
Total amount in mg (NCT00271219)
Timeframe: Start of NAS treatment until discontinuation of NAS treatment (min=0 days, max=76 days)
| Intervention | mg (Mean) |
|---|---|
| A Methadone | 10.4 |
| B Buprenorphine | 1.1 |
Fetal heart rate in beats per minute (NCT00522626)
Timeframe: 60 minutes
| Intervention | beats per minute (Mean) |
|---|---|
| Trough Fetal Heart Rate | 142.34 |
66 reviews available for methadone and Neonatal Abstinence Syndrome
| Article | Year |
|---|---|
Neonatal opioid withdrawal syndrome: a review of the science and a look toward the use of buprenorphine for affected infants.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant; Infant, Newborn; Methadone; Neonatal Abst | 2022 |
Prenatal Opioid Exposure and Neurodevelopmental Outcomes.
Topics: Analgesics, Opioid; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Methadone; Neonatal A | 2023 |
Methadone versus morphine treatment outcomes in neonatal abstinence syndrome: A meta-analysis.
Topics: Analgesics, Opioid; Humans; Infant, Newborn; Methadone; Morphine; Neonatal Abstinence Syndrome; Trea | 2019 |
Neonatal Abstinence Syndrome: Review of Epidemiology, Care Models, and Current Understanding of Outcomes.
Topics: Analgesics, Opioid; Breast Feeding; Buprenorphine; Female; Humans; Hypnotics and Sedatives; Infant, | 2019 |
Opioid Use in Pregnancy.
Topics: Buprenorphine; Child Development; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Sy | 2019 |
Opioid Management in Pregnancy and Postpartum.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cesarean Section; Female; Humans; Infant, Newborn; Labor, | 2020 |
Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches.
Topics: Buprenorphine; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Humans; Infant, Newborn; Me | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Peripartum Anesthetic Management of the Opioid-tolerant or Buprenorphine/Suboxone-dependent Patient.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Female; Humans; Methado | 2017 |
Neonatal abstinence syndrome: where are we, and where do we go from here?
Topics: Female; Humans; Incidence; Infant, Newborn; Methadone; Mothers; Neonatal Abstinence Syndrome; Preval | 2017 |
Neonatal Abstinence Syndrome: Update on Diagnostic and Therapeutic Strategies.
Topics: Analgesics, Opioid; Antidepressive Agents; Buprenorphine; Female; Humans; Infant, Newborn; Methadone | 2017 |
Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naltrexone; | 2017 |
Association of Rooming-in With Outcomes for Neonatal Abstinence Syndrome: A Systematic Review and Meta-analysis.
Topics: Analgesics, Opioid; Drug Utilization; Hospital Costs; Humans; Infant, Newborn; Length of Stay; Metha | 2018 |
Neonatal Abstinence Syndrome: Advances in Diagnosis and Treatment.
Topics: Acupuncture Therapy; Analgesics; Breast Feeding; Buprenorphine; Clonidine; Female; Humans; Infant, N | 2018 |
Treatment of Perinatal Opioid Use Disorder.
Topics: Adult; Analgesics, Opioid; Decision Making; Female; Humans; Infant, Newborn; Methadone; Neonatal Abs | 2018 |
Opioid Detoxification in Pregnancy: Systematic Review and Meta-Analysis of Perinatal Outcomes.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence S | 2019 |
Neonatal abstinence syndrome.
Topics: Adult; Female; Humans; Infant; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Opiate Subs | 2018 |
Morphine and Methadone for Neonatal Abstinence Syndrome: A Systematic Review.
Topics: Analgesics, Opioid; Female; Humans; Infant; Infant, Newborn; Length of Stay; Male; Methadone; Morphi | 2018 |
Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS).
Topics: Analgesics, Opioid; Breast Feeding; Buprenorphine; Humans; Infant, Newborn; Methadone; Morphine; Neo | 2019 |
Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome.
Topics: Analgesia, Obstetrical; Analgesics; Analgesics, Opioid; Breast Feeding; Buprenorphine; Buprenorphine | 2019 |
Therapeutic approaches for neonatal abstinence syndrome: a systematic review of randomized clinical trials.
Topics: Analgesics, Opioid; Buprenorphine; Clonidine; Drug Therapy, Combination; Humans; Infant, Newborn; Le | 2019 |
Management and monitoring of opioid use in pregnancy.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Maternal-Fetal Exchange; Methadone; Narcot | 2020 |
Comparative effectiveness of opioid replacement agents for neonatal opioid withdrawal syndrome: a systematic review and meta-analysis.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Infant, Newborn; Length of Stay; Methadone; Morphine; Neo | 2019 |
Chronic opioid use during pregnancy: maternal and fetal implications.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence S | 2013 |
Management of neonatal abstinence syndrome from opioids.
Topics: Analgesics, Opioid; Buprenorphine; Feeding Methods; Humans; Infant Care; Infant, Newborn; Methadone; | 2013 |
Managing opioid dependence in pregnancy -- a general practice perspective.
Topics: Adult; Buprenorphine; Female; General Practice; Humans; Methadone; Narcotics; Neonatal Abstinence Sy | 2013 |
Buprenorphine and methadone for opioid addiction during pregnancy.
Topics: Analgesics, Opioid; Buprenorphine; Drug Administration Schedule; Female; Humans; Methadone; Neonatal | 2014 |
Neonatal opioid withdrawal syndrome.
Topics: Analgesics, Opioid; Breast Feeding; Buprenorphine; Female; Humans; Infant, Newborn; Male; Methadone; | 2014 |
Neonatal abstinence syndrome.
Topics: Animals; Breast Feeding; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; O | 2014 |
Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis.
Topics: Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Models, Statistical; Neonatal Abstinence | 2014 |
Review of the assessment and management of neonatal abstinence syndrome.
Topics: Breast Feeding; Buprenorphine; Clonidine; Female; Humans; Infant, Newborn; Methadone; Narcotics; Neo | 2014 |
Opioid neonatal abstinence syndrome: controversies and implications for practice.
Topics: Analgesics, Opioid; Dose-Response Relationship, Drug; Gestational Age; Humans; Infant, Newborn; Leng | 2014 |
Question: is breastfeeding useful in the management of neonatal abstinence syndrome?
Topics: Breast Feeding; Female; Humans; Infant, Newborn; Methadone; Narcotics; Neonatal Abstinence Syndrome; | 2015 |
New Pain Management Options for the Surgical Patient on Methadone and Buprenorphine.
Topics: Buprenorphine; Drug Administration Schedule; Female; Humans; Methadone; Neonatal Abstinence Syndrome | 2016 |
Breastfeeding among Mothers on Opioid Maintenance Treatment: A Literature Review.
Topics: Analgesics, Opioid; Breast Feeding; Buprenorphine; Female; Health Promotion; Humans; Infant, Newborn | 2016 |
Buprenorphine Versus Methadone for Opioid Dependence in Pregnancy.
Topics: Buprenorphine; Female; Humans; Infant; Infant, Newborn; Length of Stay; Methadone; Neonatal Abstinen | 2016 |
Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome.
Topics: Analgesics, Opioid; Child Abuse; Epigenesis, Genetic; Female; Humans; Infant, Newborn; Methadone; Ne | 2016 |
Pharmacotherapy for Neonatal Abstinence Syndrome: Choosing the Right Opioid or No Opioid at All.
Topics: Analgesics; Buprenorphine; Clonidine; Drug Therapy, Combination; Humans; Hypnotics and Sedatives; In | 2016 |
Neonatal Abstinence Syndrome.
Topics: Female; Humans; Incidence; Infant, Newborn; Methadone; Morphine; Neonatal Abstinence Syndrome; Opiat | 2016 |
Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates.
Topics: Buprenorphine; Diagnosis, Dual (Psychiatry); Female; GABA Modulators; Humans; Infant, Newborn; Menta | 2008 |
[Methadone treatment and its dangers].
Topics: Adult; Analgesics, Opioid; Child, Preschool; Drug Interactions; Drug Overdose; Electrocardiography; | 2009 |
Prenatal drug exposure: infant and toddler outcomes.
Topics: Buprenorphine; Child Development; Child, Preschool; Cocaine; Cocaine-Related Disorders; Female; Hero | 2010 |
Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis.
Topics: Cohort Studies; Databases, Bibliographic; Dose-Response Relationship, Drug; Female; Humans; Infant, | 2010 |
Update on the pharmacologic management of neonatal abstinence syndrome.
Topics: Benzodiazepines; Buprenorphine; Clonidine; Female; Humans; Hypnotics and Sedatives; Infant, Newborn; | 2011 |
[Breast feeding during methadon- and buprenorphin therapy].
Topics: Analgesics, Opioid; Breast Feeding; Buprenorphine; Contraindications; Dose-Response Relationship, Dr | 2011 |
Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research.
Topics: Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naltrexone; Narcotic Antagonists; Narcoti | 2013 |
Methadone and buprenorphine for the management of opioid dependence in pregnancy.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence S | 2012 |
Novel pharmacotherapeutic strategies for treatment of opioid-induced neonatal abstinence syndrome.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Immunotherapy; Infant, Newborn; Methadone; Neonat | 2013 |
Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.
Topics: Buprenorphine; Child Development; Female; Fetus; Humans; Infant, Newborn; Length of Stay; Methadone; | 2012 |
Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.
Topics: Buprenorphine; Child Development; Female; Fetus; Humans; Infant, Newborn; Length of Stay; Methadone; | 2012 |
Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.
Topics: Buprenorphine; Child Development; Female; Fetus; Humans; Infant, Newborn; Length of Stay; Methadone; | 2012 |
Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.
Topics: Buprenorphine; Child Development; Female; Fetus; Humans; Infant, Newborn; Length of Stay; Methadone; | 2012 |
Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.
Topics: Buprenorphine; Child Development; Female; Fetus; Humans; Infant, Newborn; Length of Stay; Methadone; | 2012 |
Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.
Topics: Buprenorphine; Child Development; Female; Fetus; Humans; Infant, Newborn; Length of Stay; Methadone; | 2012 |
Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.
Topics: Buprenorphine; Child Development; Female; Fetus; Humans; Infant, Newborn; Length of Stay; Methadone; | 2012 |
Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.
Topics: Buprenorphine; Child Development; Female; Fetus; Humans; Infant, Newborn; Length of Stay; Methadone; | 2012 |
Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.
Topics: Buprenorphine; Child Development; Female; Fetus; Humans; Infant, Newborn; Length of Stay; Methadone; | 2012 |
Neonatal abstinence syndrome: therapeutic interventions.
Topics: Female; Humans; Infant; Infant Welfare; Infant, Newborn; Male; Methadone; Morphine; Narcotics; Neona | 2013 |
Opioid addiction in pregnancy.
Topics: Analgesics, Opioid; Breast Feeding; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Neona | 2012 |
Pharmacologic management of neonatal abstinence syndrome in a community hospital.
Topics: Analgesics, Opioid; Female; Florida; Humans; Infant, Newborn; Intensive Care, Neonatal; Length of St | 2013 |
Neonatal abstinence syndrome: treatment and pediatric outcomes.
Topics: Developmental Disabilities; Female; Humans; Infant, Newborn; Methadone; Narcotics; Neonatal Abstinen | 2013 |
Treatment of neonatal abstinence syndrome.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Heroin; Humans; Infant, Newborn; Methadone; Mor | 2003 |
[Is buprenorphine a potential alternative to methadone for treating pregnant drug users? Inventory of clinical data in the literature].
Topics: Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Narcotic Antagonists; Narcotics; Neonatal | 2002 |
Methadone and buprenorphine treatment during pregnancy: what are the effects on infants?
Topics: Analgesics, Opioid; Buprenorphine; Female; Fetus; Humans; Infant, Low Birth Weight; Infant, Newborn; | 2007 |
Effects of in-utero opiate exposure: new paradigms for old questions.
Topics: Female; Humans; Infant, Newborn; Methadone; Narcotics; Neonatal Abstinence Syndrome; Opioid-Related | 1994 |
Methadone during pregnancy: the search for a valid animal model.
Topics: Animals; Behavior, Animal; Child; Child, Preschool; Disease Models, Animal; Female; Heroin Dependenc | 1993 |
Current management of the neonatal abstinence syndrome: a critical analysis of the evidence.
Topics: Analgesics, Opioid; Anticonvulsants; Antipsychotic Agents; Chlorpromazine; Clinical Trials as Topic; | 1997 |
Opioid dependence during pregnancy. Effects and management.
Topics: Delivery, Obstetric; Female; Humans; Infant, Newborn; Methadone; Narcotics; Neonatal Abstinence Synd | 1998 |
Neonatal drug addiction.
Topics: Female; Heroin; Humans; Infant, Newborn; Methadone; Narcotics; Neonatal Abstinence Syndrome; Pregnan | 1998 |
[Special problems of HIV-positive women who are either drug abusers or on methadone replacement therapy].
Topics: Cocaine; Drug Administration Schedule; Female; Germany; Heroin; HIV Infections; HIV Protease Inhibit | 1999 |
[Pregnancy and drug abuse: current situation and therapeutic strategies].
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Female; Fetal Growth Retardation; Hepatit | 2000 |
Treatment of neonatal abstinence syndrome with breast milk containing methadone.
Topics: Breast Feeding; Drug Administration Schedule; Female; Humans; Infant, Newborn; Labor, Obstetric; Met | 2002 |
[Findings in newborn infants following drug abuse or drug weaning in the mother].
Topics: Abnormalities, Drug-Induced; Adult; Female; Fetal Growth Retardation; Heroin Dependence; Humans; Inf | 1991 |
Behavior and development patterns in children born to heroin-addicted and methadone-addicted mothers.
Topics: Child; Child Behavior Disorders; Child, Preschool; Developmental Disabilities; Female; Heroin; Human | 1988 |
37 trials available for methadone and Neonatal Abstinence Syndrome
| Article | Year |
|---|---|
Morphine versus methadone for neonatal opioid withdrawal syndrome: a randomized controlled pilot study.
Topics: Analgesics, Opioid; Humans; Infant, Newborn; Length of Stay; Methadone; Morphine; Neonatal Abstinenc | 2022 |
Pragmatic, randomized, blinded trial to shorten pharmacologic treatment of newborns with neonatal opioid withdrawal syndrome (NOWS).
Topics: Analgesics, Opioid; Family; Female; Humans; Infant, Newborn; Methadone; Morphine; Neonatal Abstinenc | 2023 |
Neurodevelopmental Outcomes of Neonates Randomized to Morphine or Methadone for Treatment of Neonatal Abstinence Syndrome.
Topics: Female; Humans; Infant; Infant, Newborn; Male; Methadone; Morphine; Narcotics; Neonatal Abstinence S | 2020 |
Neonatal Abstinence Syndrome Severity Index Predicts 18-Month Neurodevelopmental Outcome in Neonates Randomized to Morphine or Methadone.
Topics: Analgesics, Opioid; Cluster Analysis; Female; Humans; Infant; Infant, Newborn; Length of Stay; Male; | 2020 |
Randomized Clinical Trial of Standard- Versus High-Calorie Formula for Methadone-Exposed Infants: A Feasibility Study.
Topics: Double-Blind Method; Energy Intake; Feasibility Studies; Female; Humans; Infant Formula; Infant, New | 2018 |
Prenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes.
Topics: Adult; Buprenorphine; Child Development; Child, Preschool; Cognition; Female; Humans; Infant, Newbor | 2018 |
Comparison of Safety and Efficacy of Methadone vs Morphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Clinical Trial.
Topics: Analgesics, Opioid; Double-Blind Method; Female; Humans; Infant, Newborn; Intention to Treat Analysi | 2018 |
Comparison of Safety and Efficacy of Methadone vs Morphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Clinical Trial.
Topics: Analgesics, Opioid; Double-Blind Method; Female; Humans; Infant, Newborn; Intention to Treat Analysi | 2018 |
Comparison of Safety and Efficacy of Methadone vs Morphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Clinical Trial.
Topics: Analgesics, Opioid; Double-Blind Method; Female; Humans; Infant, Newborn; Intention to Treat Analysi | 2018 |
Comparison of Safety and Efficacy of Methadone vs Morphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Clinical Trial.
Topics: Analgesics, Opioid; Double-Blind Method; Female; Humans; Infant, Newborn; Intention to Treat Analysi | 2018 |
Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome.
Topics: Adult; Birth Weight; Buprenorphine; Female; Humans; Infant, Newborn; Length of Stay; Methadone; Neon | 2014 |
Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial.
Topics: Analgesics, Opioid; Birth Weight; Buprenorphine; Double-Blind Method; Female; Gestational Age; Human | 2015 |
The effect of prenatal alcohol co-exposure on neonatal abstinence syndrome in infants born to mothers in opioid maintenance treatment.
Topics: Adult; Alcohol Drinking; Female; Humans; Incidence; Infant, Newborn; Length of Stay; Methadone; Neon | 2016 |
Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study.
Topics: Analgesics, Opioid; Chromatography, Liquid; Humans; Infant, Newborn; Mass Spectrometry; Methadone; M | 2015 |
Psychometric assessment of the Neonatal Abstinence Scoring System and the MOTHER NAS Scale.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Neonatal Absti | 2016 |
Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes.
Topics: Adult; Buprenorphine; Cocaine; Double-Blind Method; Female; Humans; Infant, Newborn; Male; Maternal | 2008 |
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination; | 2009 |
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination; | 2009 |
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination; | 2009 |
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination; | 2009 |
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination; | 2009 |
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination; | 2009 |
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination; | 2009 |
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination; | 2009 |
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination; | 2009 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Randomized controlled trials in pregnancy: scientific and ethical aspects. Exposure to different opioid medications during pregnancy in an intra-individual comparison.
Topics: Adult; Analgesics, Opioid; Birth Weight; Buprenorphine; Double-Blind Method; Female; Humans; Infant, | 2011 |
Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study.
Topics: Adult; Analgesics, Opioid; Birth Weight; Buprenorphine; Female; Heroin; Heroin Dependence; Humans; I | 2011 |
Methadone, cocaine, opiates, and metabolite disposition in umbilical cord and correlations to maternal methadone dose and neonatal outcomes.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cocaine; Dose-Response Relationship, Drug; Female; Humans; | 2011 |
Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women.
Topics: Adult; Austria; Birth Weight; Buprenorphine; Double-Blind Method; Female; Gestational Age; Humans; I | 2011 |
Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?
Topics: Birth Weight; Buprenorphine; Double-Blind Method; Female; Humans; Infant, Newborn; Male; Methadone; | 2011 |
Maternal Opioid Treatment: Human Experimental Research (MOTHER) Study: maternal, fetal and neonatal outcomes from secondary analyses.
Topics: Adolescent; Adult; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Sy | 2012 |
Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication.
Topics: Adolescent; Adult; Analgesics, Opioid; Birth Weight; Buprenorphine; Dose-Response Relationship, Drug | 2012 |
Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates.
Topics: Adult; Analgesics, Opioid; Analysis of Variance; Buprenorphine; Double-Blind Method; Female; Humans; | 2012 |
Neonatal neurobehavior effects following buprenorphine versus methadone exposure.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Infant Behavior; Infant, Newbo | 2012 |
Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops.
Topics: Double-Blind Method; Female; Humans; Infant, Newborn; Male; Methadone; Morphine; Neonatal Abstinence | 2005 |
Neurobehavioral effects of treatment for opiate withdrawal.
Topics: Analgesics, Opioid; Drug Therapy, Combination; Heroin; Humans; Hypnotics and Sedatives; Infant Behav | 2005 |
Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome.
Topics: Administration, Sublingual; Adult; Buprenorphine; Double-Blind Method; Female; Heroin Dependence; Hu | 2005 |
Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study.
Topics: Buprenorphine; Double-Blind Method; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence | 2006 |
Management of neonatal abstinence syndrome in neonates born to opioid maintained women.
Topics: Adult; Apgar Score; Female; Gestational Age; Humans; Infant, Newborn; Male; Methadone; Morphine; Neo | 2007 |
Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates.
Topics: Adult; Apgar Score; Arrhythmia, Sinus; Electrocardiography; Female; Heart; Humans; Infant, Newborn; | 2007 |
Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the
Topics: Adult; Birth Weight; Buprenorphine; Female; Fetal Growth Retardation; Heroin; Heroin Dependence; Hum | 2008 |
Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme.
Topics: Adult; Biological Availability; Chromatography, High Pressure Liquid; Female; Humans; Infant, Newbor | 1997 |
Comparison of methadone and slow-release morphine maintenance in pregnant addicts.
Topics: Adolescent; Adult; Delayed-Action Preparations; Female; Humans; Infant, Newborn; Methadone; Morphine | 1999 |
Slow-release morphine was not more effective than methadone in reducing neonatal abstinence syndrome.
Topics: Adult; Delayed-Action Preparations; Female; Humans; Infant, Newborn; Methadone; Morphine; Narcotics; | 2000 |
[Withdrawal syndromes of newborns of pregnant drug abusers maintained under methadone or high-dose buprenorphine: 246 cases].
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Morphine; Neonatal Ab | 2001 |
Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants.
Topics: Analgesics, Opioid; Drug Therapy, Combination; Heroin; Hospital Costs; Humans; Hypnotics and Sedativ | 2002 |
Waterbed care of narcotic-exposed neonates. A useful adjunct to supportive care.
Topics: Beds; Cocaine; Heroin; Humans; Infant Care; Infant, Newborn; Methadone; Methamphetamine; Neonatal Ab | 1988 |
263 other studies available for methadone and Neonatal Abstinence Syndrome
| Article | Year |
|---|---|
Opioid Use Disorder and Perinatal Outcomes.
Topics: Adult; Analgesics, Opioid; British Columbia; Buprenorphine; Female; Humans; Incidence; Infant, Newbo | 2021 |
Neonatal Abstinence Syndrome: A Call for Mother-Infant Dyad Treatment Approach.
Topics: Adolescent; Adult; Analgesics, Opioid; Female; Humans; Infant; Infant, Newborn; Methadone; Mother-Ch | 2021 |
A retrospective, observational study on medication for opioid use disorder during pregnancy and risk for neonatal abstinence syndrome.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant; Infant, Newborn; Methadone; Neonatal Abst | 2022 |
Neonatal Abstinence Syndrome: Prevention, Recognition, Treatment, and Follow-up.
Topics: Analgesics, Opioid; Child, Preschool; Female; Follow-Up Studies; Humans; Infant, Newborn; Methadone; | 2021 |
Neonatal Opioid Withdrawal Syndrome: A Comparison of As-Needed Pharmacotherapy.
Topics: Analgesics, Opioid; Female; Humans; Infant; Infant, Newborn; Methadone; Morphine; Neonatal Abstinenc | 2022 |
Characteristics of Prescription Opioid Analgesics in Pregnancy and Risk of Neonatal Opioid Withdrawal Syndrome in Newborns.
Topics: Adult; Analgesics, Opioid; Codeine; Cohort Studies; Female; Humans; Hydrocodone; Hydromorphone; Infa | 2022 |
Resource utilization and convalescent care cost in neonatal opioid withdrawal syndrome.
Topics: Analgesics, Opioid; Buprenorphine; Child; Hospitalization; Humans; Infant; Infant, Newborn; Length o | 2023 |
Comparative Safety Analysis of Opioid Agonist Treatment in Pregnant Women with Opioid Use Disorder: A Population-Based Study.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence S | 2023 |
Effect of Neonatal Abstinence Syndrome Treatment Status and Maternal Depressive Symptomatology on Maternal Reports of Infant Behaviors.
Topics: Analgesics, Opioid; Female; Humans; Infant; Infant, Newborn; Methadone; Mothers; Neonatal Abstinence | 2023 |
Distribution of morphine and methadone to the brain in a developmental chicken embryo model.
Topics: Analgesics, Opioid; Animals; Brain; Chick Embryo; Chickens; Chromatography, Liquid; Drug Tolerance; | 2023 |
Prenatal exposure to opioid maintenance treatment and neonatal outcomes: Nationwide registry studies from the Czech Republic and Norway.
Topics: Adult; Buprenorphine; Child Development; Czech Republic; Female; Humans; Infant, Newborn; Logistic M | 2019 |
Management of Newborns with Prenatal Opioid Exposure: One Institution's Journey.
Topics: Analgesics, Opioid; Female; Humans; Infant, Newborn; Length of Stay; Methadone; Morphine; Neonatal A | 2019 |
The imperative of clinical and molecular research on neonatal opioid withdrawal syndrome.
Topics: Analgesics, Opioid; Humans; Infant; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Opioid | 2019 |
Buprenorphine compared with methadone in opioid-dependent pregnant women: How does it affect neonatal abstinence syndrome?
Topics: Adult; Buprenorphine; Female; Humans; Infant; Infant, Newborn; Length of Stay; Methadone; Narcotic A | 2019 |
Utilizing Pediatric Physiologically Based Pharmacokinetic Models to Examine Factors That Contribute to Methadone Pharmacokinetic Variability in Neonatal Abstinence Syndrome Patients.
Topics: Adolescent; Adult; Analgesics, Opioid; Area Under Curve; Cardiac Output; Computer Simulation; Cytoch | 2020 |
Diverse changes in myelin protein expression in rat brain after perinatal methadone exposure.
Topics: 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase; Animals; Brain; Female; Male; Methadone; Myelin Basic | 2019 |
Neonatal Abstinence Syndrome.
Topics: History, 19th Century; History, 20th Century; Humans; Infant, Newborn; Methadone; Morphine; Neonatal | 2020 |
Stereoselective Analysis of Methadone and EDDP in Laboring Women and Neonates in Plasma and Dried Blood Spots and Association with Neonatal Abstinence Syndrome.
Topics: Analgesics, Opioid; Anticonvulsants; Dried Blood Spot Testing; Female; Humans; Infant, Newborn; Labo | 2021 |
Screening for Opioid and Stimulant Exposure In Utero Through Targeted and Untargeted Metabolomics Analysis of Umbilical Cords.
Topics: Analgesics, Opioid; Central Nervous System Stimulants; Chromatography, Liquid; Cocaine; Female; Huma | 2020 |
Emerging therapies for the treatment of neonatal abstinence syndrome.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Morphine; Neonatal Ab | 2022 |
Necrotizing enterocolitis and its association with the neonatal abstinence syndrome.
Topics: Analgesics, Opioid; Buprenorphine; Cohort Studies; Enterocolitis, Necrotizing; Female; Fetal Blood; | 2020 |
Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome.
Topics: Analgesics, Opioid; Clonidine; Humans; Infant, Newborn; Length of Stay; Methadone; Morphine; Neonata | 2020 |
Effects of polysubstance exposure on neonatal outcomes for infants with intrauterine opioid exposure.
Topics: Analgesics, Opioid; Female; Humans; Infant; Infant, Newborn; Length of Stay; Methadone; Morphine; Ne | 2020 |
Comparison of buprenorphine and methadone in the management of maternal opioid use disorder in full term pregnancies.
Topics: Birth Weight; Buprenorphine; Delivery, Obstetric; Female; Humans; Infant, Newborn; Length of Stay; M | 2020 |
Adverse neonatal outcomes associated with maternal severe mental health diagnoses and opioid use.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Mental Health; Methadone; Neonat | 2020 |
Improving Hospital Care of Opioid-Exposed Newborns: Successes and Remaining Questions.
Topics: Analgesics, Opioid; Hospitals; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome | 2020 |
Orchestrated Testing of Formula Type to Reduce Length of Stay in Neonatal Abstinence Syndrome.
Topics: Energy Intake; Female; Humans; Infant Formula; Infant, Newborn; Lactose; Length of Stay; Methadone; | 2020 |
Neurobehavior of newborn infants exposed prenatally to methadone and identification of a neurobehavioral profile linked to poorer neurodevelopmental outcomes at age 24 months.
Topics: Adult; Analgesics, Opioid; Attention; Case-Control Studies; Child Development; Female; Humans; Infan | 2020 |
Proxy Finnegan Component Scores for Eat, Sleep, Console in a Cohort of Opioid-Exposed Neonates.
Topics: Analgesics, Opioid; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Retrospective | 2020 |
Prevalence and Geographic Distribution of Obstetrician-Gynecologists Who Treat Medicaid Enrollees and Are Trained to Prescribe Buprenorphine.
Topics: Adult; Buprenorphine; Cross-Sectional Studies; Female; Humans; Infant, Newborn; Male; Medicaid; Meth | 2020 |
Is Maternal Methadone Dose Associated with the Severity of Neonatal Abstinence Syndrome?
Topics: Female; Humans; Infant, Newborn; Methadone; Morphine; Neonatal Abstinence Syndrome; Opioid-Related D | 2022 |
Neonatal abstinence syndrome in neonates born of mothers in drug-assisted rehabilitation.
Topics: Female; Humans; Infant; Infant, Newborn; Methadone; Mothers; Neonatal Abstinence Syndrome; Norway; O | 2021 |
Cost effectiveness of buprenorphine vs. methadone for pregnant people with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Cerebral Palsy; Cost-Benefit Analysis; Female; Fetal Growth Retar | 2022 |
Conceptualizing stigma in contexts of pregnancy and opioid misuse: A qualitative study with women and healthcare providers in Ohio.
Topics: Adult; Buprenorphine; Female; Health Personnel; Humans; Infant, Newborn; Methadone; Neonatal Abstine | 2021 |
Outcomes associated with the use of medications for opioid use disorder during pregnancy.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant; Infant, Newborn; Methadone; Neonatal Abst | 2021 |
Nail disease in neonatal abstinence syndrome.
Topics: Female; Humans; Infant; Infant, Newborn; Male; Methadone; Nail Diseases; Neonatal Abstinence Syndrom | 2021 |
Variations in Infant CYP2B6 Genotype Associated with the Need for Pharmacological Treatment for Neonatal Abstinence Syndrome in Infants of Methadone-Maintained Opioid-Dependent Mothers.
Topics: Adult; Analgesics, Opioid; Cohort Studies; Cytochrome P-450 CYP2B6; Female; Genetic Variation; Human | 2017 |
Infants Born to Opioid-Dependent Women in Ontario, 2002-2014.
Topics: Adult; Buprenorphine; Congenital Abnormalities; Databases, Factual; Female; Health Care Costs; Human | 2017 |
An Outpatient Methadone Weaning Program by a Neonatal Intensive Care Unit for Neonatal Abstinence Syndrome.
Topics: Analgesics, Opioid; Female; Humans; Infant, Newborn; Intensive Care Units, Neonatal; Male; Methadone | 2017 |
A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates.
Topics: Adult; Australia; Buprenorphine; Drug Administration Routes; Female; Humans; Incidence; Infant, Newb | 2017 |
Neonatal abstinence syndrome: Neurobehavior at 6 weeks of age in infants with or without pharmacological treatment for withdrawal.
Topics: Adult; Female; Humans; Infant; Infant Behavior; Infant, Newborn; Male; Methadone; Narcotic Antagonis | 2017 |
An Initiative to Improve the Quality of Care of Infants With Neonatal Abstinence Syndrome.
Topics: Female; Hospital Costs; Humans; Infant, Newborn; Length of Stay; Male; Methadone; Morphine; Narcotic | 2017 |
Sensorimotor outcomes in children with prenatal exposure to methadone.
Topics: Age of Onset; Exotropia; Female; Humans; Infant; Methadone; Narcotics; Neonatal Abstinence Syndrome; | 2017 |
Transitioning from methadone to buprenorphine maintenance in management of opioid use disorder during pregnancy.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Drug Substitution; Female; Humans; Infant, Newborn; Methad | 2018 |
Maternal buprenorphine treatment and infant outcome.
Topics: Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Opiate Subs | 2017 |
Buprenorphine for the Neonatal Abstinence Syndrome.
Topics: Buprenorphine; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Opiate Substitution | 2017 |
Buprenorphine for the Neonatal Abstinence Syndrome.
Topics: Buprenorphine; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Opiate Substitution | 2017 |
Buprenorphine for the Neonatal Abstinence Syndrome.
Topics: Buprenorphine; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Opiate Substitution | 2017 |
Buprenorphine for the Neonatal Abstinence Syndrome.
Topics: Buprenorphine; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Opiate Substitution | 2017 |
The Effect of Morphine Dosing on Length of Stay in Neonatal Abstinence Syndrome - An Alternative Viewpoint.
Topics: Hospitals, Community; Humans; Infant, Newborn; Length of Stay; Methadone; Morphine; Neonatal Abstine | 2017 |
Antenatal methadone vs buprenorphine exposure and length of hospital stay in infants admitted to the intensive care unit with neonatal abstinence syndrome.
Topics: Adult; Buprenorphine; Female; Gestational Age; Humans; Infant, Newborn; Intensive Care Units, Neonat | 2018 |
Methadone Versus Buprenorphine for Opioid Use Dependence and Risk of Neonatal Abstinence Syndrome.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Neonatal Absti | 2018 |
Comparison of Neonatal Abstinence Syndrome Treatment with Sublingual Buprenorphine versus Conventional Opioids.
Topics: Analgesics, Opioid; Buprenorphine; Drug Administration Schedule; Female; Humans; Infant, Newborn; Le | 2018 |
The Role of Preterm Birth in the Association Between Opioid Maintenance Therapy and Neonatal Abstinence Syndrome.
Topics: Adult; Buprenorphine; Female; Humans; Infant, Newborn; Maternal Age; Methadone; Neonatal Abstinence | 2018 |
Neonatal outcomes after fetal exposure to methadone and buprenorphine: national registry studies from the Czech Republic and Norway.
Topics: Abortion, Spontaneous; Adult; Analgesics, Opioid; Apgar Score; Buprenorphine; Czech Republic; Female | 2018 |
Treating women with opioid use disorder during pregnancy in Appalachia: Initial neonatal outcomes following buprenorphine + naloxone exposure.
Topics: Adult; Appalachian Region; Birth Weight; Buprenorphine, Naloxone Drug Combination; Female; Humans; I | 2018 |
Pregnancy and the Opioid Epidemic.
Topics: Analgesics, Opioid; Epidemics; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndr | 2018 |
Opioid Utilization by Pregnant Women with Sickle Cell Disease and the Risk of Neonatal Abstinence Syndrome.
Topics: Adult; Analgesics, Opioid; Anemia, Sickle Cell; Case-Control Studies; Female; Humans; Incidence; Met | 2018 |
Barriers and Facilitators of Breastfeeding Reported by Postpartum Women in Methadone Maintenance Therapy.
Topics: Adolescent; Adult; Breast Feeding; Cross-Sectional Studies; Female; Humans; Infant; Infant Nutrition | 2018 |
Examination of Hospital, Maternal, and Infant Characteristics Associated with Breastfeeding Initiation and Continuation Among Opioid-Exposed Mother-Infant Dyads.
Topics: Adult; Breast Feeding; Evidence-Based Practice; Female; Humans; Infant; Infant Nutritional Physiolog | 2018 |
Quality improvement initiative to improve inpatient outcomes for Neonatal Abstinence Syndrome.
Topics: Adult; Female; Hospital Costs; Humans; Infant, Newborn; Inpatients; Length of Stay; Male; Methadone; | 2018 |
Outpatient Pharmacotherapy for Neonatal Abstinence Syndrome.
Topics: Ambulatory Care; Analgesics, Opioid; Drug Therapy, Combination; Emergency Service, Hospital; Facilit | 2018 |
The effect of standardizing treatment when managing neonatal abstinence syndrome
Topics: Adolescent; Adult; Analgesics, Opioid; Clinical Protocols; Comorbidity; Female; Humans; Infant; Infa | 2019 |
Early Treatment Innovation for Opioid-Dependent Newborns: A Retrospective Comparison of Outcomes, Utilization, Quality, and Safety, 2006-2014.
Topics: Child Protective Services; Community Health Services; Continuity of Patient Care; Cooperative Behavi | 2018 |
Reconsidering retrospective review of neurodevelopmental outcomes in infants treated for neonatal abstinence syndrome.
Topics: Humans; Infant; Infant, Newborn; Infant, Premature; Methadone; Neonatal Abstinence Syndrome; Retrosp | 2018 |
Impact of psychiatric medication co-exposure on Neonatal Abstinence Syndrome severity.
Topics: Adult; Analgesics, Opioid; Benzodiazepines; Buprenorphine; Female; Gabapentin; Humans; Infant; Infan | 2018 |
Morphine vs Methadone Treatment for Infants with Neonatal Abstinence Syndrome.
Topics: Cohort Studies; Databases, Factual; Female; Follow-Up Studies; Humans; Infant, Newborn; Intensive Ca | 2018 |
Relationship Between Methadone, Selective Serotonin Reuptake Inhibitors, and Neonatal Abstinence Syndrome.
Topics: Adult; Cohort Studies; Female; Humans; Infant, Newborn; Intensive Care Units, Neonatal; Length of St | 2016 |
Novel Withdrawal Symptoms of a Neonate Prenatally Exposed to a Fentanyl Analog.
Topics: Anticonvulsants; Clonidine; Female; Fentanyl; Humans; Infant, Newborn; Levetiracetam; Methadone; Myo | 2019 |
Could prenatal food insecurity influence neonatal abstinence syndrome severity?
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Food Supply; Humans; Methadone; Neonatal Abstinenc | 2019 |
Methadone dosing strategies in preterm neonates can be simplified.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Analgesics, Opioid; Drug Dosage Calculations; | 2019 |
Implications of perinatal buprenorphine exposure on infant head circumference at birth.
Topics: Buprenorphine; Female; Humans; Infant; Infant, Newborn; Male; Methadone; Neonatal Abstinence Syndrom | 2021 |
Morphine vs methadone in the treatment of neonatal abstinence syndrome.
Topics: Humans; Infant, Newborn; Methadone; Morphine; Narcotics; Neonatal Abstinence Syndrome; Opioid-Relate | 2019 |
Interventions for the Treatment of Neonatal Abstinence Syndrome.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Male; Methadone; Morphine; Neona | 2019 |
Standard Fixed-Schedule Methadone Taper Versus Symptom-Triggered Methadone Approach for Treatment of Neonatal Opioid Withdrawal Syndrome.
Topics: Adult; Analgesics, Opioid; Boston; Drug Administration Schedule; Female; Humans; Infant, Newborn; Le | 2019 |
Prevalence of Maternal-Risk Factors Related to Neonatal Abstinence Syndrome in a Commercial Claims Database: 2011-2015.
Topics: Adult; Analgesics, Opioid; Drug Prescriptions; Female; Humans; Incidence; Infant, Newborn; Insurance | 2019 |
Evaluation of a Nurse-Led Program for Rural Pregnant Women With Opioid Use Disorder to Improve Maternal-Neonatal Outcomes.
Topics: Adult; Buprenorphine; Databases, Factual; Female; Hospitals, Community; Humans; Infant Health; Massa | 2019 |
Use of naltrexone in treating opioid use disorder in pregnancy.
Topics: Abortion, Spontaneous; Adult; Analgesics, Opioid; Buprenorphine; Case-Control Studies; Female; Human | 2020 |
Predictors of neonatal outcomes amongst a methadone- and/or heroin-dependent population referred to a multidisciplinary Perinatal and Family Drug Health Service.
Topics: Adult; Child Custody; Female; Gestational Age; Heroin Dependence; Humans; Infant, Low Birth Weight; | 2013 |
The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy.
Topics: Adult; Cohort Studies; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Opi | 2013 |
Time to initiation of treatment for neonatal abstinence syndrome in neonates exposed in utero to buprenorphine or methadone.
Topics: Birth Weight; Buprenorphine; Case-Control Studies; Female; Gestational Age; Humans; Infant, Newborn; | 2013 |
Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants.
Topics: Adult; Breast Feeding; Buprenorphine; Cohort Studies; Female; Humans; Infant, Newborn; Methadone; Na | 2013 |
Development of auditory event-related potentials in infants prenatally exposed to methadone.
Topics: Acoustic Stimulation; Adult; Auditory Cortex; Electroencephalography; Evoked Potentials, Auditory; F | 2014 |
Effectiveness of a clinical pathway with methadone treatment protocol for treatment of neonatal abstinence syndrome following in utero drug exposure to substances of abuse*.
Topics: Analgesics, Opioid; Clinical Protocols; Female; Humans; Infant, Newborn; Intensive Care Units, Neona | 2014 |
External validation of the medication taper complexity score for methadone tapers in children with opioid abstinence syndrome.
Topics: Analgesics, Opioid; Child; Drug Administration Schedule; Humans; Methadone; Neonatal Abstinence Synd | 2014 |
Searching the right way to treat neonatal abstinence syndrome*.
Topics: Analgesics, Opioid; Female; Humans; Male; Methadone; Neonatal Abstinence Syndrome; Pregnancy; Pregna | 2014 |
Neonatal abstinence syndrome: on the evidence to add breastfeeding to any clinical pathway.
Topics: Analgesics, Opioid; Female; Humans; Male; Methadone; Neonatal Abstinence Syndrome; Pregnancy; Pregna | 2014 |
The authors reply.
Topics: Analgesics, Opioid; Female; Humans; Male; Methadone; Neonatal Abstinence Syndrome; Pregnancy; Pregna | 2014 |
A multicenter cohort study of treatments and hospital outcomes in neonatal abstinence syndrome.
Topics: Adult; Clinical Protocols; Female; Humans; Hypnotics and Sedatives; Infant, Newborn; Infant, Prematu | 2014 |
Identification of early developmental deficits in infants with prenatal heroin, methadone, and other opioid exposure.
Topics: Analgesics, Opioid; Child Development; Developmental Disabilities; Female; Heroin; Humans; Infant; I | 2015 |
Infants of opioid-dependent mothers: neurodevelopment at six months.
Topics: Adult; Analgesics, Opioid; Case-Control Studies; Child Development; Female; Humans; Infant; Infant, | 2015 |
Management of neonatal abstinence syndrome in the newborn nursery.
Topics: Female; Humans; Infant, Newborn; Methadone; Mother-Child Relations; Neonatal Abstinence Syndrome; Pr | 2014 |
Buprenorphine and naloxone compared with methadone treatment in pregnancy.
Topics: Adult; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naloxone; Narcotic Antagonists; Na | 2015 |
Buprenorphine and naloxone compared with methadone treatment in pregnancy.
Topics: Adult; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naloxone; Narcotic Antagonists; Na | 2015 |
Buprenorphine and naloxone compared with methadone treatment in pregnancy.
Topics: Adult; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naloxone; Narcotic Antagonists; Na | 2015 |
Buprenorphine and naloxone compared with methadone treatment in pregnancy.
Topics: Adult; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naloxone; Narcotic Antagonists; Na | 2015 |
Maternal Substance Use and Neonatal Abstinence Syndrome: A Descriptive Study.
Topics: Adolescent; Adult; Female; Humans; Infant, Newborn; Length of Stay; Methadone; Mothers; Neonatal Abs | 2015 |
Caring for Opioid-dependent Pregnant Women: Prenatal and Postpartum Care Considerations.
Topics: Alcohol-Related Disorders; Breast Feeding; Counseling; Female; Humans; Incidence; Infant, Newborn; M | 2015 |
Neonatal Abstinence Syndrome: Influence of a Combined Inpatient/Outpatient Methadone Treatment Regimen on the Average Length of Stay of a Medicaid NICU Population.
Topics: Ambulatory Care; Analgesics, Opioid; Female; Humans; Infant, Newborn; Intensive Care, Neonatal; Leng | 2015 |
Growth and developmental outcome of infants with in-utero exposure to methadone vs buprenorphine.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Infant; Infant, Newborn; Infant, Premature | 2015 |
Maternal methadone treatment and neonatal abstinence syndrome.
Topics: Female; Gestational Age; Humans; Infant, Newborn; Infant, Premature; Length of Stay; Logistic Models | 2015 |
Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study.
Topics: Adolescent; Adult; Analgesics, Opioid; Cohort Studies; Dose-Response Relationship, Drug; Female; Hum | 2015 |
Obstetrical and neonatal outcomes of methadone-maintained pregnant women: a canadian multisite cohort study.
Topics: Adult; Birth Weight; Breast Feeding; Canada; Female; Gestational Age; Humans; Infant, Newborn; Lengt | 2015 |
Design of pediatric oral formulations with a low proportion of methadone or phenobarbital for the treatment of neonatal abstinence syndrome.
Topics: Administration, Oral; Chemistry, Pharmaceutical; Drug Design; Drug Packaging; Drug Stability; Humans | 2016 |
Neonatal abstinence syndrome: a policy perspective.
Topics: Heroin; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Perinatal Care; Public Hea | 2015 |
Neonatal abstinence syndrome: Historical perspective, current focus, future directions.
Topics: Adult; Analgesics, Opioid; Female; History, 19th Century; History, 20th Century; History, 21st Centu | 2015 |
Implementation of a Neonatal Abstinence Syndrome Weaning Protocol: A Multicenter Cohort Study.
Topics: Adult; Analgesics, Opioid; Clinical Protocols; Cohort Studies; Female; Humans; Infant, Newborn; Leng | 2015 |
Neonatal abstinence syndrome: use of clonazepam?
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Methadone; Morphine; Neonatal Abstinence Sy | 2015 |
Reply to 'Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial'.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Methadone; Morphine; Neonatal Abstinence Sy | 2015 |
The Triple Aim for Neonatal Abstinence Syndrome.
Topics: Analgesics, Opioid; Humans; Methadone; Neonatal Abstinence Syndrome | 2015 |
Long-Acting Opioids for Treating Neonatal Abstinence Syndrome: A High Price for a Short Stay?
Topics: Analgesics, Opioid; Half-Life; Humans; Infant, Newborn; Length of Stay; Methadone; Morphine; Neonata | 2015 |
Cohort Analysis of a Pharmacokinetic-Modeled Methadone Weaning Optimization for Neonatal Abstinence Syndrome.
Topics: Adult; Analgesics, Opioid; Cohort Studies; Female; Humans; Infant, Newborn; Length of Stay; Male; Me | 2015 |
Revision of Breastfeeding Guidelines in the Setting of Maternal Opioid Use Disorder: One Institution's Experience.
Topics: Analgesics, Opioid; Boston; Breast Feeding; Buprenorphine; Female; Health Promotion; Humans; Infant, | 2016 |
Retrospective chart review comparing morphine and methadone in neonates treated for neonatal abstinence syndrome.
Topics: Administration, Oral; Analgesics, Opioid; Female; Humans; Infant, Newborn; Male; Methadone; Morphine | 2015 |
Rooming-in for Infants at Risk of Neonatal Abstinence Syndrome.
Topics: Adult; Analgesics, Opioid; Bottle Feeding; Breast Feeding; Canada; Female; Humans; Infant, Newborn; | 2016 |
A Cohort Comparison of Buprenorphine versus Methadone Treatment for Neonatal Abstinence Syndrome.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Clinical Protocols; Cohort Studies; Female; Humans; Infant | 2016 |
Neonatal withdrawal syndrome and perinatal asphyxia. How to manage the patient? Case Report.
Topics: Asphyxia Neonatorum; Disease Management; Humans; Infant, Newborn; Methadone; Morphine; Narcotics; Ne | 2015 |
Effect of breastfeeding on neonatal abstinence syndrome.
Topics: Breast Feeding; Humans; Infant, Newborn; Length of Stay; Methadone; Morphine; Neonatal Abstinence Sy | 2016 |
Characteristics of Maternal-Infant Interaction During Treatment for Opioid Withdrawal.
Topics: Adolescent; Adult; Bottle Feeding; Case-Control Studies; Female; Humans; Infant, Newborn; Male; Meth | 2016 |
Neonatal Abstinence Syndrome: Twelve Years of Experience at a Regional Referral Center.
Topics: Buprenorphine; Diseases in Twins; Female; Hospitalization; Humans; Infant, Newborn; Male; Methadone; | 2017 |
Neonatal abstinence syndrome and the gastrointestinal tract.
Topics: Analgesics, Opioid; Buprenorphine; Child; Child, Preschool; Dysbiosis; Female; Gastrointestinal Trac | 2016 |
The relationship between gestational age and the severity of neonatal abstinence syndrome.
Topics: Adult; Analgesics, Opioid; Female; Gestational Age; Humans; Infant, Newborn; Intensive Care Units, N | 2017 |
An Atypical Withdrawal Syndrome in Neonates Prenatally Exposed to Gabapentin and Opioids.
Topics: Amines; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid | 2017 |
Early Treatment for Neonatal Abstinence Syndrome: A Palliative Approach.
Topics: Analgesics, Opioid; Female; Humans; Infant, Newborn; Length of Stay; Male; Methadone; Neonatal Absti | 2017 |
The comparative safety of buprenorphine versus methadone in pregnancy-what about confounding?
Topics: Buprenorphine; Female; Humans; Methadone; Neonatal Abstinence Syndrome; Opiate Substitution Treatmen | 2016 |
Commentary on Gibson et al. (2017): Gestational age and the severity of neonatal abstinence syndrome.
Topics: Buprenorphine; Gestational Age; Humans; Infant, Newborn; Methadone; Morphine; Neonatal Abstinence Sy | 2017 |
Outpatient Management of Neonatal Abstinence Syndrome: A Quality Improvement Project.
Topics: Academic Medical Centers; Ambulatory Care; Disease Management; Female; Guideline Adherence; Humans; | 2016 |
Neonatal abstinence syndrome.
Topics: Female; Humans; Infant; Infant, Newborn; Male; Maternal-Fetal Exchange; Methadone; Morphine; Mothers | 2008 |
Chronic hepatitis C in pregnancy.
Topics: Adult; Cholestasis; Comorbidity; Female; Hepatitis C, Chronic; Humans; Infant, Newborn; Methadone; N | 2008 |
Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates.
Topics: Analgesics, Opioid; Benzodiazepines; Female; Gestational Age; Humans; Infant, Newborn; Male; Methado | 2008 |
Maternal and neonatal effects of substance abuse during pregnancy: our ten-year experience.
Topics: Adult; Apgar Score; Birth Weight; Croatia; Female; Heroin; Heroin Dependence; Humans; Incidence; Inf | 2008 |
High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome.
Topics: Adult; Anticonvulsants; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Infant, Ne | 2009 |
Management of neonatal abstinence syndrome: a national survey and review of practice.
Topics: Anticonvulsants; Breast Feeding; Drug Administration Schedule; Health Care Surveys; Humans; Infant C | 2009 |
[Substitution treatment of drug addicts during pregnancy: consequences for the children?].
Topics: Buprenorphine; Developmental Disabilities; Female; Humans; Infant, Newborn; Methadone; Narcotics; Ne | 2009 |
Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources.
Topics: Adolescent; Adult; Breast Feeding; Dose-Response Relationship, Drug; Drug Users; Female; Gestational | 2009 |
Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study.
Topics: Adult; Buprenorphine; Cohort Studies; Female; Humans; Infant, Newborn; Male; Methadone; Neonatal Abs | 2009 |
Buprenorphine and pregnancy.
Topics: Buprenorphine; Congenital Abnormalities; Female; France; Humans; Infant, Newborn; Methadone; Neonata | 2009 |
Women treated with methadone are at high risk for poor obstetrical and neonatal outcome.
Topics: Dose-Response Relationship, Drug; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Sy | 2009 |
Pregnancy and neonatal characteristics of opioid-dependent Indigenous Australians: a rural and metropolitan comparison.
Topics: Adult; Analgesics, Opioid; Australia; Female; Humans; Infant, Newborn; Methadone; Native Hawaiian or | 2009 |
Prenatal methadone exposure and neonatal neurobehavioral functioning.
Topics: Analysis of Variance; Female; Humans; Infant, Newborn; Lethargy; Maternal Exposure; Methadone; Movem | 2009 |
Treatment of neonatal abstinence syndrome with clonidine and chloral hydrate.
Topics: Blood Pressure; Chloral Hydrate; Clonidine; Drug Therapy, Combination; Female; Humans; Hypnotics and | 2010 |
Drug addiction during pregnancy: correlations between the placental health and the newborn's outcome - elaboration of a predictive score.
Topics: Adult; Analgesics, Opioid; Cannabis; Cocaine; Ethanol; Female; Gestational Age; Humans; Infant, Newb | 2009 |
Patterns in sleep-wakefulness in three-month old infants exposed to methadone or buprenorphine.
Topics: Adult; Buprenorphine; Chronobiology Disorders; Female; Humans; Infant; Infant Behavior; Infant, Newb | 2009 |
Infant autonomic functioning and neonatal abstinence syndrome.
Topics: Adult; Apgar Score; Autonomic Nervous System; Cocaine-Related Disorders; Data Interpretation, Statis | 2010 |
Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome.
Topics: Cohort Studies; Female; Humans; Incidence; Infant, Newborn; Methadone; Narcotics; Neonatal Abstinenc | 2010 |
Maternal and neonatal factors impacting response to methadone therapy in infants treated for neonatal abstinence syndrome.
Topics: Breast Feeding; Dose-Response Relationship, Drug; Female; Humans; Infant, Newborn; Infant, Premature | 2011 |
Gender and NAS: does sex matter?
Topics: Analgesics, Opioid; Female; Humans; Infant, Newborn; Male; Methadone; Morphine; Neonatal Abstinence | 2010 |
Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy.
Topics: Adult; Female; Humans; Infant, Newborn; Logistic Models; Methadone; Narcotics; Neonatal Abstinence S | 2010 |
Postnatal weight loss in substitute methadone-exposed infants: implications for the management of breast feeding.
Topics: Adolescent; Adult; Birth Weight; Bottle Feeding; Breast Feeding; Female; Gestational Age; Humans; In | 2012 |
Breastfeeding rates among mothers of infants with neonatal abstinence syndrome.
Topics: Adult; Breast Feeding; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Mothers; Neonatal | 2010 |
Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome.
Topics: Adult; Analgesics, Opioid; Cocaine; Cocaine-Related Disorders; Female; Gestational Age; Humans; Infa | 2010 |
Neonatal and maternal outcomes following maternal use of buprenorphine or methadone during pregnancy: findings of a retrospective audit.
Topics: Adult; Buprenorphine; Female; Humans; Infant, Newborn; Maternal Health Services; Maternal Welfare; M | 2011 |
Maternal methadone dose at delivery and neonatal abstinence syndrome.
Topics: Delivery, Obstetric; Humans; Infant, Newborn; Methadone; Narcotics; Neonatal Abstinence Syndrome | 2010 |
Association between intrapartum fetal heart rate patterns and neonatal abstinence syndrome in methadone exposed neonates.
Topics: Adult; Analgesics, Opioid; Female; Heart Rate, Fetal; Humans; Infant, Newborn; Labor, Obstetric; Mat | 2011 |
Methadone and perinatal outcomes: a retrospective cohort study.
Topics: Age Factors; Dose-Response Relationship, Drug; Female; Humans; Infant, Newborn; Methadone; Narcotics | 2011 |
Higher maternal doses of methadone does not increase neonatal abstinence syndrome.
Topics: Adult; Birth Weight; Dose-Response Relationship, Drug; Female; Humans; Infant, Newborn; Methadone; N | 2011 |
Estimated infant exposure to enantiomer-specific methadone levels in breastmilk.
Topics: Adolescent; Adult; Analgesics, Opioid; Breast Feeding; Dose-Response Relationship, Drug; Female; Hum | 2011 |
Methadone and perinatal outcomes: another perspective.
Topics: Female; Humans; Methadone; Neonatal Abstinence Syndrome; Opiate Substitution Treatment; Opioid-Relat | 2011 |
Neonatal abstinence syndrome: transitioning methadone-treated infants from an inpatient to an outpatient setting.
Topics: Ambulatory Care; Female; Hospitalization; Humans; Infant, Newborn; Infant, Premature, Diseases; Leng | 2012 |
The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome.
Topics: Boston; Buprenorphine; Cross-Sectional Studies; Drug Interactions; Drug Therapy, Combination; Female | 2011 |
The worldwide opioid epidemic: implications for treatment and research in pregnancy and the newborn.
Topics: Analgesics, Opioid; Biomedical Research; Buprenorphine; Female; Humans; Infant, Newborn; Internation | 2011 |
Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes.
Topics: Adult; Female; Fetal Monitoring; Humans; Illicit Drugs; Infant, Newborn; Methadone; Neonatal Abstine | 2012 |
Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes.
Topics: Adult; Female; Fetal Monitoring; Humans; Illicit Drugs; Infant, Newborn; Methadone; Neonatal Abstine | 2012 |
Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes.
Topics: Adult; Female; Fetal Monitoring; Humans; Illicit Drugs; Infant, Newborn; Methadone; Neonatal Abstine | 2012 |
Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes.
Topics: Adult; Female; Fetal Monitoring; Humans; Illicit Drugs; Infant, Newborn; Methadone; Neonatal Abstine | 2012 |
The impact of infant feeding method on neonatal abstinence scores of methadone-exposed infants.
Topics: Adolescent; Adult; Analysis of Variance; Breast Feeding; Female; Humans; Infant Formula; Infant, New | 2011 |
Strength in numbers: a step closer to standardising perinatal care for drug-misusing women and their infants.
Topics: Female; Humans; Methadone; Narcotics; Neonatal Abstinence Syndrome; Opioid-Related Disorders; Pregna | 2012 |
Methadone and perinatal outcomes: a prospective cohort study.
Topics: Adult; Benzodiazepines; Dose-Response Relationship, Drug; Female; Heroin Dependence; Humans; Infant, | 2012 |
Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome.
Topics: Adult; Buprenorphine; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule | 2012 |
Methadone and metabolites in hair of methadone-assisted pregnant women and their infants.
Topics: Adolescent; Adult; Female; Hair; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; O | 2012 |
Perinatal effects of combined use of heroin, methadone, and amphetamine during pregnancy and quantitative measurement of metabolites in hair.
Topics: Adult; Amphetamine; Electroencephalography; Female; Fetus; Gas Chromatography-Mass Spectrometry; Hai | 2012 |
ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence S | 2012 |
A rooming-in program to mitigate the need to treat for opiate withdrawal in the newborn.
Topics: Adult; Breast Feeding; Heroin Dependence; Humans; Infant, Newborn; Methadone; Morphine; Narcotics; N | 2012 |
Are infants exposed to methadone in utero at an increased risk for mortality?
Topics: Adult; Analgesics, Opioid; Cause of Death; Female; Humans; Infant; Infant Mortality; Infant, Newborn | 2012 |
Maternal and neonatal outcomes following methadone substitution during pregnancy.
Topics: Adult; Analgesics, Opioid; Female; Heroin Dependence; Humans; Infant, Newborn; Infant, Premature; Me | 2012 |
Treatment of opioid dependence in the setting of pregnancy.
Topics: Adolescent; Alcohol-Related Disorders; Analgesics, Opioid; Buprenorphine; Child; Comorbidity; Delive | 2012 |
Infant pupillary response to methadone administration during treatment for neonatal abstinence syndrome: a feasibility study.
Topics: Analysis of Variance; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Image I | 2012 |
Case records of the Massachusetts General Hospital. Case 19-2012. A premature newborn boy with respiratory distress.
Topics: Adrenal Glands; Diagnosis, Differential; Echocardiography; Fatal Outcome; Herpes Simplex; Humans; In | 2012 |
Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cohort Studies; Female; Follow-Up Studies; Humans; Infant, | 2013 |
Respiratory failure caused by a suspicious white powder: a case report of intentional methadone poisoning in an infant.
Topics: Child Abuse; Humans; Infant; Infant, Newborn; Male; Methadone; Narcotics; Neonatal Abstinence Syndro | 2012 |
Methadone dosing and prescribed medication use in a prospective cohort of opioid-dependent pregnant women.
Topics: Anti-Bacterial Agents; Antidepressive Agents; Benzodiazepines; Female; Humans; Hypnotics and Sedativ | 2013 |
Dual dilemma-should naltrexone be used in the treatment of opioid-dependent pregnant women?
Topics: Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naltrexone; Narcotic Antagonists; Narcoti | 2013 |
Relationship between maternal methadone dosage and neonatal withdrawal.
Topics: Adult; Analysis of Variance; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration S | 2002 |
Strabismus in infants of opiate-dependent mothers.
Topics: Australia; Codeine; Cross-Sectional Studies; Female; Heroin; Humans; Infant; Infant, Newborn; Male; | 2003 |
Methadone and breastfeeding: new horizons.
Topics: Breast Feeding; Contraindications; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 2003 |
Maternal drug use and length of neonatal unit stay.
Topics: Adult; Female; Humans; Infant, Newborn; Intensive Care, Neonatal; Length of Stay; London; Methadone; | 2003 |
Neonatal hair analysis contribution to establishing a gestational drug exposure profile and predicting a withdrawal syndrome.
Topics: Cannabinoids; Cocaine; Female; Gas Chromatography-Mass Spectrometry; Hair; Humans; Infant, Newborn; | 2003 |
Maternal methadone dose and neonatal withdrawal.
Topics: Benzodiazepines; Dose-Response Relationship, Drug; Female; Heroin Dependence; Humans; Infant, Newbor | 2003 |
Specialized drug liaison midwife services for pregnant opioid dependent women in Dublin, Ireland.
Topics: Adult; Crime; Female; Humans; Infant, Newborn; Ireland; Mental Disorders; Methadone; Midwifery; Narc | 2004 |
French field experience with buprenorphine.
Topics: Adult; Buprenorphine; Cause of Death; Cross-Cultural Comparison; Drug Approval; Drug Overdose; Drug | 2004 |
Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure.
Topics: Adult; Analysis of Variance; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrom | 2004 |
Improving the management of opioid-dependent pregnancies.
Topics: Cohort Studies; Dose-Response Relationship, Drug; Female; Gestational Age; Humans; Infant, Newborn; | 2004 |
Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome?
Topics: Adult; Drug Administration Schedule; Female; Fetal Blood; Humans; Infant, Newborn; Male; Maternal-Fe | 2004 |
Methadone maintenance program in pregnancy in a Swiss perinatal center (II): neonatal outcome and social resources.
Topics: Adult; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fetal | 2005 |
The cost of a little kindness.
Topics: Adult; Empathy; Female; Heroin Dependence; Humans; Infant, Newborn; Male; Methadone; Mother-Child Re | 2005 |
Myocardial ischemia as a result of severe benzodiazepine and opioid withdrawal.
Topics: Adjuvants, Anesthesia; Analgesics, Opioid; Benzodiazepines; Diazepam; Electrocardiography; Female; F | 2005 |
Most prominent symptoms of withdrawal in polydrug-exposed infants.
Topics: Beds; Child Development; Heroin Dependence; Humans; Infant, Newborn; Methadone; Neonatal Abstinence | 2001 |
High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes.
Topics: Adult; Analgesics, Opioid; Female; Gestational Age; Humans; Infant, Newborn; Length of Stay; Methado | 2005 |
Pregnancy outcome in women who use opiates.
Topics: Adult; England; Female; Heroin; Humans; Infant, Newborn; Male; Medical Records; Methadone; Neonatal | 2006 |
A retrospective study of length of hospital stay in infants treated for neonatal abstinence syndrome with methadone versus oral morphine preparations.
Topics: Administration, Oral; Female; Hospitalization; Humans; Infant, Newborn; Length of Stay; Male; Methad | 2005 |
Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey.
Topics: Humans; Hypnotics and Sedatives; Infant, Newborn; Injections, Intravenous; Intensive Care Units, Neo | 2006 |
[A multidisciplinary approach is necessary in the neonatal withdrawal syndrome].
Topics: Adult; Female; Humans; Hypnotics and Sedatives; Infant, Newborn; Male; Methadone; Narcotics; Neonata | 2006 |
Substance abuse in pregnancy: opioid substitution in a northern Ireland maternity unit.
Topics: Adult; Buprenorphine; Codeine; Female; Heroin Dependence; Humans; Infant, Newborn; Maternal-Fetal Ex | 2006 |
Methadone-exposed newborn infants: outcome after alterations to a service for mothers and infants.
Topics: Delivery of Health Care; Female; Humans; Infant Care; Infant, Newborn; Interprofessional Relations; | 2007 |
[Drugs, pregnancy and newborn infants from the viewpoint of pediatric nursing].
Topics: Breast Feeding; Education; Female; Humans; Infant, Newborn; Male; Methadone; Mother-Child Relations; | 2002 |
Sequela of preterm versus term infants born to mothers on a methadone maintenance program: differential course of neonatal abstinence syndrome.
Topics: Cohort Studies; Female; Gestational Age; Humans; Infant, Newborn; Infant, Premature; Methadone; Narc | 2007 |
Variability in the evaluation and management of opiate-exposed newborns in Maryland.
Topics: Adolescent; Adult; Data Collection; Female; Humans; Infant, Newborn; Maryland; Methadone; Neonatal A | 2007 |
Using population data to examine the prevalence and correlates of neonatal abstinence syndrome.
Topics: Adult; Cross-Sectional Studies; Databases, Factual; Female; Gravidity; Humans; Infant, Newborn; Inte | 2007 |
Rooming-in compared with standard care for newborns of mothers using methadone or heroin.
Topics: Adult; Breast Feeding; British Columbia; Child Custody; Cohort Studies; Comorbidity; Female; Heroin; | 2007 |
[The effect of substitution therapy on the birth weight of the newborn, its postpartum adaptation, trophic and course of the neonatal abstinence syndrome].
Topics: Apgar Score; Birth Weight; Buprenorphine; Female; Fetal Growth Retardation; Heroin Dependence; Human | 2007 |
Hospital morphine preparation for abstinence syndrome in newborns exposed to buprenorphine or methadone.
Topics: Buprenorphine; Chromatography, High Pressure Liquid; Drug Contamination; Drug Stability; Female; Hum | 2008 |
Outcomes of neonates conceived on methadone maintenance therapy.
Topics: Adult; Analgesics, Opioid; Birth Weight; Female; Follow-Up Studies; Gestational Age; Humans; Infant, | 2008 |
Methadone maintenance and breastfeeding in the neonatal period.
Topics: Adult; Bottle Feeding; Breast Feeding; Case-Control Studies; Cohort Studies; Dose-Response Relations | 2008 |
Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series.
Topics: Birth Weight; Buprenorphine; Female; Fetal Growth Retardation; Heroin Dependence; Humans; Infant Mor | 2008 |
Methadone maintenance and breastfeeding in the neonatal period.
Topics: Bottle Feeding; Breast Feeding; Dose-Response Relationship, Drug; Drug Administration Schedule; Fema | 2008 |
Development after prenatal exposure to cocaine, heroin and methadone.
Topics: Case-Control Studies; Child; Child of Impaired Parents; Child, Preschool; Cocaine; Developmental Dis | 1994 |
Neonatal abstinence syndrome.
Topics: Cocaine; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Risk Factors | 1995 |
[Withdrawal syndrome in a newborn infant born to an addicted mother receiving methadone].
Topics: Adult; Female; Heroin Dependence; Humans; Infant, Newborn; Male; Methadone; Neonatal Abstinence Synd | 1995 |
Maternal methadone dosage and neonatal withdrawal.
Topics: Birth Weight; Dose-Response Relationship, Drug; Female; Humans; Infant, Newborn; Methadone; Neonatal | 1995 |
Children of methadone-dependent women: developmental outcomes.
Topics: Affective Symptoms; Child; Child Behavior Disorders; Child, Preschool; Developmental Disabilities; E | 1993 |
Neonatal abstinence syndrome after maternal methadone treatment.
Topics: Birth Weight; England; Female; Gestational Age; Humans; Incidence; Infant; Infant, Newborn; Male; Me | 1994 |
Methadone maintenance treatment. Pregnant women taking methadone should be warned about withdrawal symptoms in babies.
Topics: Female; Heroin Dependence; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Patient | 1995 |
Methadone maintenance treatment. We don't know whether heroin or methadone produces more withdrawal symptoms in babies.
Topics: Heroin Dependence; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome | 1995 |
Cognitive development at preschool-age of infants of drug-dependent mothers.
Topics: Child, Preschool; Cocaine; Cognition; Female; Heroin; Humans; Infant; Infant, Newborn; Language; Mal | 1994 |
[Neonatal abstinence syndrome and maternal toxicological profile].
Topics: Dose-Response Relationship, Drug; Female; Gestational Age; Heroin; Humans; Infant, Newborn; Maternal | 1994 |
Methadone therapy.
Topics: Female; Heroin Dependence; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Pregnan | 1993 |
[The clinical and epidemiological aspects of the neonatal abstinence syndrome].
Topics: Adult; Chi-Square Distribution; Cocaine; Female; Heroin; HIV Seropositivity; Humans; Incidence; Infa | 1993 |
[The consequences for the child of drug addiction in the mother: current status in relation to knowledge and management policy in The Netherlands].
Topics: Child Development; Child, Preschool; Female; Humans; Infant; Infant Care; Infant, Newborn; Methadone | 1993 |
[Neonatal abstinence syndrome: current and future aspects].
Topics: Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Opium; Parasympatholytics; | 1993 |
Relationship between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal.
Topics: Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Pregnancy; Pregnancy Compl | 1993 |
Methadone use during pregnancy.
Topics: Animals; Female; Humans; Infant, Newborn; Methadone; Narcotics; Neonatal Abstinence Syndrome; Pregna | 1995 |
Perinatal exposure to methadone affects central cholinergic activity in the weanling rat.
Topics: Acetylcholine; Animals; Animals, Newborn; Brain; Brain Mapping; Female; Humans; Infant, Newborn; Mal | 1996 |
Neonatal withdrawal syndrome in infants exposed to cocaine and methadone.
Topics: Cocaine; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Neurologic Examin | 1996 |
[Pregnancy and drug dependence].
Topics: Administration, Oral; Adult; Austria; Delayed-Action Preparations; Dose-Response Relationship, Drug; | 1996 |
Abnormal umbilical artery flow velocity waveform--a sign of fetal narcotic withdrawal?
Topics: Adult; Blood Flow Velocity; Cesarean Section; Female; Fetal Growth Retardation; Fetal Monitoring; He | 1997 |
Infants born to narcotic dependent mothers: physical growth patterns in the first 12 months of life.
Topics: Adult; Cohort Studies; Female; Fetal Growth Retardation; Growth; Humans; Infant; Infant, Newborn; Me | 1997 |
Neonatal withdrawal following pre- and postnatal exposure to methadone in the rat.
Topics: Animals; Animals, Newborn; Behavior, Animal; Female; Humans; Infant, Newborn; Male; Methadone; Motor | 1998 |
Neonatal abstinence syndrome following abrupt cessation of breastfeeding.
Topics: Breast Feeding; Female; Humans; Infant, Newborn; Male; Methadone; Milk, Human; Neonatal Abstinence S | 1999 |
Shorter dosing interval of opiate solution shortens hospital stay for methadone babies.
Topics: Drug Administration Schedule; Female; Hospitalization; Humans; Infant, Newborn; Length of Stay; Mate | 1999 |
Use of methadone.
Topics: Analgesics, Opioid; Drug Interactions; Female; Humans; Infant, Newborn; Methadone; Narcotics; Neonat | 2000 |
[Methadone treatment during pregnancy and its effect on the child. Better than continuing drug abuse, should be monitored by a specialized antenatal care center].
Topics: Adult; Embryonic and Fetal Development; Female; Heroin Dependence; Humans; Infant, Newborn; Maternal | 2000 |
[Drug dependence in pregnancy. Better to substitute than complete withdrawal].
Topics: Analgesics, Opioid; Buprenorphine; Female; Heroin Dependence; Humans; Infant, Newborn; Methadone; Ne | 2000 |
[Postpartum risk factors in the development of children born to opiate-addicted mothers; comparison between mothers with and without methadone substitution].
Topics: Adult; Birth Weight; Case-Control Studies; Child Advocacy; Child Development; Female; Germany; Gesta | 2000 |
Treatment of opioid dependence in pregnant women.
Topics: Adult; Female; HIV Infections; Humans; Infant, Newborn; Life Style; Methadone; Narcotics; Neonatal A | 2000 |
[Neonatal withdrawal syndrome in twins born to a mother on methadone substitution].
Topics: Adult; Diseases in Twins; Female; Follow-Up Studies; Heroin Dependence; Humans; Infant, Newborn; Met | 2000 |
Mothers and methadone.
Topics: Analgesics, Opioid; Female; Heroin Dependence; Humans; Infant, Newborn; Methadone; Neonatal Abstinen | 2000 |
[Opiate dependent pregnant patients and mothers. What must be regarded in drug substitution and detoxification].
Topics: Ambulatory Care; Female; Germany; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; | 2001 |
Narcotic addiction in pregnancy with adverse maternal and perinatal outcome.
Topics: Adult; Female; Fetal Growth Retardation; Heroin Dependence; Hong Kong; Humans; Infant, Low Birth Wei | 1992 |
Improving treatment outcome in pregnant opiate-dependent women.
Topics: Adult; Combined Modality Therapy; Female; Fetal Growth Retardation; Follow-Up Studies; Heroin; Heroi | 1992 |
[Heroin abuse and methadone substitution in pregnancy].
Topics: Asphyxia Neonatorum; Cardiotocography; Dose-Response Relationship, Drug; Female; Fetal Growth Retard | 1992 |
[Drug substitution and withdrawal in pregnancy. Indication, side effects, acute status, monitoring and results].
Topics: Contraindications; Counseling; Drug Overdose; Female; Heroin Dependence; Humans; Infant, Newborn; Me | 1991 |
[Jurisprudence aspects of drug substitution and withdrawal in pregnancy].
Topics: Female; Germany; Humans; Infant, Newborn; Jurisprudence; Methadone; Neonatal Abstinence Syndrome; Pr | 1991 |
Methadone levels and neonatal withdrawal.
Topics: Adult; Dose-Response Relationship, Drug; Female; Fetal Blood; Humans; Infant, Newborn; Male; Methado | 1991 |
A comparison of the effects of single- and split-dose methadone administration on the fetus: ultrasound evaluation.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fetal Movement; Humans; Infa | 1991 |
Neonatal opiate abstinence syndrome in term and preterm infants.
Topics: Central Nervous System; Cocaine; Dose-Response Relationship, Drug; Gestational Age; Heroin; Humans; | 1991 |
Narcotic addiction: the expectant mother and her baby.
Topics: Adolescent; Adult; Diseases in Twins; Female; Heroin Dependence; Humans; Infant, Newborn; Infant, Pr | 1990 |
[Prenatal development and postnatal morbidity of newborn infants of HIV positive mothers].
Topics: Birth Weight; Female; Fetal Growth Retardation; Gestational Age; HIV Seropositivity; Humans; Infant, | 1990 |
Development of infants of drug dependent mothers.
Topics: Child Behavior Disorders; Child of Impaired Parents; Child, Preschool; Cocaine; Female; Follow-Up St | 1990 |
Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy.
Topics: Adult; Birth Weight; Embryonic and Fetal Development; Female; Humans; Infant, Newborn; Maternal-Feta | 1990 |
Neonatal behavior after drug dependent pregnancy.
Topics: Child; Child Behavior; Child, Preschool; Developmental Disabilities; Electroencephalography; Female; | 1989 |
Profile of opioid withdrawal in newly hatched chickens.
Topics: Animals; Arousal; Brain; Chick Embryo; Chickens; Disease Models, Animal; Dose-Response Relationship, | 1989 |
Perinatal cocaine intoxication.
Topics: Adult; Cocaine; Female; Follow-Up Studies; Humans; Infant, Newborn; Male; Methadone; Neonatal Abstin | 1989 |
Behaviour in first year after drug dependent pregnancy.
Topics: Child Behavior; Child Development; Electroencephalography; Female; Humans; Illicit Drugs; Infant; In | 1989 |
The influence of pharmacotherapy on the neonatal sleep patterns of infants born to opiate-addicted mothers.
Topics: Drug Therapy, Combination; Female; Humans; Infant, Newborn; Male; Methadone; Narcotics; Neonatal Abs | 1987 |
Inhaling heroin during pregnancy.
Topics: Female; Heroin; Heroin Dependence; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; | 1988 |
Neurobehavioral functioning in children exposed to narcotics in utero.
Topics: Adolescent; Child; Follow-Up Studies; Heroin; Humans; Infant, Newborn; Intelligence; Methadone; Neon | 1988 |
Methadone maintenance has a tragic price.
Topics: Adolescent; Child; Child Behavior Disorders; Female; Humans; Infant, Newborn; Methadone; Neonatal Ab | 1988 |
Maternal narcotic abuse and the newborn.
Topics: Adolescent; Adult; Female; Heroin; Humans; Infant, Newborn; Methadone; Narcotics; Neonatal Abstinenc | 1988 |
Perinatal cocaine and methamphetamine exposure: maternal and neonatal correlates.
Topics: Apgar Score; Birth Weight; Child Behavior; Cocaine; Female; Fetal Growth Retardation; Gestational Ag | 1987 |